[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_cd9e2652-addb-469f-8063-6cd2e890cb12":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:cd9e2652-addb-469f-8063-6cd2e890cb12,\"}":98},{"code":4,"data":5,"meta":18},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":20,"manageAffiliations":51,"indexDatabases":59,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},"cd9e2652-addb-469f-8063-6cd2e890cb12","2023-12-05T07:13:04.795+00:00","2025-11-21T09:47:06.178+00:00",[],"Drug-Resistance-Updates",{"issn":12,"title":14},{"VOID":13},"13687646",{"EN":15},"Drug Resistance Updates","PUBLISHER","PENDING",null,0,[21,27,33,39,45],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":23,"label":24,"description":26,"parentId":18,"standard":18,"scholarHubFieldId":18},"740fbbd4-0204-4499-bc5d-be3ba61fc9be",[],{"EN":25},"Cancer Research",{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":29,"label":30,"description":32,"parentId":18,"standard":18,"scholarHubFieldId":18},"8b51d244-613f-4ff9-b308-d32de7c33ed9",[],{"EN":31},"Pharmacology",{},{"id":34,"createTime":18,"updateTime":18,"relativeEntities":35,"label":36,"description":38,"parentId":18,"standard":18,"scholarHubFieldId":18},"8d3ee16d-8f93-4e34-b94e-cd3a00dde338",[],{"EN":37},"Pharmacology (medical)",{},{"id":40,"createTime":18,"updateTime":18,"relativeEntities":41,"label":42,"description":44,"parentId":18,"standard":18,"scholarHubFieldId":18},"d9687dc3-fd83-46ff-aef4-1925044c24eb",[],{"EN":43},"Oncology",{},{"id":46,"createTime":18,"updateTime":18,"relativeEntities":47,"label":48,"description":50,"parentId":18,"standard":18,"scholarHubFieldId":18},"837c26ad-ce88-445d-9621-a6d173c82561",[],{"EN":49},"Infectious Diseases",{},[52],{"id":53,"createTime":18,"updateTime":18,"relativeEntities":54,"slug":18,"properties":55,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":58,"statistic":18},"353f4a78-4364-4142-a6fb-e8ac89c7d65e",[],{"title":56},{"EN":57},"Churchill Livingstone",[],[60,77],{"id":61,"indexDatabase":62,"url":74,"indexYears":18,"academicFieldIds":75,"indexDatabaseRanking":18},"f4b7af60-be4e-47ba-ba04-efc78af845dc",{"id":63,"createTime":18,"updateTime":18,"relativeEntities":64,"label":65,"description":67,"key":70,"publicationTags":71,"standard":18},"a4921856-b128-4d9f-8f1f-e80813d3bbd4",[],{"EN":66,"VI":66},"ISI\u002FSCIE - Science Citation Index Expanded",{"EN":68,"VI":69},"SCIE database","Cơ sở dữ liệu SCIE","scie",[72,73],"SCIE","ISI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=1368-7646",[76],"2b943d65-24a8-4546-9232-a1e32c12cb6c",{"id":78,"indexDatabase":79,"url":89,"indexYears":90,"academicFieldIds":91,"indexDatabaseRanking":97},"f8a2c2a9-7b86-450d-9aaa-a7c549a853bc",{"id":80,"createTime":18,"updateTime":18,"relativeEntities":81,"label":82,"description":84,"key":86,"publicationTags":87,"standard":18},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9",[],{"EN":83,"VI":83},"Scopus - Elsevier",{"EN":83,"VI":85},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[88],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F12611","1998-2025",[92,93,94,95,96],"46eddd1f-e049-4237-8609-9d60083086ad","ee505398-b96f-423d-82ed-9f73f07d49d4","462e3fe4-4fc0-4c02-80d6-8d2af4fc74ea","1a7c8bc3-0575-4f8d-b22c-aec346a0168a","e39d1b91-b03d-48ed-87bb-ab5b714ad558","SCOPUS__Q1",{"meta":99,"data":101},{"total":100},"362",[102,1549,1643,1990,2399,2607,2710,2797,2905,3000],{"id":103,"createTime":104,"updateTime":105,"relativeEntities":106,"slug":107,"properties":108,"entityType":115,"verifyStatus":116,"verifyTime":117,"verifyNote":118,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":119,"fullTextUrl":18,"authors":120,"publicationType":279,"publisherRelationship":280,"citationCount":333,"citationInfo":334,"publishDate":342,"publishYear":335,"citationAnalyzeStatus":343,"lastCitationAnalyze":105,"indexDatabases":344,"openAccess":18,"references":345,"isForceReanalyzing":1548},"1a608940-9bc7-459e-807f-ddaa93c1effc","2023-12-31T10:49:16.245+00:00","2026-07-19T05:00:51.554+00:00",[],"Repositioning-chloroquine-and-metformin-to-eliminate-cancer-stem-cell-traits-in-pre-malignant-lesions",{"title":109,"gsPaper":111,"doi":113},{"EN":110},"Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions",{"VOID":112},"[\"2161273402343699944\"]",{"VOID":114},"10.1016\u002Fj.drup.2011.04.003","PUBLICATION","VERIFIED","2024-05-04T01:38:24.668+00:00","Auto Verify","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1368764611000392",[121,148,170,191,212,235,258],{"id":122,"sortIndex":19,"researcher":18,"roles":123,"affiliations":125,"properties":143,"displayName":145,"givenName":18,"familyName":18},"322b645c-e963-4708-ba65-dc52d4b232cc",[124],"AUTHOR",[126,134],{"id":127,"sortIndex":19,"affiliation":128,"properties":18},"131d8ed9-9470-4ab0-bfd9-7cc099454365",{"id":127,"createTime":18,"updateTime":18,"relativeEntities":129,"slug":18,"properties":130,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":133,"statistic":18},[],{"title":131},{"VI":132},"Unit of Translational Research, Catalan Institute of Oncology-Girona (ICO-Girona), Avenida de Francia s\u002Fn, E-17007 Girona, Catalonia, Spain",[],{"id":135,"sortIndex":136,"affiliation":137,"properties":18},"3311af94-aabe-40ba-b311-2b4722f5b5ed",1,{"id":135,"createTime":18,"updateTime":18,"relativeEntities":138,"slug":18,"properties":139,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":142,"statistic":18},[],{"title":140},{"VI":141},"Girona Biomedical Research Institute (IdIBGi), Avenida de Francia s\u002Fn, E-17007 Girona, Catalonia, Spain",[],{"title":144,"gsAuthor":146},{"VI":145},"Alejandro Vazquez-Martin",{"VOID":147},"[\"NojwQAYAAAAJ\"]",{"id":149,"sortIndex":136,"researcher":18,"roles":150,"affiliations":151,"properties":167,"displayName":169,"givenName":18,"familyName":18},"5970403f-a9d1-4a3e-87c0-6c8140a1e0fc",[124],[152,158],{"id":135,"sortIndex":19,"affiliation":153,"properties":18},{"id":135,"createTime":18,"updateTime":18,"relativeEntities":154,"slug":18,"properties":155,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":157,"statistic":18},[],{"title":156},{"VI":141},[],{"id":159,"sortIndex":136,"affiliation":160,"properties":166},"7058e7c4-0052-4b35-9a07-008d21e6110a",{"id":159,"createTime":18,"updateTime":18,"relativeEntities":161,"slug":18,"properties":162,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":165,"statistic":18},[],{"title":163},{"VI":164},"Department of Anatomical Pathology, Dr. Josep Trueta University Hospital, Avenida de Francia S\u002FN, E-17007 Girona, Catalonia, Spain",[],{},{"title":168},{"VI":169},"Eugeni López-Bonetc",{"id":171,"sortIndex":172,"researcher":18,"roles":173,"affiliations":174,"properties":188,"displayName":190,"givenName":18,"familyName":18},"8ee45e1c-e0e2-4ade-976a-ef7a6a355768",2,[124],[175,181],{"id":127,"sortIndex":19,"affiliation":176,"properties":18},{"id":127,"createTime":18,"updateTime":18,"relativeEntities":177,"slug":18,"properties":178,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":180,"statistic":18},[],{"title":179},{"VI":132},[],{"id":135,"sortIndex":136,"affiliation":182,"properties":187},{"id":135,"createTime":18,"updateTime":18,"relativeEntities":183,"slug":18,"properties":184,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":186,"statistic":18},[],{"title":185},{"VI":141},[],{},{"title":189},{"VI":190},"Sílvia Cufí",{"id":192,"sortIndex":193,"researcher":18,"roles":194,"affiliations":195,"properties":209,"displayName":211,"givenName":18,"familyName":18},"afd4e9bc-b940-4207-bc04-a6bf069b34af",3,[124],[196,202],{"id":127,"sortIndex":19,"affiliation":197,"properties":18},{"id":127,"createTime":18,"updateTime":18,"relativeEntities":198,"slug":18,"properties":199,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":201,"statistic":18},[],{"title":200},{"VI":132},[],{"id":135,"sortIndex":136,"affiliation":203,"properties":208},{"id":135,"createTime":18,"updateTime":18,"relativeEntities":204,"slug":18,"properties":205,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":207,"statistic":18},[],{"title":206},{"VI":141},[],{},{"title":210},{"VI":211},"Cristina Oliveras-Ferraros",{"id":213,"sortIndex":214,"researcher":18,"roles":215,"affiliations":216,"properties":232,"displayName":234,"givenName":18,"familyName":18},"3a748004-e981-49b7-9318-4b484f7c8380",4,[124],[217,223],{"id":135,"sortIndex":19,"affiliation":218,"properties":18},{"id":135,"createTime":18,"updateTime":18,"relativeEntities":219,"slug":18,"properties":220,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":222,"statistic":18},[],{"title":221},{"VI":141},[],{"id":224,"sortIndex":136,"affiliation":225,"properties":231},"64b9b9b8-0cc9-41b7-8b0d-75b0c64bdcb7",{"id":224,"createTime":18,"updateTime":18,"relativeEntities":226,"slug":18,"properties":227,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":230,"statistic":18},[],{"title":228},{"VI":229},"Medical Oncology, Catalan Institute of Oncology-Girona (ICO-Girona), Avenida de Francia s\u002Fn, E-17007 Girona, Catalonia, Spain",[],{},{"title":233},{"VI":234},"Sonia Del Barco",{"id":236,"sortIndex":237,"researcher":18,"roles":238,"affiliations":239,"properties":255,"displayName":257,"givenName":18,"familyName":18},"8fe237c0-1af7-4527-98af-2f0db485ca76",5,[124],[240,246],{"id":135,"sortIndex":19,"affiliation":241,"properties":18},{"id":135,"createTime":18,"updateTime":18,"relativeEntities":242,"slug":18,"properties":243,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":245,"statistic":18},[],{"title":244},{"VI":141},[],{"id":247,"sortIndex":136,"affiliation":248,"properties":254},"d0609b5c-69cf-4c70-87cb-f8f7ec72bdc6",{"id":247,"createTime":18,"updateTime":18,"relativeEntities":249,"slug":18,"properties":250,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":253,"statistic":18},[],{"title":251},{"VI":252},"Unit of Clinical Research, Catalan Institute of Oncology-Girona (ICO-Girona), Avenida de Francia s\u002Fn, E-17007 Girona, Catalonia, Spain",[],{},{"title":256},{"VI":257},"Begoña Martin-Castillo",{"id":259,"sortIndex":260,"researcher":18,"roles":261,"affiliations":262,"properties":276,"displayName":278,"givenName":18,"familyName":18},"7afec695-698c-4dec-a2e4-711ee3a301bd",6,[124],[263,269],{"id":127,"sortIndex":19,"affiliation":264,"properties":18},{"id":127,"createTime":18,"updateTime":18,"relativeEntities":265,"slug":18,"properties":266,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":268,"statistic":18},[],{"title":267},{"VI":132},[],{"id":135,"sortIndex":136,"affiliation":270,"properties":275},{"id":135,"createTime":18,"updateTime":18,"relativeEntities":271,"slug":18,"properties":272,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":274,"statistic":18},[],{"title":273},{"VI":141},[],{},{"title":277},{"VI":278},"Javier A. Menendez","ARTICLE",{"url":119,"publisher":281,"properties":328},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":282,"slug":10,"properties":283,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":286,"manageAffiliations":307,"indexDatabases":313,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":284,"title":285},{"VOID":13},{"EN":15},[287,291,295,299,303],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":288,"label":289,"description":290,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":292,"label":293,"description":294,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":31},{},{"id":34,"createTime":18,"updateTime":18,"relativeEntities":296,"label":297,"description":298,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":37},{},{"id":40,"createTime":18,"updateTime":18,"relativeEntities":300,"label":301,"description":302,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":43},{},{"id":46,"createTime":18,"updateTime":18,"relativeEntities":304,"label":305,"description":306,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":49},{},[308],{"id":53,"createTime":18,"updateTime":18,"relativeEntities":309,"slug":18,"properties":310,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":312,"statistic":18},[],{"title":311},{"EN":57},[],[314,321],{"id":61,"indexDatabase":315,"url":74,"indexYears":18,"academicFieldIds":320,"indexDatabaseRanking":18},{"id":63,"createTime":18,"updateTime":18,"relativeEntities":316,"label":317,"description":318,"key":70,"publicationTags":319,"standard":18},[],{"EN":66,"VI":66},{"EN":68,"VI":69},[72,73],[76],{"id":78,"indexDatabase":322,"url":89,"indexYears":90,"academicFieldIds":327,"indexDatabaseRanking":97},{"id":80,"createTime":18,"updateTime":18,"relativeEntities":323,"label":324,"description":325,"key":86,"publicationTags":326,"standard":18},[],{"EN":83,"VI":83},{"EN":83,"VI":85},[88],[92,93,94,95,96],{"pages":329,"volume":331},{"VOID":330},"212-223",{"VOID":332},"14",92,{"total":333,"publishYear":335,"statisticByYear":336},2011,{"2011":193,"2012":337,"2013":338,"2014":339,"2015":340,"2016":341,"2017":341,"2018":193,"2019":260,"2020":214,"2021":193,"2022":193,"2023":172,"2025":136,"2026":136},8,13,11,12,9,"2011-08-01","DONE_ANALYZE_CITATION",[72,97],[346,354,362,368,376,384,393,399,407,415,420,425,431,440,448,456,464,472,480,488,497,505,514,522,531,539,547,556,564,572,581,587,593,602,610,616,622,631,639,643,651,660,669,677,683,692,698,706,715,723,732,740,748,757,763,772,775,783,789,798,806,814,823,829,834,843,852,861,869,875,884,892,901,909,917,922,930,938,944,952,958,967,976,985,991,999,1007,1016,1024,1030,1038,1046,1054,1060,1069,1077,1085,1088,1094,1102,1105,1114,1123,1131,1138,1147,1155,1164,1169,1172,1181,1189,1197,1206,1214,1218,1223,1229,1235,1243,1252,1261,1264,1272,1280,1286,1292,1297,1301,1310,1318,1324,1333,1339,1348,1354,1358,1366,1374,1380,1386,1390,1398,1401,1407,1410,1416,1424,1432,1441,1447,1453,1456,1465,1471,1479,1487,1495,1500,1508,1514,1520,1528,1533,1542],{"id":18,"text":347,"url":348,"identifiers":349},"Algire, 2011, Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo, Oncogene, 30, 1174, 10.1038\u002Fonc.2010.483","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fonc.2010.483",{"mag":350,"openalex":351,"pm":352,"doi":353},"1991473393","W1991473393","21102522","10.1038\u002Fonc.2010.483",{"id":18,"text":355,"url":356,"identifiers":357},"Algire, 2010, Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase, Endocr. Relat. Cancer, 17, 351, 10.1677\u002FERC-09-0252","https:\u002F\u002Fdoi.org\u002F10.1677\u002Ferc-09-0252",{"mag":358,"openalex":359,"pm":360,"doi":361},"2126464915","W2126464915","20228137","10.1677\u002Ferc-09-0252",{"id":363,"text":364,"url":365,"identifiers":366},"cfb055db-77d7-4f2c-ab56-881d4ab8cc13","Al-Hajj, 2003, Prospective identification of tumorigenic breast cancer cells, Proc. Natl. Acad. Sci. U.S.A., 100, 3983, 10.1073\u002Fpnas.0530291100","https:\u002F\u002Fpnas.org\u002Fdoi\u002Ffull\u002F10.1073\u002Fpnas.0530291100",{"doi":367},"10.1073\u002Fpnas.0530291100",{"id":18,"text":369,"url":370,"identifiers":371},"Alimova, 2009, Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro, Cell Cycle, 8, 909, 10.4161\u002Fcc.8.6.7933","https:\u002F\u002Fdoi.org\u002F10.4161\u002Fcc.8.6.7933",{"mag":372,"openalex":373,"pm":374,"doi":375},"1990063646","W1990063646","19221498","10.4161\u002Fcc.8.6.7933",{"id":18,"text":377,"url":378,"identifiers":379},"Alli, 2005, Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice, Oncogene, 24, 39, 10.1038\u002Fsj.onc.1208174","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fsj.onc.1208174",{"mag":380,"openalex":381,"pm":382,"doi":383},"2003260126","W2003260126","15489885","10.1038\u002Fsj.onc.1208174",{"id":18,"text":385,"url":386,"identifiers":387},"Anisimov, 2010, Metformin for aging and cancer prevention, Aging (Albany, NY), 2, 760, 10.18632\u002Faging.100230","https:\u002F\u002Fdoi.org\u002F10.18632\u002Faging.100230",{"mag":388,"pmc":389,"openalex":390,"pm":391,"doi":392},"2144528369","3006019","W2144528369","21084729","10.18632\u002Faging.100230",{"id":394,"text":395,"url":396,"identifiers":397},"43db480b-9a4f-47b6-8f33-32ab4a6d2b93","Ansieau, 2008, Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence, Cancer Cell, 14, 79, 10.1016\u002Fj.ccr.2008.06.005","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1535610808001955",{"doi":398},"10.1016\u002Fj.ccr.2008.06.005",{"id":18,"text":400,"url":401,"identifiers":402},"Ansieau, 2010, TWISTing an embryonic transcription factor into an oncoprotein, Oncogene, 29, 3173, 10.1038\u002Fonc.2010.92","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fonc.2010.92",{"mag":403,"openalex":404,"pm":405,"doi":406},"2058437379","W2058437379","20383196","10.1038\u002Fonc.2010.92",{"id":18,"text":408,"url":409,"identifiers":410},"Arima, 2008, Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition, Cancer Res., 68, 5104, 10.1158\u002F0008-5472.CAN-07-5680","https:\u002F\u002Fdoi.org\u002F10.1158\u002F0008-5472.can-07-5680",{"mag":411,"openalex":412,"pm":413,"doi":414},"2140618607","W2140618607","18593909","10.1158\u002F0008-5472.can-07-5680",{"id":18,"text":416,"url":417,"identifiers":418},"Armengol, 2007, 4E-binding protein 1: a key molecular “funnel factor” in human cancer with clinical implications, Cancer Res., 67, 7551, 10.1158\u002F0008-5472.CAN-07-0881","http:\u002F\u002Fdx.doi.org\u002F10.1158\u002F0008-5472.can-07-0881",{"doi":419},"10.1158\u002F0008-5472.can-07-0881",{"id":18,"text":421,"url":422,"identifiers":423},"Arnal-Estape, 2010, HER2 silences tumor suppression in breast cancer cells by switching expression of C\u002FEBPss isoforms, Cancer Res., 70, 9927, 10.1158\u002F0008-5472.CAN-10-0869","http:\u002F\u002Fdx.doi.org\u002F10.1158\u002F0008-5472.can-10-0869",{"doi":424},"10.1158\u002F0008-5472.can-10-0869",{"id":426,"text":427,"url":428,"identifiers":429},"093a5d70-cc51-473b-8bed-8a2646b6b592","Ashburn, 2004, Drug repositioning: identifying and developing new uses for existing drugs, Nat. Rev. Drug Discov., 3, 673, 10.1038\u002Fnrd1468","https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fnrd1468",{"doi":430},"10.1038\u002Fnrd1468",{"id":18,"text":432,"url":433,"identifiers":434},"Batsche, 1998, RB and c-Myc activate expression of the E-cadherin gene in epithelial cells through interaction with transcription factor AP-2, Mol. Cell. Biol., 18, 3647, 10.1128\u002FMCB.18.7.3647","https:\u002F\u002Fdoi.org\u002F10.1128\u002Fmcb.18.7.3647",{"mag":435,"pmc":436,"openalex":437,"pm":438,"doi":439},"2120331294","108947","W2120331294","9632747","10.1128\u002Fmcb.18.7.3647",{"id":18,"text":441,"url":442,"identifiers":443},"Ben Sahra, 2010, Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells, Cancer Res., 70, 2465, 10.1158\u002F0008-5472.CAN-09-2782","https:\u002F\u002Fdoi.org\u002F10.1158\u002F0008-5472.can-09-2782",{"mag":444,"openalex":445,"pm":446,"doi":447},"2146780639","W2146780639","20215500","10.1158\u002F0008-5472.can-09-2782",{"id":18,"text":449,"url":450,"identifiers":451},"Ben Sahra, 2008, The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level, Oncogene, 27, 3576, 10.1038\u002Fsj.onc.1211024","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fsj.onc.1211024",{"mag":452,"openalex":453,"pm":454,"doi":455},"2093664485","W2093664485","18212742","10.1038\u002Fsj.onc.1211024",{"id":18,"text":457,"url":458,"identifiers":459},"Ben Sahra, 2010, Metformin in cancer therapy: a new perspective for an old antidiabetic drug?, Mol. Cancer Ther., 9, 1092, 10.1158\u002F1535-7163.MCT-09-1186","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1535-7163.mct-09-1186",{"mag":460,"openalex":461,"pm":462,"doi":463},"2153980878","W2153980878","20442309","10.1158\u002F1535-7163.mct-09-1186",{"id":18,"text":465,"url":466,"identifiers":467},"Ben Sahra, 2010, The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK dependent apoptosis in prostate cancer cells, Autophagy, 6, 670, 10.4161\u002Fauto.6.5.12434","https:\u002F\u002Fdoi.org\u002F10.4161\u002Fauto.6.5.12434",{"mag":468,"openalex":469,"pm":470,"doi":471},"2053495637","W2053495637","28157435","10.4161\u002Fauto.6.5.12434",{"id":18,"text":473,"url":474,"identifiers":475},"Bendall, 2007, IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro, Nature, 448, 1015, 10.1038\u002Fnature06027","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnature06027",{"mag":476,"openalex":477,"pm":478,"doi":479},"2082292567","W2082292567","17625568","10.1038\u002Fnature06027",{"id":18,"text":481,"url":482,"identifiers":483},"Berstein, 2010, Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond, Future Oncol., 6, 1313, 10.2217\u002Ffon.10.87","https:\u002F\u002Fdoi.org\u002F10.2217\u002Ffon.10.87",{"mag":484,"openalex":485,"pm":486,"doi":487},"2130592216","W2130592216","20799876","10.2217\u002Ffon.10.87",{"id":18,"text":489,"url":490,"identifiers":491},"Bodmer, 2010, Long-term metformin use is associated with decreased risk of breast cancer, Diabetes Care, 33, 1304, 10.2337\u002Fdc09-1791","https:\u002F\u002Fdoi.org\u002F10.2337\u002Fdc09-1791",{"mag":492,"pmc":493,"openalex":494,"pm":495,"doi":496},"2121225884","2875444","W2121225884","20299480","10.2337\u002Fdc09-1791",{"id":18,"text":498,"url":499,"identifiers":500},"Bosco, 2007, RB in breast cancer: at the crossroads of tumorigenesis and treatment, Cell Cycle, 6, 667, 10.4161\u002Fcc.6.6.3988","https:\u002F\u002Fdoi.org\u002F10.4161\u002Fcc.6.6.3988",{"mag":501,"openalex":502,"pm":503,"doi":504},"2003309405","W2003309405","17361100","10.4161\u002Fcc.6.6.3988",{"id":18,"text":506,"url":507,"identifiers":508},"Boya, 2005, Inhibition of macroautophagy triggers apoptosis, Mol. Cell. Biol., 25, 1025, 10.1128\u002FMCB.25.3.1025-1040.2005","https:\u002F\u002Fdoi.org\u002F10.1128\u002Fmcb.25.3.1025-1040.2005",{"mag":509,"pmc":510,"openalex":511,"pm":512,"doi":513},"2167656141","543994","W2167656141","15657430","10.1128\u002Fmcb.25.3.1025-1040.2005",{"id":18,"text":515,"url":516,"identifiers":517},"Boyerinas, 2010, The role of let-7 in cell differentiation and cancer, Endocr. Relat. Cancer, 17, F19, 10.1677\u002FERC-09-0184","https:\u002F\u002Fdoi.org\u002F10.1677\u002Ferc-09-0184",{"mag":518,"openalex":519,"pm":520,"doi":521},"2142489285","W2142489285","19779035","10.1677\u002Ferc-09-0184",{"id":18,"text":523,"url":524,"identifiers":525},"Brabletz, 2010, The ZEB\u002FmiR-200 feedback loop—a motor of cellular plasticity in development and cancer?, EMBO Rep., 11, 670, 10.1038\u002Fembor.2010.117","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fembor.2010.117",{"mag":526,"pmc":527,"openalex":528,"pm":529,"doi":530},"2101136328","2933868","W2101136328","20706219","10.1038\u002Fembor.2010.117",{"id":18,"text":532,"url":533,"identifiers":534},"Braig, 2006, Oncogene-induced senescence: putting the brakes on tumor development, Cancer Res., 66, 2881, 10.1158\u002F0008-5472.CAN-05-4006","https:\u002F\u002Fdoi.org\u002F10.1158\u002F0008-5472.can-05-4006",{"mag":535,"openalex":536,"pm":537,"doi":538},"2044729521","W2044729521","16540631","10.1158\u002F0008-5472.can-05-4006",{"id":18,"text":540,"url":541,"identifiers":542},"Brunet, 2008, BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer, Mol. Carcinog., 47, 157, 10.1002\u002Fmc.20364","https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmc.20364",{"mag":543,"openalex":544,"pm":545,"doi":546},"2012902516","W2012902516","17620310","10.1002\u002Fmc.20364",{"id":18,"text":548,"url":549,"identifiers":550},"Burkhart, 2008, Cellular mechanisms of tumour suppression by the retinoblastoma gene, Nat. Rev. Cancer, 8, 671, 10.1038\u002Fnrc2399","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnrc2399",{"mag":551,"pmc":552,"openalex":553,"pm":554,"doi":555},"2071333117","6996492","W2071333117","18650841","10.1038\u002Fnrc2399",{"id":18,"text":557,"url":558,"identifiers":559},"Buzzai, 2007, Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth, Cancer Res., 67, 6745, 10.1158\u002F0008-5472.CAN-06-4447","https:\u002F\u002Fdoi.org\u002F10.1158\u002F0008-5472.can-06-4447",{"mag":560,"openalex":561,"pm":562,"doi":563},"2123014930","W2123014930","17638885","10.1158\u002F0008-5472.can-06-4447",{"id":18,"text":565,"url":566,"identifiers":567},"Campaner, 2010, Cdk2 suppresses cellular senescence induced by the c-myc oncogene, Nat. Cell Biol., 12, 54, 10.1038\u002Fncb2004","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fncb2004",{"mag":568,"openalex":569,"pm":570,"doi":571},"2006547874","W2006547874","20010815","10.1038\u002Fncb2004",{"id":18,"text":573,"url":574,"identifiers":575},"Chen, 2010, Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion, Br. J. Cancer, 102, 351, 10.1038\u002Fsj.bjc.6605486","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fsj.bjc.6605486",{"mag":576,"pmc":577,"openalex":578,"pm":579,"doi":580},"2027497744","2816657","W2027497744","20010940","10.1038\u002Fsj.bjc.6605486",{"id":582,"text":583,"url":584,"identifiers":585},"49dddb3b-c95e-4c3a-bb9b-d9c0df0fe592","Chicas, 2010, Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence, Cancer Cell, 17, 376, 10.1016\u002Fj.ccr.2010.01.023","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1535610810000723",{"doi":586},"10.1016\u002Fj.ccr.2010.01.023",{"id":588,"text":589,"url":590,"identifiers":591},"4c68646b-0035-4279-8000-0006b275d4fa","Ciavarra, 2011, Direct and indirect effects of the pRb tumor suppressor on autophagy, Autophagy, 7","https:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs10440-022-00541-7",{"doi":592},"10.1007\u002Fs10440-022-00541-7",{"id":18,"text":594,"url":595,"identifiers":596},"Collado, 2010, Senescence in tumours: evidence from mice and humans, Nat. Rev. Cancer, 10, 51, 10.1038\u002Fnrc2772","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnrc2772",{"mag":597,"pmc":598,"openalex":599,"pm":600,"doi":601},"2087999409","3672965","W2087999409","20029423","10.1038\u002Fnrc2772",{"id":18,"text":603,"url":604,"identifiers":605},"Creighton, 2010, Epithelial–mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer, J. Mammary Gland Biol. Neoplasia, 15, 253, 10.1007\u002Fs10911-010-9173-1","https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs10911-010-9173-1",{"mag":606,"openalex":607,"pm":608,"doi":609},"2126793001","W2126793001","20354771","10.1007\u002Fs10911-010-9173-1",{"id":611,"text":612,"url":613,"identifiers":614},"58e6b5ad-4e24-4421-b9cf-fdca6e4a220f","Cufi, 2010, Metformin against TGFbeta-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis, Cell Cycle, 9, 4461, 10.4161\u002Fcc.9.22.14048","http:\u002F\u002Fwww.tandfonline.com\u002Fdoi\u002Fabs\u002F10.4161\u002Fcc.9.22.14048",{"doi":615},"10.4161\u002Fcc.9.22.14048",{"id":617,"text":618,"url":619,"identifiers":620},"fb4cc5a2-bd8e-4da4-8ce7-44045d9950fa","Dimri, 1995, A biomarker that identifies senescent human cells in culture and in aging skin in vivo, Proc. Natl. Acad. Sci. U.S.A., 92, 9363, 10.1073\u002Fpnas.92.20.9363","https:\u002F\u002Fpnas.org\u002Fdoi\u002Ffull\u002F10.1073\u002Fpnas.92.20.9363",{"doi":621},"10.1073\u002Fpnas.92.20.9363",{"id":18,"text":623,"url":624,"identifiers":625},"Dontu, 2003, In vitro propagation and transcriptional profiling of human mammary stem\u002Fprogenitor cells, Genes Dev., 17, 1253, 10.1101\u002Fgad.1061803","https:\u002F\u002Fdoi.org\u002F10.1101\u002Fgad.1061803",{"mag":626,"pmc":627,"openalex":628,"pm":629,"doi":630},"2127617517","196056","W2127617517","12756227","10.1101\u002Fgad.1061803",{"id":18,"text":632,"url":633,"identifiers":634},"Dowling, 2007, Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells, Cancer Res., 67, 10804, 10.1158\u002F0008-5472.CAN-07-2310","https:\u002F\u002Fdoi.org\u002F10.1158\u002F0008-5472.can-07-2310",{"mag":635,"openalex":636,"pm":637,"doi":638},"2064656431","W2064656431","18006825","10.1158\u002F0008-5472.can-07-2310",{"id":18,"text":640,"url":18,"identifiers":641},"Eberle, 2004, SREBP transcription factors: master regulators of lipid homeostasis, Biochimie, 86, 839, 10.1016\u002Fj.biochi.2004.09.018",{"doi":642},"10.1016\u002Fj.biochi.2004.09.018",{"id":18,"text":644,"url":645,"identifiers":646},"Elmore, 2002, Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction, J. Biol. Chem., 277, 35509, 10.1074\u002Fjbc.M205477200","https:\u002F\u002Fdoi.org\u002F10.1074\u002Fjbc.m205477200",{"mag":647,"openalex":648,"pm":649,"doi":650},"2166029855","W2166029855","12101184","10.1074\u002Fjbc.m205477200",{"id":18,"text":652,"url":653,"identifiers":654},"Espina, 2011, What is the malignant nature of human ductal carcinoma in situ?, Nat. Rev. Cancer, 11, 68, 10.1038\u002Fnrc2950","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnrc2950",{"mag":655,"pmc":656,"openalex":657,"pm":658,"doi":659},"1973148098","3756606","W1973148098","21150936","10.1038\u002Fnrc2950",{"id":18,"text":661,"url":662,"identifiers":663},"Espina, 2010, Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival, PLoS One, 5, e10240, 10.1371\u002Fjournal.pone.0010240","https:\u002F\u002Fdoi.org\u002F10.1371\u002Fjournal.pone.0010240",{"mag":664,"pmc":665,"openalex":666,"pm":667,"doi":668},"2077965927","2857649","W2077965927","20421921","10.1371\u002Fjournal.pone.0010240",{"id":18,"text":670,"url":671,"identifiers":672},"Esslimani-Sahla, 2007, Increased expression of fatty acid synthase and progesterone receptor in early steps of human mammary carcinogenesis, Int. J. Cancer, 120, 224, 10.1002\u002Fijc.22202","https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.22202",{"mag":673,"openalex":674,"pm":675,"doi":676},"1974628766","W1974628766","17044016","10.1002\u002Fijc.22202",{"id":678,"text":679,"url":680,"identifiers":681},"641f20e5-096d-47ca-8bde-6ab130a3f2c8","Evans, 2005, Metformin and reduced risk of cancer in diabetic patients, BMJ, 330, 1304, 10.1136\u002Fbmj.38415.708634.F7","https:\u002F\u002Fwww.bmj.com\u002Flookup\u002Fdoi\u002F10.1136\u002Fbmj.38415.708634.F7",{"doi":682},"10.1136\u002Fbmj.38415.708634.f7",{"id":18,"text":684,"url":685,"identifiers":686},"Fillmore, 2010, Estrogen expands breast cancer stem-like cells through paracrine FGF\u002FTbx3 signaling, Proc. Natl. Acad. Sci. U.S.A., 107, 21737, 10.1073\u002Fpnas.1007863107","https:\u002F\u002Fdoi.org\u002F10.1073\u002Fpnas.1007863107",{"mag":687,"pmc":688,"openalex":689,"pm":690,"doi":691},"2100502993","3003123","W2100502993","21098263","10.1073\u002Fpnas.1007863107",{"id":693,"text":694,"url":695,"identifiers":696},"891b4880-b42c-4c5e-921d-bdab59dc616a","Fisher, 1998, Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, J. Natl. Cancer Inst., 90, 1371, 10.1093\u002Fjnci\u002F90.18.1371","https:\u002F\u002Facademic.oup.com\u002Fjnci\u002Farticle\u002F90\u002F18\u002F1371\u002F897928",{"doi":697},"10.1093\u002Fjnci\u002F90.18.1371",{"id":18,"text":699,"url":700,"identifiers":701},"Gatenby, 2008, A microenvironmental model of carcinogenesis, Nat. Rev. Cancer, 8, 56, 10.1038\u002Fnrc2255","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnrc2255",{"mag":702,"openalex":703,"pm":704,"doi":705},"2078684128","W2078684128","18059462","10.1038\u002Fnrc2255",{"id":18,"text":707,"url":708,"identifiers":709},"Gauthier, 2007, Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors, Cancer Cell, 12, 479, 10.1016\u002Fj.ccr.2007.10.017","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ccr.2007.10.017",{"mag":710,"pmc":711,"openalex":712,"pm":713,"doi":714},"2055395862","3605202","W2055395862","17996651","10.1016\u002Fj.ccr.2007.10.017",{"id":18,"text":716,"url":717,"identifiers":718},"Giovannucci, 2010, Diabetes and cancer: a consensus report, CA Cancer J. Clin., 60, 207, 10.3322\u002Fcaac.20078","https:\u002F\u002Fdoi.org\u002F10.3322\u002Fcaac.20078",{"mag":719,"openalex":720,"pm":721,"doi":722},"1988782755","W1988782755","20554718","10.3322\u002Fcaac.20078",{"id":18,"text":724,"url":725,"identifiers":726},"Gonzalez-Angulo, 2010, Metformin: a therapeutic opportunity in breast cancer, Clin. Cancer Res., 16, 1695, 10.1158\u002F1078-0432.CCR-09-1805","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1078-0432.ccr-09-1805",{"mag":727,"pmc":728,"openalex":729,"pm":730,"doi":731},"2115325946","2840206","W2115325946","20215559","10.1158\u002F1078-0432.ccr-09-1805",{"id":18,"text":733,"url":734,"identifiers":735},"Goodwin, 2008, Insulin-lowering effects of metformin in women with early breast cancer, Clin. Breast Cancer, 8, 501, 10.3816\u002FCBC.2008.n.060","https:\u002F\u002Fdoi.org\u002F10.3816\u002Fcbc.2008.n.060",{"mag":736,"openalex":737,"pm":738,"doi":739},"2051872169","W2051872169","19073504","10.3816\u002Fcbc.2008.n.060",{"id":18,"text":741,"url":742,"identifiers":743},"Goodwin, 2011, Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents, Breast Cancer Res. Treatm., 126, 215, 10.1007\u002Fs10549-010-1224-1","https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs10549-010-1224-1",{"mag":744,"openalex":745,"pm":746,"doi":747},"2074876140","W2074876140","20976543","10.1007\u002Fs10549-010-1224-1",{"id":18,"text":749,"url":750,"identifiers":751},"Hannemann, 2006, Classification of ductal carcinoma in situ by gene expression profiling, Breast Cancer Res., 8, R61, 10.1186\u002Fbcr1613","https:\u002F\u002Fdoi.org\u002F10.1186\u002Fbcr1613",{"mag":752,"pmc":753,"openalex":754,"pm":755,"doi":756},"1951386398","1779498","W1951386398","17069663","10.1186\u002Fbcr1613",{"id":758,"text":759,"url":760,"identifiers":761},"e331c131-7be5-4d56-a76c-7fca0c385532","Hemkens, 2009, Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study, Diabetologia, 52, 1732, 10.1007\u002Fs00125-009-1418-4","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs00125-009-1418-4",{"doi":762},"10.1007\u002Fs00125-009-1418-4",{"id":18,"text":764,"url":765,"identifiers":766},"Hirsch, 2009, Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission, Cancer Res., 69, 7507, 10.1158\u002F0008-5472.CAN-09-2994","https:\u002F\u002Fdoi.org\u002F10.1158\u002F0008-5472.can-09-2994",{"mag":767,"pmc":768,"openalex":769,"pm":770,"doi":771},"2125747634","2756324","W2125747634","19752085","10.1158\u002F0008-5472.can-09-2994",{"id":18,"text":773,"url":18,"identifiers":774},"Hochachka, 1980",{},{"id":18,"text":776,"url":777,"identifiers":778},"Hochachka, 2002, Going malignant: the hypoxia-cancer connection in the prostate, Bioessays, 24, 749, 10.1002\u002Fbies.10131","https:\u002F\u002Fdoi.org\u002F10.1002\u002Fbies.10131",{"mag":779,"openalex":780,"pm":781,"doi":782},"1983259239","W1983259239","12210536","10.1002\u002Fbies.10131",{"id":784,"text":785,"url":786,"identifiers":787},"810688a5-1b23-4373-a7e3-c0321756562a","Honeth, 2008, The CD44+\u002FCD24− phenotype is enriched in basal-like breast tumors, Breast Cancer Res., 10, R53, 10.1186\u002Fbcr2108","https:\u002F\u002Fbreast-cancer-research.biomedcentral.com\u002Farticles\u002F10.1186\u002Fbcr2108",{"doi":788},"10.1186\u002Fbcr2108",{"id":18,"text":790,"url":791,"identifiers":792},"Horwitz, 2008, Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis, J. Clin. Endocrinol. Metab., 93, 3295, 10.1210\u002Fjc.2008-0938","https:\u002F\u002Fdoi.org\u002F10.1210\u002Fjc.2008-0938",{"mag":793,"pmc":794,"openalex":795,"pm":796,"doi":797},"2007624933","2567860","W2007624933","18647813","10.1210\u002Fjc.2008-0938",{"id":18,"text":799,"url":800,"identifiers":801},"Hosono, 2010, Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial, Cancer Prev. Res. (Phila), 3, 1077, 10.1158\u002F1940-6207.CAPR-10-0186","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1940-6207.capr-10-0186",{"mag":802,"openalex":803,"pm":804,"doi":805},"2166393423","W2166393423","20810669","10.1158\u002F1940-6207.capr-10-0186",{"id":18,"text":807,"url":808,"identifiers":809},"Hugo, 2011, Defining the E-cadherin repressor interactome in epithelial–mesenchymal transition: the PMC42 model as a case study, Cells Tissues Organs, 193, 23, 10.1159\u002F000320174","https:\u002F\u002Fdoi.org\u002F10.1159\u002F000320174",{"mag":810,"openalex":811,"pm":812,"doi":813},"1995507236","W1995507236","21051859","10.1159\u002F000320174",{"id":18,"text":815,"url":816,"identifiers":817},"Ibarra, 2007, A role for microRNAs in maintenance of mouse mammary epithelial progenitor cells, Genes Dev., 21, 3238, 10.1101\u002Fgad.1616307","https:\u002F\u002Fdoi.org\u002F10.1101\u002Fgad.1616307",{"mag":818,"pmc":819,"openalex":820,"pm":821,"doi":822},"2126079508","2113025","W2126079508","18079172","10.1101\u002Fgad.1616307",{"id":824,"text":825,"url":826,"identifiers":827},"e25c8821-cb52-4941-bb45-ddd54e5ced69","Jalving, 2010, Metformin: taking away the candy for cancer?, Eur. J. Cancer, 46, 2369, 10.1016\u002Fj.ejca.2010.06.012","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0959804910004879",{"doi":828},"10.1016\u002Fj.ejca.2010.06.012",{"id":18,"text":830,"url":831,"identifiers":832},"Janda, 2006, Raf plus TGFbeta-dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin, Oncogene, 25, 7117, 10.1038\u002Fsj.onc.1209701","http:\u002F\u002Fdx.doi.org\u002F10.1038\u002Fsj.onc.1209701",{"doi":833},"10.1038\u002Fsj.onc.1209701",{"id":18,"text":835,"url":836,"identifiers":837},"Jiang, 2010, The RB-E2F1 pathway regulates autophagy, Cancer Res., 70, 7882, 10.1158\u002F0008-5472.CAN-10-1604","https:\u002F\u002Fdoi.org\u002F10.1158\u002F0008-5472.can-10-1604",{"mag":838,"pmc":839,"openalex":840,"pm":841,"doi":842},"2146731647","3104680","W2146731647","20807803","10.1158\u002F0008-5472.can-10-1604",{"id":18,"text":844,"url":845,"identifiers":846},"Jiang, 2010, Rb deletion in mouse mammary progenitors induces luminal-B or basal-like\u002FEMT tumor subtypes depending on p53 status, J. Clin. Invest., 120, 3296, 10.1172\u002FJCI41490","https:\u002F\u002Fdoi.org\u002F10.1172\u002Fjci41490",{"mag":847,"pmc":848,"openalex":849,"pm":850,"doi":851},"2040267618","2929714","W2040267618","20679727","10.1172\u002Fjci41490",{"id":18,"text":853,"url":854,"identifiers":855},"Jiralerspong, 2009, Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer, J. Clin. Oncol., 27, 3297, 10.1200\u002FJCO.2009.19.6410","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2009.19.6410",{"mag":856,"pmc":857,"openalex":858,"pm":859,"doi":860},"2171998898","2736070","W2171998898","19487376","10.1200\u002Fjco.2009.19.6410",{"id":18,"text":862,"url":863,"identifiers":864},"Jonasson, 2009, Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden, Diabetologia, 52, 1745, 10.1007\u002Fs00125-009-1444-2","https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs00125-009-1444-2",{"mag":865,"openalex":866,"pm":867,"doi":868},"2108632093","W2108632093","19588120","10.1007\u002Fs00125-009-1444-2",{"id":870,"text":871,"url":872,"identifiers":873},"a5f654f7-4683-47ba-95e8-b2ce9035d1ba","Kalluri, 2009, The basics of epithelial–mesenchymal transition, J. Clin. Invest., 119, 1420, 10.1172\u002FJCI39104","http:\u002F\u002Fwww.jci.org\u002Farticles\u002Fview\u002F39104",{"doi":874},"10.1172\u002Fjci39104",{"id":18,"text":876,"url":877,"identifiers":878},"Karantza-Wadsworth, 2007, Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis, Genes Dev., 21, 1621, 10.1101\u002Fgad.1565707","https:\u002F\u002Fdoi.org\u002F10.1101\u002Fgad.1565707",{"mag":879,"pmc":880,"openalex":881,"pm":882,"doi":883},"2110025151","1899472","W2110025151","17606641","10.1101\u002Fgad.1565707",{"id":18,"text":885,"url":886,"identifiers":887},"Kelloff, 2007, Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug development, Nat. Rev. Cancer, 7, 508, 10.1038\u002Fnrc2154","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnrc2154",{"mag":888,"openalex":889,"pm":890,"doi":891},"2016131697","W2016131697","17568791","10.1038\u002Fnrc2154",{"id":18,"text":893,"url":894,"identifiers":895},"Knudsen, 2008, Tailoring to RB: tumour suppressor status and therapeutic response, Nat. Rev. Cancer, 8, 714, 10.1038\u002Fnrc2401","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnrc2401",{"mag":896,"pmc":897,"openalex":898,"pm":899,"doi":900},"2079941948","2914856","W2079941948","19143056","10.1038\u002Fnrc2401",{"id":18,"text":902,"url":903,"identifiers":904},"Kroemer, 2005, Lysosomes and autophagy in cell death control, Nat. Rev. Cancer, 5, 886, 10.1038\u002Fnrc1738","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnrc1738",{"mag":905,"openalex":906,"pm":907,"doi":908},"2055793916","W2055793916","16239905","10.1038\u002Fnrc1738",{"id":18,"text":910,"url":911,"identifiers":912},"Lacerda, 2010, The role of tumor initiating cells in drug resistance of breast cancer: implications for future therapeutic approaches, Drug Resist. Updates, 13, 99, 10.1016\u002Fj.drup.2010.08.001","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.drup.2010.08.001",{"mag":913,"openalex":914,"pm":915,"doi":916},"2078771990","W2078771990","20739212","10.1016\u002Fj.drup.2010.08.001",{"id":18,"text":918,"url":919,"identifiers":920},"Lee, 2006, Senescence-associated beta-galactosidase is lysosomal beta-galactosidase, Aging Cell, 5, 187, 10.1111\u002Fj.1474-9726.2006.00199.x","http:\u002F\u002Fdx.doi.org\u002F10.1111\u002Fj.1474-9726.2006.00199.x",{"doi":921},"10.1111\u002Fj.1474-9726.2006.00199.x",{"id":18,"text":923,"url":924,"identifiers":925},"Li, 2006, Normal stem cells and cancer stem cells: the niche matters, Cancer Res., 66, 4553, 10.1158\u002F0008-5472.CAN-05-3986","https:\u002F\u002Fdoi.org\u002F10.1158\u002F0008-5472.can-05-3986",{"mag":926,"openalex":927,"pm":928,"doi":929},"1985760249","W1985760249","16651403","10.1158\u002F0008-5472.can-05-3986",{"id":18,"text":931,"url":932,"identifiers":933},"Li, 2008, Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy, J. Natl. Cancer Inst., 100, 672, 10.1093\u002Fjnci\u002Fdjn123","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fjnci\u002Fdjn123",{"mag":934,"openalex":935,"pm":936,"doi":937},"2159640574","W2159640574","18445819","10.1093\u002Fjnci\u002Fdjn123",{"id":939,"text":940,"url":941,"identifiers":942},"cee262c2-0b5b-4b10-ac87-3107d604673e","Liang, 1999, Induction of autophagy and inhibition of tumorigenesis by beclin 1, Nature, 402, 672, 10.1038\u002F45257","https:\u002F\u002Fwww.nature.com\u002Farticles\u002F45257",{"doi":943},"10.1038\u002F45257",{"id":18,"text":945,"url":946,"identifiers":947},"Liu, 2009, Metformin induces unique biological and molecular responses in triple negative breast cancer cells, Cell Cycle, 8, 2031, 10.4161\u002Fcc.8.13.8814","https:\u002F\u002Fdoi.org\u002F10.4161\u002Fcc.8.13.8814",{"mag":948,"openalex":949,"pm":950,"doi":951},"2108183713","W2108183713","19440038","10.4161\u002Fcc.8.13.8814",{"id":953,"text":954,"url":955,"identifiers":956},"0e001f05-733e-440b-a3cf-b610655457db","Liu, 2010, Targeting breast cancer stem cells, J. Clin. Oncol., 28, 4006, 10.1200\u002FJCO.2009.27.5388","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1574789110000517",{"doi":957},"10.1016\u002Fj.molonc.2010.06.005",{"id":18,"text":959,"url":960,"identifiers":961},"Liu, 2009, Mouse fibroblasts lacking RB1 function form spheres and undergo reprogramming to a cancer stem cell phenotype, Cell Stem Cell, 4, 336, 10.1016\u002Fj.stem.2009.02.015","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.stem.2009.02.015",{"mag":962,"pmc":963,"openalex":964,"pm":965,"doi":966},"1974145397","2743858","W1974145397","19341623","10.1016\u002Fj.stem.2009.02.015",{"id":18,"text":968,"url":969,"identifiers":970},"Liu, 2008, Zeb1 links epithelial–mesenchymal transition and cellular senescence, Development (Cambridge, England), 135, 579, 10.1242\u002Fdev.007047","https:\u002F\u002Fdoi.org\u002F10.1242\u002Fdev.007047",{"mag":971,"pmc":972,"openalex":973,"pm":974,"doi":975},"2112575854","2507753","W2112575854","18192284","10.1242\u002Fdev.007047",{"id":18,"text":977,"url":978,"identifiers":979},"Louie, 2010, Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation, Breast Cancer Res., 12, R94, 10.1186\u002Fbcr2773","https:\u002F\u002Fdoi.org\u002F10.1186\u002Fbcr2773",{"mag":980,"pmc":981,"openalex":982,"pm":983,"doi":984},"2155779354","3046435","W2155779354","21067584","10.1186\u002Fbcr2773",{"id":986,"text":987,"url":988,"identifiers":989},"c4693ad5-d4ca-4dac-bac0-b3fcc681d21b","Lu, 2009, 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial–mesenchymal transition, Cancer Cell, 16, 195, 10.1016\u002Fj.ccr.2009.08.010","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1535610809002566",{"doi":990},"10.1016\u002Fj.ccr.2009.08.010",{"id":18,"text":992,"url":993,"identifiers":994},"Lu, 2005, Fatty acid synthase is a potential molecular target for the chemoprevention of breast cancer, Carcinogenesis, 26, 153, 10.1093\u002Fcarcin\u002Fbgh278","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fcarcin\u002Fbgh278",{"mag":995,"openalex":996,"pm":997,"doi":998},"2154746629","W2154746629","15358634","10.1093\u002Fcarcin\u002Fbgh278",{"id":18,"text":1000,"url":1001,"identifiers":1002},"Lum, 2005, Autophagy in metazoans: cell survival in the land of plenty, Nat. Rev. Mol. Cell Biol., 6, 439, 10.1038\u002Fnrm1660","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnrm1660",{"mag":1003,"openalex":1004,"pm":1005,"doi":1006},"2071221374","W2071221374","15928708","10.1038\u002Fnrm1660",{"id":18,"text":1008,"url":1009,"identifiers":1010},"Lundgren, 2009, Hypoxia, Snail and incomplete epithelial–mesenchymal transition in breast cancer, Br. J. Cancer, 101, 1769, 10.1038\u002Fsj.bjc.6605369","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fsj.bjc.6605369",{"mag":1011,"pmc":1012,"openalex":1013,"pm":1014,"doi":1015},"2167458465","2778529","W2167458465","19844232","10.1038\u002Fsj.bjc.6605369",{"id":18,"text":1017,"url":1018,"identifiers":1019},"Magnifico, 2009, Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab, Clin. Cancer Res., 15, 2010, 10.1158\u002F1078-0432.CCR-08-1327","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1078-0432.ccr-08-1327",{"mag":1020,"openalex":1021,"pm":1022,"doi":1023},"2113844650","W2113844650","19276287","10.1158\u002F1078-0432.ccr-08-1327",{"id":1025,"text":1026,"url":1027,"identifiers":1028},"262fe90b-9a11-41a0-8aee-1903e9351773","Mani, 2008, The epithelial–mesenchymal transition generates cells with properties of stem cells, Cell, 133, 704, 10.1016\u002Fj.cell.2008.03.027","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0092867408004443",{"doi":1029},"10.1016\u002Fj.cell.2008.03.027",{"id":18,"text":1031,"url":1032,"identifiers":1033},"Martin, 2010, Tumorigenesis: Twist1 links EMT to self-renewal, Nat. Cell Biol., 12, 924, 10.1038\u002Fncb1010-924","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fncb1010-924",{"mag":1034,"openalex":1035,"pm":1036,"doi":1037},"1968861372","W1968861372","20885418","10.1038\u002Fncb1010-924",{"id":18,"text":1039,"url":1040,"identifiers":1041},"Martin-Castillo, 2010, Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology, Ann. Oncol., 21, 187, 10.1093\u002Fannonc\u002Fmdp494","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fannonc\u002Fmdp494",{"mag":1042,"openalex":1043,"pm":1044,"doi":1045},"1967241377","W1967241377","19884247","10.1093\u002Fannonc\u002Fmdp494",{"id":18,"text":1047,"url":1048,"identifiers":1049},"Martin-Castillo, 2010, Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena, Cell Cycle, 9, 1057, 10.4161\u002Fcc.9.6.10994","https:\u002F\u002Fdoi.org\u002F10.4161\u002Fcc.9.6.10994",{"mag":1050,"openalex":1051,"pm":1052,"doi":1053},"2057139536","W2057139536","20305377","10.4161\u002Fcc.9.6.10994",{"id":1055,"text":1056,"url":1057,"identifiers":1058},"93d97b61-7eff-4da7-9bbe-401396688b1b","Massague, 2008, TGFbeta in cancer, Cell, 134, 215, 10.1016\u002Fj.cell.2008.07.001","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0092867408008787",{"doi":1059},"10.1016\u002Fj.cell.2008.07.001",{"id":18,"text":1061,"url":1062,"identifiers":1063},"Mathew, 2007, Role of autophagy in cancer, Nat. Rev. Cancer, 7, 961, 10.1038\u002Fnrc2254","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnrc2254",{"mag":1064,"pmc":1065,"openalex":1066,"pm":1067,"doi":1068},"2078893058","2866167","W2078893058","17972889","10.1038\u002Fnrc2254",{"id":18,"text":1070,"url":1071,"identifiers":1072},"Meley, 2006, AMP-activated protein kinase and the regulation of autophagic proteolysis, J. Biol. Chem., 281, 34870, 10.1074\u002Fjbc.M605488200","https:\u002F\u002Fdoi.org\u002F10.1074\u002Fjbc.m605488200",{"mag":1073,"openalex":1074,"pm":1075,"doi":1076},"2088970299","W2088970299","16990266","10.1074\u002Fjbc.m605488200",{"id":18,"text":1078,"url":1079,"identifiers":1080},"Memmott, 2009, LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin, J. Clin. Oncol., 27, e226, 10.1200\u002FJCO.2009.25.3963","https:\u002F\u002Fdoi.org\u002F10.1200\u002Fjco.2009.25.3963",{"mag":1081,"openalex":1082,"pm":1083,"doi":1084},"2100228746","W2100228746","19858366","10.1200\u002Fjco.2009.25.3963",{"id":18,"text":1086,"url":18,"identifiers":1087},"Menendez, 2011, Gerosuppressant metformin: less is more, Aging (Albany, NY)",{},{"id":1089,"text":1090,"url":1091,"identifiers":1092},"84b8ccca-72a7-4fa2-9115-4053b28f54a7","Menendez, 2007, Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis, Nat. Rev. Cancer, 7, 763, 10.1038\u002Fnrc2222","https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fnrc2222",{"doi":1093},"10.1038\u002Fnrc2222",{"id":18,"text":1095,"url":1096,"identifiers":1097},"Menendez, 2004, Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2\u002Fneu (erbB-2) oncogene-induced malignant transformation, Mol. Carcinog., 41, 164, 10.1002\u002Fmc.20054","https:\u002F\u002Fdoi.org\u002F10.1002\u002Fmc.20054",{"mag":1098,"openalex":1099,"pm":1100,"doi":1101},"1972889113","W1972889113","15390078","10.1002\u002Fmc.20054",{"id":18,"text":1103,"url":18,"identifiers":1104},"Menendez, 2009, Int. J. Oncol., 34, 43",{},{"id":18,"text":1106,"url":1107,"identifiers":1108},"Mineno, 2006, The expression profile of microRNAs in mouse embryos, Nucleic Acids Res., 34, 1765, 10.1093\u002Fnar\u002Fgkl096","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fnar\u002Fgkl096",{"mag":1109,"pmc":1110,"openalex":1111,"pm":1112,"doi":1113},"2123159256","1421506","W2123159256","16582102","10.1093\u002Fnar\u002Fgkl096",{"id":18,"text":1115,"url":1116,"identifiers":1117},"Morel, 2008, Generation of breast cancer stem cells through epithelial–mesenchymal transition, PLoS One, 3, e2888, 10.1371\u002Fjournal.pone.0002888","https:\u002F\u002Fdoi.org\u002F10.1371\u002Fjournal.pone.0002888",{"mag":1118,"pmc":1119,"openalex":1120,"pm":1121,"doi":1122},"1985339653","2492808","W1985339653","18682804","10.1371\u002Fjournal.pone.0002888",{"id":18,"text":1124,"url":1125,"identifiers":1126},"Morgan, 2010, More patent protection for medicines with a new purpose, Nature, 465, 1005, 10.1038\u002F4651005b","https:\u002F\u002Fdoi.org\u002F10.1038\u002F4651005b",{"mag":1127,"openalex":1128,"pm":1129,"doi":1130},"1999619686","W1999619686","20577188","10.1038\u002F4651005b",{"id":18,"text":1132,"url":1133,"identifiers":1134},"Muggerud, 2010, Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer, Mol. Oncol., 4, 357, 10.1016\u002Fj.molonc.2010.06.007","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fs1359-6349(10)71592-5",{"mag":1135,"openalex":1136,"doi":1137},"2092132314","W2092132314","10.1016\u002Fs1359-6349(10)71592-5",{"id":18,"text":1139,"url":1140,"identifiers":1141},"Muthuswamy, 2001, ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini, Nat. Cell Biol., 3, 785, 10.1038\u002Fncb0901-785","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fncb0901-785",{"mag":1142,"pmc":1143,"openalex":1144,"pm":1145,"doi":1146},"2038653804","2952547","W2038653804","11533657","10.1038\u002Fncb0901-785",{"id":18,"text":1148,"url":1149,"identifiers":1150},"Negri, 2010, Chromosome band 17q21 in breast cancer: significant association between beclin 1 loss and HER2\u002FNEU amplification, Genes Chromosomes Cancer, 49, 901, 10.1002\u002Fgcc.20798","https:\u002F\u002Fdoi.org\u002F10.1002\u002Fgcc.20798",{"mag":1151,"openalex":1152,"pm":1153,"doi":1154},"2012089500","W2012089500","20589936","10.1002\u002Fgcc.20798",{"id":18,"text":1156,"url":1157,"identifiers":1158},"Ohashi, 2010, Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors, Cancer Res., 70, 4174, 10.1158\u002F0008-5472.CAN-09-4614","https:\u002F\u002Fdoi.org\u002F10.1158\u002F0008-5472.can-09-4614",{"mag":1159,"pmc":1160,"openalex":1161,"pm":1162,"doi":1163},"2045301073","3007622","W2045301073","20424117","10.1158\u002F0008-5472.can-09-4614",{"id":18,"text":1165,"url":1166,"identifiers":1167},"Oliveras-Ferraros, 2011, Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a, Cell Cycle, 10, 1144, 10.4161\u002Fcc.10.7.15210","http:\u002F\u002Fdx.doi.org\u002F10.4161\u002Fcc.10.7.15210",{"doi":1168},"10.4161\u002Fcc.10.7.15210",{"id":588,"text":1170,"url":590,"identifiers":1171},"O'Shaughnessy, 2002, Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development, Clin. Cancer Res., 8, 314",{"doi":592},{"id":18,"text":1173,"url":1174,"identifiers":1175},"Palacios, 2005, Lysosomal targeting of E-cadherin: a unique mechanism for the down-regulation of cell–cell adhesion during epithelial to mesenchymal transitions, Mol. Cell. Biol., 25, 389, 10.1128\u002FMCB.25.1.389-402.2005","https:\u002F\u002Fdoi.org\u002F10.1128\u002Fmcb.25.1.389-402.2005",{"mag":1176,"pmc":1177,"openalex":1178,"pm":1179,"doi":1180},"1984759958","538771","W1984759958","15601859","10.1128\u002Fmcb.25.1.389-402.2005",{"id":18,"text":1182,"url":1183,"identifiers":1184},"Park, 2007, Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2, Cell Cycle, 6, 2585, 10.4161\u002Fcc.6.21.4845","https:\u002F\u002Fdoi.org\u002F10.4161\u002Fcc.6.21.4845",{"mag":1185,"openalex":1186,"pm":1187,"doi":1188},"2067213721","W2067213721","17957144","10.4161\u002Fcc.6.21.4845",{"id":18,"text":1190,"url":1191,"identifiers":1192},"Peinado, 2008, A hypoxic twist in metastasis, Nat. Cell Biol., 10, 253, 10.1038\u002Fncb0308-253","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fncb0308-253",{"mag":1193,"openalex":1194,"pm":1195,"doi":1196},"1987486152","W1987486152","18311179","10.1038\u002Fncb0308-253",{"id":18,"text":1198,"url":1199,"identifiers":1200},"Peter, 2009, Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression, Cell Cycle, 8, 843, 10.4161\u002Fcc.8.6.7907","https:\u002F\u002Fdoi.org\u002F10.4161\u002Fcc.8.6.7907",{"mag":1201,"pmc":1202,"openalex":1203,"pm":1204,"doi":1205},"2059160575","2688687","W2059160575","19221491","10.4161\u002Fcc.8.6.7907",{"id":18,"text":1207,"url":1208,"identifiers":1209},"Pollak, 2008, Insulin and insulin-like growth factor signalling in neoplasia, Nat. Rev. Cancer, 8, 915, 10.1038\u002Fnrc2536","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnrc2536",{"mag":1210,"openalex":1211,"pm":1212,"doi":1213},"2089171551","W2089171551","19029956","10.1038\u002Fnrc2536",{"id":18,"text":1215,"url":18,"identifiers":1216},"Pollak, 2010, Metformin and other biguanides in oncology: advancing the research agenda, Cancer Prev. Res. (Phila), 3, 1060, 10.1158\u002F1940-6207.CAPR-10-0175",{"doi":1217},"10.1158\u002F1940-6207.CAPR-10-0175",{"id":18,"text":1219,"url":1220,"identifiers":1221},"Pollak, 2010, Insulin analogues and cancer risk: cause for concern or cause celebre?, Int. J. Clin. Pract., 64, 628, 10.1111\u002Fj.1742-1241.2010.02354.x","http:\u002F\u002Fdx.doi.org\u002F10.1111\u002Fj.1742-1241.2010.02354.x",{"doi":1222},"10.1111\u002Fj.1742-1241.2010.02354.x",{"id":1224,"text":1225,"url":1226,"identifiers":1227},"75f378a6-4665-456a-9ffc-f7fbd44bba55","Polyak, 2009, Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits, Nat. Rev. Cancer, 9, 265, 10.1038\u002Fnrc2620","https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fnrc2620",{"doi":1228},"10.1038\u002Fnrc2620",{"id":1230,"text":1231,"url":1232,"identifiers":1233},"f87186af-3aee-43b9-ad81-3488b56b4f2c","Qadir, 2008, Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization, Breast Cancer Res. Treatm., 112, 389, 10.1007\u002Fs10549-007-9873-4","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs10549-007-9873-4",{"doi":1234},"10.1007\u002Fs10549-007-9873-4",{"id":18,"text":1236,"url":1237,"identifiers":1238},"Reichert, 2003, Trends in development and approval times for new therapeutics in the United States, Nat. Rev. Drug Discov., 2, 695, 10.1038\u002Fnrd1178","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnrd1178",{"mag":1239,"openalex":1240,"pm":1241,"doi":1242},"1502809559","W1502809559","12951576","10.1038\u002Fnrd1178",{"id":18,"text":1244,"url":1245,"identifiers":1246},"Rice, 2009, Metformin inhibits aromatase via an extracellular signal-regulated kinase-mediated pathway, Endocrinology, 150, 4794, 10.1210\u002Fen.2009-0540","https:\u002F\u002Fdoi.org\u002F10.1210\u002Fen.2009-0540",{"mag":1247,"pmc":1248,"openalex":1249,"pm":1250,"doi":1251},"2090047695","2749730","W2090047695","19574398","10.1210\u002Fen.2009-0540",{"id":18,"text":1253,"url":1254,"identifiers":1255},"Rodier, 2011, Four faces of cellular senescence, J. Cell Biol., 192, 546, 10.1083\u002Fjcb.201009094","https:\u002F\u002Fdoi.org\u002F10.1083\u002Fjcb.201009094",{"mag":1256,"pmc":1257,"openalex":1258,"pm":1259,"doi":1260},"2077450385","3044123","W2077450385","21321098","10.1083\u002Fjcb.201009094",{"id":588,"text":1262,"url":590,"identifiers":1263},"Roninson, 2003, Tumor cell senescence in cancer treatment, Cancer Res., 63, 2705",{"doi":592},{"id":18,"text":1265,"url":1266,"identifiers":1267},"Rubinsztein, 2007, Potential therapeutic applications of autophagy, Nat. Rev. Drug Discov., 6, 304, 10.1038\u002Fnrd2272","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnrd2272",{"mag":1268,"openalex":1269,"pm":1270,"doi":1271},"1991075835","W1991075835","17396135","10.1038\u002Fnrd2272",{"id":18,"text":1273,"url":1274,"identifiers":1275},"Samaddar, 2008, A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance, Mol. Cancer Ther., 7, 2977, 10.1158\u002F1535-7163.MCT-08-0447","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1535-7163.mct-08-0447",{"mag":1276,"openalex":1277,"pm":1278,"doi":1279},"2136929919","W2136929919","18790778","10.1158\u002F1535-7163.mct-08-0447",{"id":1281,"text":1282,"url":1283,"identifiers":1284},"e7c45e61-7b32-4624-8a15-b9c3c8a9cb7e","Samari, 1998, Inhibition of hepatocytic autophagy by adenosine, aminoimidazole-4-carboxamide riboside, and N6-mercaptopurine riboside. Evidence for involvement of amp-activated protein kinase, J. Biol. Chem., 273, 23758, 10.1074\u002Fjbc.273.37.23758","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0021925819602024",{"doi":1285},"10.1074\u002Fjbc.273.37.23758",{"id":1287,"text":1288,"url":1289,"identifiers":1290},"94d3462a-edc8-449c-861c-86a75873f7c9","Savarese, 2006, Normal breast stem cells, malignant breast stem cells, and the perinatal origin of breast cancer, Stem Cell Rev., 2, 103, 10.1007\u002Fs12015-006-0016-9","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs12015-006-0016-9",{"doi":1291},"10.1007\u002Fs12015-006-0016-9",{"id":18,"text":1293,"url":1294,"identifiers":1295},"Schoenlein, 2009, Autophagy facilitates the progression of ERalpha-positive breast cancer cells to antiestrogen resistance, Autophagy, 5, 400, 10.4161\u002Fauto.5.3.7784","http:\u002F\u002Fdx.doi.org\u002F10.4161\u002Fauto.5.3.7784",{"doi":1296},"10.4161\u002Fauto.5.3.7784",{"id":18,"text":1298,"url":18,"identifiers":1299},"Serrano, 2010, Cancer: a lower bar for senescence, Nature, 464, 363, 10.1038\u002F464363a",{"doi":1300},"10.1038\u002F464363a",{"id":18,"text":1302,"url":1303,"identifiers":1304},"Shell, 2007, Let-7 expression defines two differentiation stages of cancer, Proc. Natl. Acad. Sci. U.S.A., 104, 11400, 10.1073\u002Fpnas.0704372104","https:\u002F\u002Fdoi.org\u002F10.1073\u002Fpnas.0704372104",{"mag":1305,"pmc":1306,"openalex":1307,"pm":1308,"doi":1309},"1973816411","2040910","W1973816411","17600087","10.1073\u002Fpnas.0704372104",{"id":18,"text":1311,"url":1312,"identifiers":1313},"Shiota, 2008, Twist and p53 reciprocally regulate target genes via direct interaction, Oncogene, 27, 5543, 10.1038\u002Fonc.2008.176","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fonc.2008.176",{"mag":1314,"openalex":1315,"pm":1316,"doi":1317},"2086517441","W2086517441","18504427","10.1038\u002Fonc.2008.176",{"id":1319,"text":1320,"url":1321,"identifiers":1322},"f28d724c-708a-49ff-9214-b26b692e6fae","Simpson, 2007, In situ carcinoma—can we predict which patient will come back with a recurrence?, Cancer Cell, 12, 409, 10.1016\u002Fj.ccr.2007.10.026","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1535610807003054",{"doi":1323},"10.1016\u002Fj.ccr.2007.10.026",{"id":18,"text":1325,"url":1326,"identifiers":1327},"Singh, 2010, EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer, Oncogene, 29, 4741, 10.1038\u002Fonc.2010.215","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fonc.2010.215",{"mag":1328,"pmc":1329,"openalex":1330,"pm":1331,"doi":1332},"2028593825","3176718","W2028593825","20531305","10.1038\u002Fonc.2010.215",{"id":1334,"text":1335,"url":1336,"identifiers":1337},"14e63a22-4317-4a27-bc00-444a5484416e","Smit, 2008, Deregulating EMT and senescence: double impact by a single twist, Cancer Cell, 14, 5, 10.1016\u002Fj.ccr.2008.06.012","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1535610808001992",{"doi":1338},"10.1016\u002Fj.ccr.2008.06.012",{"id":18,"text":1340,"url":1341,"identifiers":1342},"Smit, 2010, Epithelial–mesenchymal transition and senescence: two cancer-related processes are crossing paths, Aging (Albany, NY), 2, 735, 10.18632\u002Faging.100209","https:\u002F\u002Fdoi.org\u002F10.18632\u002Faging.100209",{"mag":1343,"pmc":1344,"openalex":1345,"pm":1346,"doi":1347},"2163898661","2993803","W2163898661","20975209","10.18632\u002Faging.100209",{"id":1349,"text":1350,"url":1351,"identifiers":1352},"801702c4-0cd6-441e-99ab-e4a4fb199698","Smith, 2009, Does diabetes therapy influence the risk of cancer?, Diabetologia, 52, 1699, 10.1007\u002Fs00125-009-1441-5","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs00125-009-1441-5",{"doi":1353},"10.1007\u002Fs00125-009-1441-5",{"id":18,"text":1355,"url":18,"identifiers":1356},"Stoll, 2000, Biological mechanisms in breast cancer invasiveness: relevance to preventive interventions, Eur. J. Cancer Prev., 9, 73, 10.1097\u002F00008469-200004000-00002",{"doi":1357},"10.1097\u002F00008469-200004000-00002",{"id":18,"text":1359,"url":1360,"identifiers":1361},"Stoll, 2002, Oestrogen\u002Finsulin-like growth factor-I receptor interaction in early breast cancer: clinical implications, Ann. Oncol., 13, 191, 10.1093\u002Fannonc\u002Fmdf059","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fannonc\u002Fmdf059",{"mag":1362,"openalex":1363,"pm":1364,"doi":1365},"2117663055","W2117663055","11885994","10.1093\u002Fannonc\u002Fmdf059",{"id":18,"text":1367,"url":1368,"identifiers":1369},"Swinnen, 2005, Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype, Cancer Res., 65, 2441, 10.1158\u002F0008-5472.CAN-04-3025","https:\u002F\u002Fdoi.org\u002F10.1158\u002F0008-5472.can-04-3025",{"mag":1370,"openalex":1371,"pm":1372,"doi":1373},"2151510581","W2151510581","15781660","10.1158\u002F0008-5472.can-04-3025",{"id":1375,"text":1376,"url":1377,"identifiers":1378},"39f25ab7-e7ed-4a66-a6b1-abc9100505fe","Tan, 2009, Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?, Breast Cancer Res. Treatm., 115, 453, 10.1007\u002Fs10549-008-0184-1","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs10549-008-0184-1",{"doi":1379},"10.1007\u002Fs10549-008-0184-1",{"id":1381,"text":1382,"url":1383,"identifiers":1384},"559bce2c-7082-43e2-abe8-3db0e1e4e49f","Taylor, 2010, The pathophysiology of epithelial–mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells, J. Mammary Gland Biol. Neoplasia, 15, 169, 10.1007\u002Fs10911-010-9181-1","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs10911-010-9181-1",{"doi":1385},"10.1007\u002Fs10911-010-9181-1",{"id":18,"text":1387,"url":18,"identifiers":1388},"Tracy, 2007, BNIP3 is an RB\u002FE2F target gene required for hypoxia-induced autophagy, Mol. Cell. Biol., 27, 6229, 10.1128\u002FMCB.02246-06",{"doi":1389},"10.1128\u002FMCB.02246-06",{"id":18,"text":1391,"url":1392,"identifiers":1393},"Tsai, 2011, Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST, Blood, 117, 459, 10.1182\u002Fblood-2010-05-287508","https:\u002F\u002Fdoi.org\u002F10.1182\u002Fblood-2010-05-287508",{"mag":1394,"openalex":1395,"pm":1396,"doi":1397},"2069641472","W2069641472","20952688","10.1182\u002Fblood-2010-05-287508",{"id":588,"text":1399,"url":590,"identifiers":1400},"Vazquez-Martin, 2011, Expression status of the autophagy-regulatory gene ATG6\u002FBECN1 in ERBB2-positive breast carcinomas: bypassing ERBB2-induced oncogenic senescence to regulate the efficacy of ERBB2-targeted therapies, Genes Chromosomes Cancer, 50, 284",{"doi":592},{"id":1402,"text":1403,"url":1404,"identifiers":1405},"302cddc7-58d3-4491-b02c-ac9ddbd14a0c","Vazquez-Martin, 2011, The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells, Breast Cancer Res. Treatm., 126, 355, 10.1007\u002Fs10549-010-0924-x","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs10549-010-0924-x",{"doi":1406},"10.1007\u002Fs10549-010-0924-x",{"id":588,"text":1408,"url":590,"identifiers":1409},"Vazquez-Martin, 2011, The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells, Oncol. Rep., 25, 135",{"doi":592},{"id":1411,"text":1412,"url":1413,"identifiers":1414},"9767106d-5455-46aa-ae08-1a04175c06ed","Vazquez-Martin, 2010, Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial–mesenchymal transition (EMT) status, Cell Cycle, 9, 3807, 10.4161\u002Fcc.9.18.13131","http:\u002F\u002Fwww.tandfonline.com\u002Fdoi\u002Fabs\u002F10.4161\u002Fcc.9.18.13131",{"doi":1415},"10.4161\u002Fcc.9.18.13131",{"id":18,"text":1417,"url":1418,"identifiers":1419},"Vazquez-Martin, 2010, Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells, Curr. Mol. Med., 10, 674, 10.2174\u002F156652410792630625","https:\u002F\u002Fdoi.org\u002F10.2174\u002F156652410792630625",{"mag":1420,"openalex":1421,"pm":1422,"doi":1423},"2073722741","W2073722741","20712585","10.2174\u002F156652410792630625",{"id":18,"text":1425,"url":1426,"identifiers":1427},"Vazquez-Martin, 2009, The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells, Cell Cycle, 8, 88, 10.4161\u002Fcc.8.1.7499","https:\u002F\u002Fdoi.org\u002F10.4161\u002Fcc.8.1.7499",{"mag":1428,"openalex":1429,"pm":1430,"doi":1431},"1974130263","W1974130263","19106626","10.4161\u002Fcc.8.1.7499",{"id":18,"text":1433,"url":1434,"identifiers":1435},"Vazquez-Martin, 2009, Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab, PLoS One, 4, e6251, 10.1371\u002Fjournal.pone.0006251","https:\u002F\u002Fdoi.org\u002F10.1371\u002Fjournal.pone.0006251",{"mag":1436,"pmc":1437,"openalex":1438,"pm":1439,"doi":1440},"1972612572","2708925","W1972612572","19606230","10.1371\u002Fjournal.pone.0006251",{"id":1442,"text":1443,"url":1444,"identifiers":1445},"afb65866-72cc-4ea2-ab69-ffc5e27a3897","Vogelstein, 2004, Cancer genes and the pathways they control, Nat. Med., 10, 789, 10.1038\u002Fnm1087","https:\u002F\u002Fwww.nature.com\u002Farticles\u002Fnm1087",{"doi":1446},"10.1038\u002Fnm1087",{"id":1448,"text":1449,"url":1450,"identifiers":1451},"3e519523-7bad-4f86-9d7b-587a0c9b0c5f","Wang, 2010, Increasing CD44+\u002FCD24(−) tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis, Mol. Cancer, 9, 288, 10.1186\u002F1476-4598-9-288","https:\u002F\u002Fmolecular-cancer.biomedcentral.com\u002Farticles\u002F10.1186\u002F1476-4598-9-288",{"doi":1452},"10.1186\u002F1476-4598-9-288",{"id":588,"text":1454,"url":590,"identifiers":1455},"Wang, 2010, Transforming growth factor-beta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM, Oncogene, 30, 1470, 10.1038\u002Fonc.2010.531",{"doi":592},{"id":18,"text":1457,"url":1458,"identifiers":1459},"Wang, 2010, Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance, Drug Resist. Updat., 13, 109, 10.1016\u002Fj.drup.2010.07.001","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.drup.2010.07.001",{"mag":1460,"pmc":1461,"openalex":1462,"pm":1463,"doi":1464},"2078810029","2956795","W2078810029","20692200","10.1016\u002Fj.drup.2010.07.001",{"id":1466,"text":1467,"url":1468,"identifiers":1469},"1be8c5a4-d12b-4f9d-96d3-f1ae226ceefd","Weinberg, 1995, The retinoblastoma protein and cell cycle control, Cell, 81, 323, 10.1016\u002F0092-8674(95)90385-2","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002F0092867495903852",{"doi":1470},"10.1016\u002F0092-8674(95)90385-2",{"id":18,"text":1472,"url":1473,"identifiers":1474},"Weinberg, 2008, Twisted epithelial–mesenchymal transition blocks senescence, Nat. Cell Biol., 10, 1021, 10.1038\u002Fncb0908-1021","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fncb0908-1021",{"mag":1475,"openalex":1476,"pm":1477,"doi":1478},"2062823751","W2062823751","18758491","10.1038\u002Fncb0908-1021",{"id":18,"text":1480,"url":1481,"identifiers":1482},"Welch, 1997, Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: how much more breast cancer can we find?, Ann. Intern. Med., 127, 1023, 10.7326\u002F0003-4819-127-11-199712010-00014","https:\u002F\u002Fdoi.org\u002F10.7326\u002F0003-4819-127-11-199712010-00014",{"mag":1483,"openalex":1484,"pm":1485,"doi":1486},"2096166071","W2096166071","9412284","10.7326\u002F0003-4819-127-11-199712010-00014",{"id":18,"text":1488,"url":1489,"identifiers":1490},"Yang, 2010, Bmi1 is essential in Twist1-induced epithelial–mesenchymal transition, Nat. Cell Biol., 12, 982, 10.1038\u002Fncb2099","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fncb2099",{"mag":1491,"openalex":1492,"pm":1493,"doi":1494},"2076375511","W2076375511","20818389","10.1038\u002Fncb2099",{"id":18,"text":1496,"url":1497,"identifiers":1498},"Yang, 2008, Direct regulation of TWIST by HIF-1alpha promotes metastasis, Nat. Cell Biol., 10, 295, 10.1038\u002Fncb1691","http:\u002F\u002Fdx.doi.org\u002F10.1038\u002Fncb1691",{"doi":1499},"10.1038\u002Fncb1691",{"id":18,"text":1501,"url":1502,"identifiers":1503},"Yang, 2008, TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development, Cell Cycle, 7, 2090, 10.4161\u002Fcc.7.14.6324","https:\u002F\u002Fdoi.org\u002F10.4161\u002Fcc.7.14.6324",{"mag":1504,"openalex":1505,"pm":1506,"doi":1507},"2025486904","W2025486904","18635960","10.4161\u002Fcc.7.14.6324",{"id":1509,"text":1510,"url":1511,"identifiers":1512},"edd68bf4-d0a7-4b00-8711-ae928e98acd1","Young, 2010, Connecting autophagy to senescence in pathophysiology, Curr. Opin. Cell Biol., 22, 234, 10.1016\u002Fj.ceb.2009.12.005","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0955067409002348",{"doi":1513},"10.1016\u002Fj.ceb.2009.12.005",{"id":1515,"text":1516,"url":1517,"identifiers":1518},"b3b3c0bf-54ad-4255-a0b8-a3e7de33ccfc","Yu, 2007, let-7 regulates self renewal and tumorigenicity of breast cancer cells, Cell, 131, 1109, 10.1016\u002Fj.cell.2007.10.054","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0092867407014171",{"doi":1519},"10.1016\u002Fj.cell.2007.10.054",{"id":18,"text":1521,"url":1522,"identifiers":1523},"Zakikhani, 2006, Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells, Cancer Res., 66, 10269, 10.1158\u002F0008-5472.CAN-06-1500","https:\u002F\u002Fdoi.org\u002F10.1158\u002F0008-5472.can-06-1500",{"mag":1524,"openalex":1525,"pm":1526,"doi":1527},"2078190084","W2078190084","17062558","10.1158\u002F0008-5472.can-06-1500",{"id":18,"text":1529,"url":1530,"identifiers":1531},"Zheng, 2004, Regulation of cellular senescence and p16(INK4a) expression by Id1 and E47 proteins in human diploid fibroblast, J. Biol. Chem., 279, 31524, 10.1074\u002Fjbc.M400365200","http:\u002F\u002Fdx.doi.org\u002F10.1074\u002Fjbc.m400365200",{"doi":1532},"10.1074\u002Fjbc.m400365200",{"id":18,"text":1534,"url":1535,"identifiers":1536},"Zhou, 2001, Role of AMP-activated protein kinase in mechanism of metformin action, J. Clin. Invest., 108, 1167, 10.1172\u002FJCI13505","https:\u002F\u002Fdoi.org\u002F10.1172\u002Fjci13505",{"mag":1537,"pmc":1538,"openalex":1539,"pm":1540,"doi":1541},"2138226825","209533","W2138226825","11602624","10.1172\u002Fjci13505",{"id":1543,"text":1544,"url":1545,"identifiers":1546},"2c0ce816-3f37-4a85-ab67-3cb1c8348a00","Zhuang, 2008, Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1, J. Mol. Signal., 3, 18, 10.1186\u002F1750-2187-3-18","http:\u002F\u002Fwww.jmolecularsignaling.com\u002Farticles\u002F10.1186\u002F1750-2187-3-18\u002F",{"doi":1547},"10.1186\u002F1750-2187-3-18",false,{"id":1550,"createTime":1551,"updateTime":1552,"relativeEntities":1553,"slug":1554,"properties":1555,"entityType":115,"verifyStatus":116,"verifyTime":1564,"verifyNote":118,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1565,"fullTextUrl":18,"authors":1566,"publicationType":279,"publisherRelationship":1584,"citationCount":19,"citationInfo":1637,"publishDate":1640,"publishYear":1638,"citationAnalyzeStatus":17,"lastCitationAnalyze":1641,"indexDatabases":1642,"openAccess":18,"references":18,"isForceReanalyzing":1548},"ad675d71-2bc1-48c4-8110-4e5dd2f9f239","2023-12-25T11:59:40.219+00:00","2026-07-13T12:09:23.118+00:00",[],"Cyclin-dependent-kinases-inhibitors-as-potential-anticancer-antineurodegenerative-antiviral-and-antiparasitic-agents",{"title":1556,"gsPaper":1558,"references":1560,"doi":1562},{"EN":1557},"Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents",{"VOID":1559},"[\"690299095552107343\"]",{"VOID":1561},"Morgan, 1997, Cyclin-dependent kinases: engines, clocks, and microprocessors, Annu Rev Cell Dev Biol, 13, 261, 10.1146\u002Fannurev.cellbio.13.1.261\nVogt, 1998, Cyclin dependent kinase (CDK) inhibitors, Current topics in microbiology and immunology.\nPavletich, 1999, Mechanisms of cyclin-dependent kinase regulation: structures of cdks, their cyclin activators, and Cip and INK4 inhibitors, J Mol Biol, 287, 821, 10.1006\u002Fjmbi.1999.2640\n2000\nMeyerson, 1992, A family of human cdc2-related protein kinases, EMBO J, 11, 2909, 10.1002\u002Fj.1460-2075.1992.tb05360.x\nPlowman, 1999, The protein kinases of Caenorhabditis elegans: a model for signal transduction in multicellular organisms, Proc Natl Acad Sci USA, 96, 13603, 10.1073\u002Fpnas.96.24.13603\nMandelkow, 1999, The tangled tale of tau, Nature, 402, 588, 10.1038\u002F45095\nPatrick, 1999, Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration, Nature, 402, 615, 10.1038\u002F45159\nBibb, 1999, Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signaling in neurons, Nature, 402, 669, 10.1038\u002F45251\nGil-Gomez, 1998, A link between cell cycle and cell death: Bax and Bcl-2 modulate cdk2 activation during thymocyte apoptosis, EMBO J, 17, 7209, 10.1093\u002Femboj\u002F17.24.7209\nHakem, 1999, The cyclin-dependent kinase cdk2 regulates thymocyte apoptosis, J Exp Med, 6, 957, 10.1084\u002Fjem.189.6.957\nZhou, 1998, Caspase-dependent activation of cyclin-dependent kinases during Fas-induced apoptosis in Jurkat cells, Proc Natl Acad Sci USA, 95, 6785, 10.1073\u002Fpnas.95.12.6785\nHarvey, 2000, Caspase-dependent cdk activity is a requisite effector of apoptotic death events, J Cell Sci, 148, 59, 10.1083\u002Fjcb.148.1.59\nGuo, 1999, Cell proliferation and apoptosis, Curr Opin Cell Biol, 11, 745, 10.1016\u002FS0955-0674(99)00046-0\nMeijer, 1996, Chemical inhibitors of cyclin-dependent kinases, Trends in Cell Biol, 6, 393, 10.1016\u002F0962-8924(96)10034-9\nMeijer, 1997, Chemical inhibitors of cyclin-dependent kinases, Methods Enzymol, 283, 113, 10.1016\u002FS0076-6879(97)83011-X\nGarrett, 1999, Cyclin-dependent kinase inhibition and cancer therapy, Curr Opin Genet & Dev, 9, 104, 10.1016\u002FS0959-437X(99)80015-X\nGray, 1999, ATP-site directed inhibitors of cyclin-dependent kinases, Curr Med Chem, 6, 859\nMeijer, 1999, Properties and potential applications of chemical inhibitors of cyclin-dependent kinases, Pharmacol & Ther, 82, 279, 10.1016\u002FS0163-7258(98)00057-6\nSielecki, 2000, Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation, J Med Chem, 43, 1, 10.1021\u002Fjm990256j\nVesely, 1994, Inhibition of cyclin-dependent kinases by purine derivatives, Eur J Biochem, 224, 771, 10.1111\u002Fj.1432-1033.1994.00771.x\nMeijer, 1997, Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5, Eur J Biochem, 243, 527, 10.1111\u002Fj.1432-1033.1997.t01-2-00527.x\nde Azevedo, 1997, Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine, Eur J Biochem, 243, 518, 10.1111\u002Fj.1432-1033.1997.0518a.x\nGray, 1998, Exploiting chemical libraries, structure, and genomics in the search for new kinase inhibitors, Science, 281, 533, 10.1126\u002Fscience.281.5376.533\nChang, 1999, Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors, Chem & Biol, 6, 361, 10.1016\u002FS1074-5521(99)80048-9\nBrooks, 1997, CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation, J Biol Chem, 272, 29207, 10.1074\u002Fjbc.272.46.29207\nPark, 1996, A specific inhibitor of cyclin-dependent protein kinases, CDC2 and CDK2, Mol Cell, 6, 679\nSedlacek, 1996, Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy, Internat J Oncol, 9, 1143\nZimmermann, J. Pharmacologically active pyrimidine derivatives and processes for the preparation thereof. PCT Ciba-Geigy, 1995, WO 95\u002F09853.\nHoessel, 1999, Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases, Nature Cell Biol, 1, 60\nSchultz, 1999, The paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1\u002Fcyclin B inhibition, and in vitro antitumor activity, J Med Chem, 42, 2909, 10.1021\u002Fjm9900570\nZaharevitz, 1999, Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases, Cancer Res, 59, 2566\nKitagawa, 1993, Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase, Oncogene, 8, 2425\nMeijer, 2000, Inhibition of cyclin-dependent kinases, GSK-3β and casein kinase 1 by hymenialdisine, a marine sponge constituent, Chem & Biol, 7, 51, 10.1016\u002FS1074-5521(00)00063-6\nRialet, 1991, A new screening test for antimitotic compounds using the universal M phase-specific protein kinase, p34cdc2\u002Fcyclin Bcdc13, affinity-immobilized on p13suc1-coated microtitration plates, Anticancer Res, 11, 1581\nRosania, 1999, A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification usingXenopus egg extracts, Proc Natl Acad Sci USA, 96, 4797, 10.1073\u002Fpnas.96.9.4797\nKnockaert, 2000, Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised ligants, Chem & Biol, 10.1016\u002FS1074-5521(00)00124-1\nNurse, 1981, Gene required in G1 for commitment to cell cycle and in G2 for control of mitosis in fission yeast, Nature, 292, 558, 10.1038\u002F292558a0\nLee, 1987, Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2, Nature, 237, 31, 10.1038\u002F327031a0\nSenderowicz, 1998, Phase I trial of continuous infusion flavopiridol, a novel cylin-dependent kinase inhibitor in patients with refractory neoplasms, Clin Oncol, 16, 2986, 10.1200\u002FJCO.1998.16.9.2986\nHooijberg, 1999, Potent interaction of flavopiridol with MRP1, Br J Cancer, 81, 269, 10.1038\u002Fsj.bjc.6690687\nBresnahan, 1997, Inhibition of cellular cdk2 activity blocks human cytomegalovirus replication, Virology, 231, 239\nSchang, 1998, Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription, J. Virol, 72, 5626, 10.1128\u002FJVI.72.7.5626-5637.1998\nYe, 1999, Varicella-zoster virus Fc receptor component gI is phosphorylated on its endodomain by a cyclin-dependent kinase, J Virol, 73, 1320, 10.1128\u002FJVI.73.2.1320-1330.1999\nKappes, 1999, An overview of Plasmodium protein kinases, Parasitology Today, 15, 449, 10.1016\u002FS0169-4758(99)01527-6",{"VOID":1563},"10.1054\u002Fdrup.2000.0129","2024-06-24T12:03:49.901+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1368764600901298",[1567],{"id":1568,"sortIndex":19,"researcher":18,"roles":1569,"affiliations":1570,"properties":1579,"displayName":1581,"givenName":18,"familyName":18},"b255d604-fb9a-4aad-b8f3-30323e11280b",[124],[1571],{"id":1572,"sortIndex":19,"affiliation":1573,"properties":18},"059d9a16-ccb6-44a6-b67c-2a47fb377422",{"id":1572,"createTime":18,"updateTime":18,"relativeEntities":1574,"slug":18,"properties":1575,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1578,"statistic":18},[],{"title":1576},{"VI":1577},"Station Biologique de Roscoff, CNRS UPR, Roscoff cedex, Bretagne, France",[],{"title":1580,"gsAuthor":1582},{"VI":1581},"Laurent Meijer",{"VOID":1583},"[\"WTSm2TQAAAAJ\"]",{"url":1565,"publisher":1585,"properties":1632},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1586,"slug":10,"properties":1587,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1590,"manageAffiliations":1611,"indexDatabases":1617,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1588,"title":1589},{"VOID":13},{"EN":15},[1591,1595,1599,1603,1607],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":1592,"label":1593,"description":1594,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":1596,"label":1597,"description":1598,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":31},{},{"id":34,"createTime":18,"updateTime":18,"relativeEntities":1600,"label":1601,"description":1602,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":37},{},{"id":40,"createTime":18,"updateTime":18,"relativeEntities":1604,"label":1605,"description":1606,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":43},{},{"id":46,"createTime":18,"updateTime":18,"relativeEntities":1608,"label":1609,"description":1610,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":49},{},[1612],{"id":53,"createTime":18,"updateTime":18,"relativeEntities":1613,"slug":18,"properties":1614,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1616,"statistic":18},[],{"title":1615},{"EN":57},[],[1618,1625],{"id":61,"indexDatabase":1619,"url":74,"indexYears":18,"academicFieldIds":1624,"indexDatabaseRanking":18},{"id":63,"createTime":18,"updateTime":18,"relativeEntities":1620,"label":1621,"description":1622,"key":70,"publicationTags":1623,"standard":18},[],{"EN":66,"VI":66},{"EN":68,"VI":69},[72,73],[76],{"id":78,"indexDatabase":1626,"url":89,"indexYears":90,"academicFieldIds":1631,"indexDatabaseRanking":97},{"id":80,"createTime":18,"updateTime":18,"relativeEntities":1627,"label":1628,"description":1629,"key":86,"publicationTags":1630,"standard":18},[],{"EN":83,"VI":83},{"EN":83,"VI":85},[88],[92,93,94,95,96],{"pages":1633,"volume":1635},{"VOID":1634},"83-88",{"VOID":1636},"3",{"total":19,"publishYear":1638,"statisticByYear":1639},2000,{},"2000-04-01","2026-07-13T12:09:23.117+00:00",[72,97],{"id":1644,"createTime":1645,"updateTime":1646,"relativeEntities":1647,"slug":1648,"properties":1649,"entityType":115,"verifyStatus":116,"verifyTime":1656,"verifyNote":118,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1657,"fullTextUrl":18,"authors":1658,"publicationType":279,"publisherRelationship":1817,"citationCount":1870,"citationInfo":1871,"publishDate":1876,"publishYear":1872,"citationAnalyzeStatus":17,"lastCitationAnalyze":1877,"indexDatabases":1878,"openAccess":18,"references":1879,"isForceReanalyzing":1548},"4f68c38b-0108-4191-8019-81dc70e99b4e","2024-01-16T18:32:22.398+00:00","2026-04-29T18:33:40.494+00:00",[],"Characterization-difference-of-typical-KL1-KL2-and-ST11-KL64-hypervirulent-and-carbapenem-resistant-Klebsiella-pneumoniae",{"title":1650,"gsPaper":1652,"doi":1654},{"EN":1651},"Characterization difference of typical KL1, KL2 and ST11-KL64 hypervirulent and carbapenem-resistant Klebsiella pneumoniae",{"VOID":1653},"[\"10460672707700573711\"]",{"VOID":1655},"10.1016\u002Fj.drup.2023.100918","2024-04-27T00:38:40.895+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1368764623000018",[1659,1674,1689,1702,1715,1728,1741,1754,1768,1781,1794],{"id":1660,"sortIndex":19,"researcher":18,"roles":1661,"affiliations":1662,"properties":1671,"displayName":1673,"givenName":18,"familyName":18},"09d9e5b2-74b1-4ba6-b0df-6f861369c610",[124],[1663],{"id":1664,"sortIndex":19,"affiliation":1665,"properties":18},"34b21fe8-3cf3-45c0-ac5e-82b02980acde",{"id":1664,"createTime":18,"updateTime":18,"relativeEntities":1666,"slug":18,"properties":1667,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1670,"statistic":18},[],{"title":1668},{"VI":1669},"Department of Clinical Laboratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200082, People’s Republic of China",[],{"title":1672},{"VI":1673},"Ying Zhou",{"id":1675,"sortIndex":136,"researcher":18,"roles":1676,"affiliations":1677,"properties":1686,"displayName":1688,"givenName":18,"familyName":18},"13b6f561-9e2c-4949-aec8-eb50426eac5e",[124],[1678],{"id":1679,"sortIndex":19,"affiliation":1680,"properties":18},"54c988bf-9184-409c-bf23-9834723be163",{"id":1679,"createTime":18,"updateTime":18,"relativeEntities":1681,"slug":18,"properties":1682,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1685,"statistic":18},[],{"title":1683},{"VI":1684},"Department of Respiratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, People’s Republic of China",[],{"title":1687},{"VI":1688},"Chunyang Wu",{"id":1690,"sortIndex":172,"researcher":18,"roles":1691,"affiliations":1692,"properties":1699,"displayName":1701,"givenName":18,"familyName":18},"baf7a8f7-0a71-4e4a-9435-c479985ced85",[124],[1693],{"id":1664,"sortIndex":19,"affiliation":1694,"properties":18},{"id":1664,"createTime":18,"updateTime":18,"relativeEntities":1695,"slug":18,"properties":1696,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1698,"statistic":18},[],{"title":1697},{"VI":1669},[],{"title":1700},{"VI":1701},"Bingjie Wang",{"id":1703,"sortIndex":193,"researcher":18,"roles":1704,"affiliations":1705,"properties":1712,"displayName":1714,"givenName":18,"familyName":18},"8ee45db3-fd1d-4e25-8dfe-d40a599ddcc3",[124],[1706],{"id":1664,"sortIndex":19,"affiliation":1707,"properties":18},{"id":1664,"createTime":18,"updateTime":18,"relativeEntities":1708,"slug":18,"properties":1709,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1711,"statistic":18},[],{"title":1710},{"VI":1669},[],{"title":1713},{"VI":1714},"YanLei Xu",{"id":1716,"sortIndex":214,"researcher":18,"roles":1717,"affiliations":1718,"properties":1725,"displayName":1727,"givenName":18,"familyName":18},"1a9e4f04-4bb1-439d-9e3f-858bde972084",[124],[1719],{"id":1664,"sortIndex":19,"affiliation":1720,"properties":18},{"id":1664,"createTime":18,"updateTime":18,"relativeEntities":1721,"slug":18,"properties":1722,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1724,"statistic":18},[],{"title":1723},{"VI":1669},[],{"title":1726},{"VI":1727},"Huilin Zhao",{"id":1729,"sortIndex":237,"researcher":18,"roles":1730,"affiliations":1731,"properties":1738,"displayName":1740,"givenName":18,"familyName":18},"d39ad1fb-5fd8-49d7-8ee4-6e2b4b09aace",[124],[1732],{"id":1664,"sortIndex":19,"affiliation":1733,"properties":18},{"id":1664,"createTime":18,"updateTime":18,"relativeEntities":1734,"slug":18,"properties":1735,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1737,"statistic":18},[],{"title":1736},{"VI":1669},[],{"title":1739},{"VI":1740},"Yinjuan Guo",{"id":1742,"sortIndex":260,"researcher":18,"roles":1743,"affiliations":1744,"properties":1751,"displayName":1753,"givenName":18,"familyName":18},"677d02ff-4c59-4849-af89-962cda65a8f6",[124],[1745],{"id":1664,"sortIndex":19,"affiliation":1746,"properties":18},{"id":1664,"createTime":18,"updateTime":18,"relativeEntities":1747,"slug":18,"properties":1748,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1750,"statistic":18},[],{"title":1749},{"VI":1669},[],{"title":1752},{"VI":1753},"Xiaocui Wu",{"id":1755,"sortIndex":1756,"researcher":18,"roles":1757,"affiliations":1758,"properties":1765,"displayName":1767,"givenName":18,"familyName":18},"09b62e10-4cba-41cf-a04b-6855495e9a78",7,[124],[1759],{"id":1664,"sortIndex":19,"affiliation":1760,"properties":18},{"id":1664,"createTime":18,"updateTime":18,"relativeEntities":1761,"slug":18,"properties":1762,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1764,"statistic":18},[],{"title":1763},{"VI":1669},[],{"title":1766},{"VI":1767},"Jingyi Yu",{"id":1769,"sortIndex":337,"researcher":18,"roles":1770,"affiliations":1771,"properties":1778,"displayName":1780,"givenName":18,"familyName":18},"790b2645-f4d3-4599-b9d2-e809a55319fb",[124],[1772],{"id":1664,"sortIndex":19,"affiliation":1773,"properties":18},{"id":1664,"createTime":18,"updateTime":18,"relativeEntities":1774,"slug":18,"properties":1775,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1777,"statistic":18},[],{"title":1776},{"VI":1669},[],{"title":1779},{"VI":1780},"Lulin Rao",{"id":1782,"sortIndex":341,"researcher":18,"roles":1783,"affiliations":1784,"properties":1791,"displayName":1793,"givenName":18,"familyName":18},"b2a4182d-fc95-4b30-ba8c-737f2d1b99ce",[124],[1785],{"id":1664,"sortIndex":19,"affiliation":1786,"properties":18},{"id":1664,"createTime":18,"updateTime":18,"relativeEntities":1787,"slug":18,"properties":1788,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1790,"statistic":18},[],{"title":1789},{"VI":1669},[],{"title":1792},{"VI":1793},"Xinyi Wang",{"id":1795,"sortIndex":1796,"researcher":18,"roles":1797,"affiliations":1798,"properties":1814,"displayName":1816,"givenName":18,"familyName":18},"d58ab382-2d33-4dbb-bda2-babae5fbf20a",10,[124],[1799,1805],{"id":1664,"sortIndex":19,"affiliation":1800,"properties":18},{"id":1664,"createTime":18,"updateTime":18,"relativeEntities":1801,"slug":18,"properties":1802,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1804,"statistic":18},[],{"title":1803},{"VI":1669},[],{"id":1806,"sortIndex":136,"affiliation":1807,"properties":1813},"b808ecc0-be7f-457d-816b-bcaefb74f9c3",{"id":1806,"createTime":18,"updateTime":18,"relativeEntities":1808,"slug":18,"properties":1809,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1812,"statistic":18},[],{"title":1810},{"EN":1811},"Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People’s Republic of China",[],{},{"title":1815},{"VI":1816},"Fangyou Yu",{"url":1657,"publisher":1818,"properties":1865},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1819,"slug":10,"properties":1820,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1823,"manageAffiliations":1844,"indexDatabases":1850,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1821,"title":1822},{"VOID":13},{"EN":15},[1824,1828,1832,1836,1840],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":1825,"label":1826,"description":1827,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":1829,"label":1830,"description":1831,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":31},{},{"id":34,"createTime":18,"updateTime":18,"relativeEntities":1833,"label":1834,"description":1835,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":37},{},{"id":40,"createTime":18,"updateTime":18,"relativeEntities":1837,"label":1838,"description":1839,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":43},{},{"id":46,"createTime":18,"updateTime":18,"relativeEntities":1841,"label":1842,"description":1843,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":49},{},[1845],{"id":53,"createTime":18,"updateTime":18,"relativeEntities":1846,"slug":18,"properties":1847,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":1849,"statistic":18},[],{"title":1848},{"EN":57},[],[1851,1858],{"id":61,"indexDatabase":1852,"url":74,"indexYears":18,"academicFieldIds":1857,"indexDatabaseRanking":18},{"id":63,"createTime":18,"updateTime":18,"relativeEntities":1853,"label":1854,"description":1855,"key":70,"publicationTags":1856,"standard":18},[],{"EN":66,"VI":66},{"EN":68,"VI":69},[72,73],[76],{"id":78,"indexDatabase":1859,"url":89,"indexYears":90,"academicFieldIds":1864,"indexDatabaseRanking":97},{"id":80,"createTime":18,"updateTime":18,"relativeEntities":1860,"label":1861,"description":1862,"key":86,"publicationTags":1863,"standard":18},[],{"EN":83,"VI":83},{"EN":83,"VI":85},[88],[92,93,94,95,96],{"pages":1866,"volume":1868},{"VOID":1867},"100918",{"VOID":1869},"67",69,{"total":1870,"publishYear":1872,"statisticByYear":1873},2023,{"2023":260,"2024":1874,"2025":1875,"2026":1796},20,34,"2023-03-01","2026-04-29T18:33:40.493+00:00",[72,97],[1880,1889,1898,1907,1913,1916,1925,1934,1940,1948,1955,1962,1971,1977,1985],{"id":18,"text":1881,"url":1882,"identifiers":1883},"Buckner, 2018, Clinically relevant plasmid-host interactions indicate that transcriptional and not genomic modifications ameliorate fitness costs of Klebsiella pneumoniae carbapenemase-carrying plasmids, Mbio, 9, 10.1128\u002FmBio.02303-17","https:\u002F\u002Fdoi.org\u002F10.1128\u002Fmbio.02303-17",{"mag":1884,"pmc":1885,"openalex":1886,"pm":1887,"doi":1888},"2800768460","5915730","W2800768460","29691332","10.1128\u002Fmbio.02303-17",{"id":18,"text":1890,"url":1891,"identifiers":1892},"Cejas, 2014, First isolate of kpc-2-producing klebsiella pneumonaie sequence type 23 from the americas, J. Clin. Microbiol., 52, 3483, 10.1128\u002FJCM.00726-14","https:\u002F\u002Fdoi.org\u002F10.1128\u002Fjcm.00726-14",{"mag":1893,"pmc":1894,"openalex":1895,"pm":1896,"doi":1897},"2090295005","4313191","W2090295005","25031447","10.1128\u002Fjcm.00726-14",{"id":18,"text":1899,"url":1900,"identifiers":1901},"Chen, 2014, Carbapenemase-producing Klebsiella pneumoniae: molecular and genetic decoding, Trends Microbiol., 22, 686, 10.1016\u002Fj.tim.2014.09.003","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.tim.2014.09.003",{"mag":1902,"pmc":1903,"openalex":1904,"pm":1905,"doi":1906},"2078043965","4365952","W2078043965","25304194","10.1016\u002Fj.tim.2014.09.003",{"id":1908,"text":1909,"url":1910,"identifiers":1911},"a9dfc890-899d-4036-a4b8-20c1d62caae8","Chiarelli, 2020, Diversity of mucoid to non-mucoid switch among carbapenemase-producing Klebsiella pneumoniae, Bmc Microbiol., 20, 10.1186\u002Fs12866-020-02007-y","https:\u002F\u002Fbmcmicrobiol.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12866-020-02007-y",{"doi":1912},"10.1186\u002Fs12866-020-02007-y",{"id":1908,"text":1914,"url":1910,"identifiers":1915},"Chiarelli, 2020, Diversity of mucoid to non-mucoid switch among carbapenemase-producing Klebsiella pneumoniae, Bmc Microbiol., 20, 325, 10.1186\u002Fs12866-020-02007-y",{"doi":1912},{"id":18,"text":1917,"url":1918,"identifiers":1919},"Chou, 2004, Isolation of a chromosomal region of Klebsiella pneumoniae associated with allantoin metabolism and liver infection, Infect. Immun., 72, 3783, 10.1128\u002FIAI.72.7.3783-3792.2004","https:\u002F\u002Fdoi.org\u002F10.1128\u002Fiai.72.7.3783-3792.2004",{"mag":1920,"pmc":1921,"openalex":1922,"pm":1923,"doi":1924},"2124970172","427404","W2124970172","15213119","10.1128\u002Fiai.72.7.3783-3792.2004",{"id":18,"text":1926,"url":1927,"identifiers":1928},"Conlan, 2016, Plasmid dynamics in kpc-positive Klebsiella pneumoniae during long-term patient colonization, Mbio, 7, 10.1128\u002FmBio.00742-16","https:\u002F\u002Fdoi.org\u002F10.1128\u002Fmbio.00742-16",{"mag":1929,"pmc":1930,"openalex":1931,"pm":1932,"doi":1933},"2475182620","4937214","W2475182620","27353756","10.1128\u002Fmbio.00742-16",{"id":1935,"text":1936,"url":1937,"identifiers":1938},"499e03e5-9e1a-4d27-a079-869d3dd8268c","Gu, 2018, A fatal outbreak of st11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a chinese hospital: a molecular epidemiological study, Lancet Infect. Dis., 18, 37, 10.1016\u002FS1473-3099(17)30489-9","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1473309917304899",{"doi":1939},"10.1016\u002Fs1473-3099(17)30489-9",{"id":18,"text":1941,"url":1942,"identifiers":1943},"Lan, 2021, A global perspective on the convergence of hypervirulence and carbapenem resistance in Klebsiella pneumoniae, J. Glob. Antimicrob. Resist., 25, 26, 10.1016\u002Fj.jgar.2021.02.020","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jgar.2021.02.020",{"mag":1944,"openalex":1945,"pm":1946,"doi":1947},"3133997740","W3133997740","33667703","10.1016\u002Fj.jgar.2021.02.020",{"id":18,"text":1949,"url":1950,"identifiers":1951},"Tian, 2022, Prevalence of hypervirulent and carbapenem-resistant Klebsiella pneumoniae under divergent evolutionary patterns, Emerg. Microbes Infect., 11, 1936, 10.1080\u002F22221751.2022.2103454","https:\u002F\u002Fdoi.org\u002F10.1080\u002F22221751.2022.2103454",{"openalex":1952,"pm":1953,"doi":1954},"W4285732264","35844192","10.1080\u002F22221751.2022.2103454",{"id":18,"text":1956,"url":1957,"identifiers":1958},"Wu, 2022, Global evolution and geographic diversity of hypervirulent carbapenem-resistant Klebsiella pneumoniae, Lancet Infect. Dis., 22, 761, 10.1016\u002FS1473-3099(22)00275-4","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fs1473-3099(22)00275-4",{"openalex":1959,"pm":1960,"doi":1961},"W4281573018","35643096","10.1016\u002Fs1473-3099(22)00275-4",{"id":18,"text":1963,"url":1964,"identifiers":1965},"Wyres, 2019, Distinct evolutionary dynamics of horizontal gene transfer in drug resistant and virulent clones of Klebsiella pneumoniae, PLoS Genet., 15, 10.1371\u002Fjournal.pgen.1008114","https:\u002F\u002Fdoi.org\u002F10.1371\u002Fjournal.pgen.1008114",{"mag":1966,"pmc":1967,"openalex":1968,"pm":1969,"doi":1970},"2950284789","6483277","W2950284789","30986243","10.1371\u002Fjournal.pgen.1008114",{"id":1972,"text":1973,"url":1974,"identifiers":1975},"eb36f071-86ef-411a-9a7f-efd60d6b76d1","Xu, 2021, Mobilization of the nonconjugative virulence plasmid from hypervirulent Klebsiella pneumoniae, Genome Med., 13, 119, 10.1186\u002Fs13073-021-00936-5","https:\u002F\u002Fgenomemedicine.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs13073-021-00936-5",{"doi":1976},"10.1186\u002Fs13073-021-00936-5",{"id":18,"text":1978,"url":1979,"identifiers":1980},"Yang, 2021, Carbapenem resistance-encoding and virulence-encoding conjugative plasmids in Klebsiella pneumoniae, Trends Microbiol., 29, 65, 10.1016\u002Fj.tim.2020.04.012","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.tim.2020.04.012",{"mag":1981,"openalex":1982,"pm":1983,"doi":1984},"3028438231","W3028438231","32448764","10.1016\u002Fj.tim.2020.04.012",{"id":18,"text":1986,"url":1987,"identifiers":1988},"Zhou, 2020, Novel subclone of carbapenem-resistant Klebsiella pneumoniae sequence type 11 with enhanced virulence and transmissibility, china, Emerg. Infect. Dis., 26, 289, 10.3201\u002Feid2602.190594","http:\u002F\u002Fdx.doi.org\u002F10.3201\u002Feid2602.190594",{"doi":1989},"10.3201\u002Feid2602.190594",{"id":1991,"createTime":1992,"updateTime":1993,"relativeEntities":1994,"slug":1995,"properties":1996,"entityType":115,"verifyStatus":116,"verifyTime":2003,"verifyNote":118,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":2004,"fullTextUrl":18,"authors":2005,"publicationType":279,"publisherRelationship":2049,"citationCount":2102,"citationInfo":2103,"publishDate":2106,"publishYear":2104,"citationAnalyzeStatus":17,"lastCitationAnalyze":2107,"indexDatabases":2108,"openAccess":18,"references":2109,"isForceReanalyzing":1548},"c1167b3a-b395-4743-80bf-52958e164b24","2023-12-10T04:55:41.229+00:00","2026-04-23T21:10:41.356+00:00",[],"Mechanisms-of-isoniazid-resistance-in-Mycobacterium-tuberculosis",{"title":1997,"gsPaper":1999,"doi":2001},{"EN":1998},"Mechanisms of isoniazid resistance in Mycobacterium tuberculosis",{"VOID":2000},"[\"11689523740981005015\"]",{"VOID":2002},"10.1016\u002Fs1368-7646(98)80028-9","2024-05-13T00:21:18.933+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1368764698800289",[2006,2021,2036],{"id":2007,"sortIndex":19,"researcher":18,"roles":2008,"affiliations":2009,"properties":2018,"displayName":2020,"givenName":18,"familyName":18},"1626399f-9639-4993-9ce0-b4dab796de62",[124],[2010],{"id":2011,"sortIndex":19,"affiliation":2012,"properties":18},"0d06c5db-c0f7-47fe-a800-78d4bc3868e2",{"id":2011,"createTime":18,"updateTime":18,"relativeEntities":2013,"slug":18,"properties":2014,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2017,"statistic":18},[],{"title":2015},{"VI":2016},"Tuberculosis Research Unit, Rocky Mountain Laboratories, National Institutes for Allergy and Infectious Disease, National Institutes of Health, Hamilton, Montana, USA",[],{"title":2019},{"VI":2020},"Clifton E. Barry",{"id":2022,"sortIndex":136,"researcher":18,"roles":2023,"affiliations":2024,"properties":2031,"displayName":2033,"givenName":18,"familyName":18},"ec626971-1940-4281-93e4-d96edd9d3973",[124],[2025],{"id":2011,"sortIndex":19,"affiliation":2026,"properties":18},{"id":2011,"createTime":18,"updateTime":18,"relativeEntities":2027,"slug":18,"properties":2028,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2030,"statistic":18},[],{"title":2029},{"VI":2016},[],{"title":2032,"gsAuthor":2034},{"VI":2033},"Richard A. Slayden",{"VOID":2035},"[\"vxmBdTwAAAAJ\"]",{"id":2037,"sortIndex":172,"researcher":18,"roles":2038,"affiliations":2039,"properties":2046,"displayName":2048,"givenName":18,"familyName":18},"e46ee4c0-9d43-4c4e-9003-8cac19331a34",[124],[2040],{"id":2011,"sortIndex":19,"affiliation":2041,"properties":18},{"id":2011,"createTime":18,"updateTime":18,"relativeEntities":2042,"slug":18,"properties":2043,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2045,"statistic":18},[],{"title":2044},{"VI":2016},[],{"title":2047},{"VI":2048},"Khisimuzi Mdluli",{"url":2004,"publisher":2050,"properties":2097},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2051,"slug":10,"properties":2052,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":2055,"manageAffiliations":2076,"indexDatabases":2082,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":2053,"title":2054},{"VOID":13},{"EN":15},[2056,2060,2064,2068,2072],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":2057,"label":2058,"description":2059,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":2061,"label":2062,"description":2063,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":31},{},{"id":34,"createTime":18,"updateTime":18,"relativeEntities":2065,"label":2066,"description":2067,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":37},{},{"id":40,"createTime":18,"updateTime":18,"relativeEntities":2069,"label":2070,"description":2071,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":43},{},{"id":46,"createTime":18,"updateTime":18,"relativeEntities":2073,"label":2074,"description":2075,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":49},{},[2077],{"id":53,"createTime":18,"updateTime":18,"relativeEntities":2078,"slug":18,"properties":2079,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2081,"statistic":18},[],{"title":2080},{"EN":57},[],[2083,2090],{"id":61,"indexDatabase":2084,"url":74,"indexYears":18,"academicFieldIds":2089,"indexDatabaseRanking":18},{"id":63,"createTime":18,"updateTime":18,"relativeEntities":2085,"label":2086,"description":2087,"key":70,"publicationTags":2088,"standard":18},[],{"EN":66,"VI":66},{"EN":68,"VI":69},[72,73],[76],{"id":78,"indexDatabase":2091,"url":89,"indexYears":90,"academicFieldIds":2096,"indexDatabaseRanking":97},{"id":80,"createTime":18,"updateTime":18,"relativeEntities":2092,"label":2093,"description":2094,"key":86,"publicationTags":2095,"standard":18},[],{"EN":83,"VI":83},{"EN":83,"VI":85},[88],[92,93,94,95,96],{"pages":2098,"volume":2100},{"VOID":2099},"128-134",{"VOID":2101},"1",40,{"total":2102,"publishYear":2104,"statisticByYear":2105},1998,{"1999":172,"2000":214,"2004":136,"2006":136,"2007":193,"2008":136,"2010":136,"2011":193,"2012":136,"2013":172,"2015":136,"2016":172,"2017":172,"2018":136,"2019":172,"2022":172,"2023":172,"2024":172,"2025":193,"2026":214},"1998-01-01","2026-04-23T21:10:41.355+00:00",[72,97],[2110,2116,2119,2125,2128,2133,2136,2142,2148,2154,2160,2166,2172,2178,2184,2190,2196,2202,2208,2214,2220,2226,2232,2238,2244,2250,2253,2259,2265,2271,2277,2280,2286,2292,2297,2300,2309,2318,2327,2333,2342,2348,2354,2360,2366,2372,2378,2381,2387,2393],{"id":2111,"text":2112,"url":2113,"identifiers":2114},"7462d5a7-9518-4ed6-b203-b637421074bf","Bass, 1994, Treatment of tuberculosis and tuberculosis infection in adults and children, Am J Respir Crit Care Med, 149, 1359, 10.1164\u002Fajrccm.149.5.8173779","https:\u002F\u002Fwww.atsjournals.org\u002Fdoi\u002F10.1164\u002Fajrccm.149.5.8173779",{"doi":2115},"10.1164\u002Fajrccm.149.5.8173779",{"id":18,"text":2117,"url":18,"identifiers":2118},"WHO\u002FIUATLD, 1997",{},{"id":2120,"text":2121,"url":2122,"identifiers":2123},"2983f313-06cf-45b1-8d12-e9374e73cc30","Moore, 1997, Trends in drug-resistant tuberculosis in the United States, 1993–1996, J Am Med Assoc, 278, 833, 10.1001\u002Fjama.278.10.833","http:\u002F\u002Fjama.ama-assn.org\u002Fcgi\u002Fdoi\u002F10.1001\u002Fjama.278.10.833",{"doi":2124},"10.1001\u002Fjama.278.10.833",{"id":588,"text":2126,"url":590,"identifiers":2127},"Middlebrook, 1952, Sterilization of tubercle bacilli by isonicotinic acid hydrazide and the incidence of variants resistant to the drug in vitro, Am Rev Tuberc, 65, 765",{"doi":592},{"id":18,"text":2129,"url":2130,"identifiers":2131},"Mdluli, 1996, Drug sensitivity and environmental adaptation of mycobacterial cell wall components, Trends Microbiol, 4, 275, 10.1016\u002F0966-842X(96)10031-7","http:\u002F\u002Fdx.doi.org\u002F10.1016\u002F0966-842x(96)10031-7",{"doi":2132},"10.1016\u002F0966-842x(96)10031-7",{"id":18,"text":2134,"url":18,"identifiers":2135},"Middlebrook, 1954, Isoniazid-resistance and catalase activity of tubercle bacilli, Am Rev Tuberc, 69, 471",{},{"id":2137,"text":2138,"url":2139,"identifiers":2140},"532ce550-98cc-410f-aa05-0da41991a3ae","Zhang, 1992, The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis, Nature (London), 358, 591, 10.1038\u002F358591a0","https:\u002F\u002Fwww.nature.com\u002Farticles\u002F358591a0",{"doi":2141},"10.1038\u002F358591a0",{"id":2143,"text":2144,"url":2145,"identifiers":2146},"7c26f4b8-6666-48e0-bab4-1429faa28710","Zhang, 1993, Transformation with KatG restores isoniazid-sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations, Mol Microbiol, 8, 521, 10.1111\u002Fj.1365-2958.1993.tb01596.x","https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1111\u002Fj.1365-2958.1993.tb01596.x",{"doi":2147},"10.1111\u002Fj.1365-2958.1993.tb01596.x",{"id":2149,"text":2150,"url":2151,"identifiers":2152},"5c7a08ee-54a3-459f-9322-2218cb2ccb0c","Rouse, 1995, Molecular mechanisms of isoniazid resistance in Mycobacterium tuberculosis and Mycobacterium bovis, Infect Immun, 63, 1427, 10.1128\u002FIAI.63.4.1427-1433.1995","https:\u002F\u002Fjournals.asm.org\u002Fdoi\u002F10.1128\u002Fiai.63.4.1427-1433.1995",{"doi":2153},"10.1128\u002Fiai.63.4.1427-1433.1995",{"id":2155,"text":2156,"url":2157,"identifiers":2158},"3e603535-b53a-40ca-bc84-33e01b683120","Ferrazoli, 1995, Catalase expression, katG, and MIC of isoniazid for Mycobacterium tuberculosis isolates from Sao Paulo, Brazil, J Infect Dis, 171, 237, 10.1093\u002Finfdis\u002F171.1.237","https:\u002F\u002Facademic.oup.com\u002Fjid\u002Farticle-lookup\u002Fdoi\u002F10.1093\u002Finfdis\u002F171.1.237",{"doi":2159},"10.1093\u002Finfdis\u002F171.1.237",{"id":2161,"text":2162,"url":2163,"identifiers":2164},"7cd453f0-32f8-40ac-855b-fb4b0a868352","Heym, 1995, Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis, Mol Microbiol, 15, 235, 10.1111\u002Fj.1365-2958.1995.tb02238.x","https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1111\u002Fj.1365-2958.1995.tb02238.x",{"doi":2165},"10.1111\u002Fj.1365-2958.1995.tb02238.x",{"id":2167,"text":2168,"url":2169,"identifiers":2170},"b5dae58c-1037-4313-a950-dfa743280d10","Goto, 1995, katG sequence deletion is not the major cause of isoniazid resistance in Japanese and Yemeni Mycobacterium tuberculosis isolates, Mol Cell Probes, 9, 433, 10.1006\u002Fmcpr.1995.0066","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0890850885700667",{"doi":2171},"10.1006\u002Fmcpr.1995.0066",{"id":2173,"text":2174,"url":2175,"identifiers":2176},"9e3ccec6-fe79-4b64-9871-96c765654aa1","Stoeckle, 1993, Catalase-peroxidase gene sequences in isoniazid-sensitive and -resistant strains of Mycobacterium tuberculosis from New York City, J Infect Dis, 168, 1063, 10.1093\u002Finfdis\u002F168.4.1063","https:\u002F\u002Facademic.oup.com\u002Fjid\u002Farticle-lookup\u002Fdoi\u002F10.1093\u002Finfdis\u002F168.4.1063",{"doi":2177},"10.1093\u002Finfdis\u002F168.4.1063",{"id":2179,"text":2180,"url":2181,"identifiers":2182},"c59e8b49-693f-43b3-a5fb-b98daf1858b4","Altamirano, 1994, Mutations in the catalase peroxidase gene from isoniazid-resistant Mycobacterium tuberculosis isolates, J Infect Dis, 169, 1162, 10.1093\u002Finfdis\u002F169.5.1162","https:\u002F\u002Facademic.oup.com\u002Fjid\u002Farticle-lookup\u002Fdoi\u002F10.1093\u002Finfdis\u002F169.5.1162",{"doi":2183},"10.1093\u002Finfdis\u002F169.5.1162",{"id":2185,"text":2186,"url":2187,"identifiers":2188},"8ef7f1a8-fa19-496f-b892-1b853a3bd71d","Victor, 1996, katG mutations in isoniazid-resistant strains of Mycobacterium tuberculosis are not infrequent, Antimicrob Agents Chemother, 40, 1572, 10.1128\u002FAAC.40.6.1572","https:\u002F\u002Fjournals.asm.org\u002Fdoi\u002F10.1128\u002FAAC.40.6.1572",{"doi":2189},"10.1128\u002Faac.40.6.1572",{"id":2191,"text":2192,"url":2193,"identifiers":2194},"88b38e71-ac64-401b-a283-639fc20d44c6","O'Brien, 1996, Evaluation of inhA gene and catalase-peroxidase gene among isoniazid-sensitive and resistant Mycobacterium tuberculosis isolates, Mol Cell Probes, 10, 1, 10.1006\u002Fmcpr.1996.0001","https:\u002F\u002Flinkinghub.elsevier.com\u002Fretrieve\u002Fpii\u002FS0890850896900018",{"doi":2195},"10.1006\u002Fmcpr.1996.0001",{"id":2197,"text":2198,"url":2199,"identifiers":2200},"f19bfca2-0408-4e3a-8f41-62f1b0639381","Morris, 1995, Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis, J Infect Dis, 171, 954, 10.1093\u002Finfdis\u002F171.4.954","https:\u002F\u002Facademic.oup.com\u002Fjid\u002Farticle-lookup\u002Fdoi\u002F10.1093\u002Finfdis\u002F171.4.954",{"doi":2201},"10.1093\u002Finfdis\u002F171.4.954",{"id":2203,"text":2204,"url":2205,"identifiers":2206},"a5264259-6ebf-42cf-9c71-159d2db03f69","Heym, 1994, Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study, Lancet, 344, 293, 10.1016\u002FS0140-6736(94)91338-2","https:\u002F\u002Flinkinghub.elsevier.com\u002Fretrieve\u002Fpii\u002FS0140673694913382",{"doi":2207},"10.1016\u002Fs0140-6736(94)91338-2",{"id":2209,"text":2210,"url":2211,"identifiers":2212},"8900d72c-8551-46bb-a470-01849f9a3b98","Musser, 1996, Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance, J Infect Dis, 173, 196, 10.1093\u002Finfdis\u002F173.1.196","https:\u002F\u002Facademic.oup.com\u002Fjid\u002Farticle-lookup\u002Fdoi\u002F10.1093\u002Finfdis\u002F173.1.196",{"doi":2213},"10.1093\u002Finfdis\u002F173.1.196",{"id":2215,"text":2216,"url":2217,"identifiers":2218},"fa4d8edc-97ae-4ce6-90a2-4d5da97f4cbc","Marttila, 1996, katG mutations in isoniazid-resistant Mycobacterium tuberculosis isolates recovered from Finnish patients, Antimicrob Agents Chemother, 40, 2187, 10.1128\u002FAAC.40.9.2187","https:\u002F\u002Fjournals.asm.org\u002Fdoi\u002F10.1128\u002FAAC.40.9.2187",{"doi":2219},"10.1128\u002Faac.40.9.2187",{"id":2221,"text":2222,"url":2223,"identifiers":2224},"41bd36ba-3e5d-47cb-a76d-58eec274d5ef","Rouse, 1996, Site-directed mutagenesis of the katG gene of Mycobacterium tuberculosis: effects on catalase-peroxidase activities and isoniazid resistance, Mol Microbiol, 22, 583, 10.1046\u002Fj.1365-2958.1996.00133.x","https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1046\u002Fj.1365-2958.1996.00133.x",{"doi":2225},"10.1046\u002Fj.1365-2958.1996.00133.x",{"id":2227,"text":2228,"url":2229,"identifiers":2230},"6a558699-7364-410d-be84-64313a66d7bc","Wengenack, 1997, Recombinant Mycobacterium tuberculosis KatG(S315T) is a competent catalase-peroxidase with reduced activity toward isoniazid, J Infect Dis, 176, 722, 10.1086\u002F514096","https:\u002F\u002Facademic.oup.com\u002Fjid\u002Farticle-lookup\u002Fdoi\u002F10.1086\u002F514096",{"doi":2231},"10.1086\u002F514096",{"id":2233,"text":2234,"url":2235,"identifiers":2236},"659ac7fe-74cf-4e97-9dac-398daf3697a0","Johnsson, 1997, Overexpression, purification, and characterization of the catalase-peroxidase KatG from Mycobacterium tuberculosis, J Biol Chem, 272, 2834, 10.1074\u002Fjbc.272.5.2834","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0021925819673813",{"doi":2237},"10.1074\u002Fjbc.272.5.2834",{"id":2239,"text":2240,"url":2241,"identifiers":2242},"91c46e30-f186-486d-a448-0498075a413b","Lee, 1997, Lack of clinical significance for the common arginine-to-leucine substitution at codon 463 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis in Singapore, J Infect Dis, 176, 1125, 10.1086\u002F517320","https:\u002F\u002Facademic.oup.com\u002Fjid\u002Farticle-lookup\u002Fdoi\u002F10.1086\u002F517320",{"doi":2243},"10.1086\u002F517320",{"id":2245,"text":2246,"url":2247,"identifiers":2248},"af96aeb1-8ee3-47a5-9c60-973cbc139cef","Telenti, 1997, Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level, J Clin Microbiol, 35, 719, 10.1128\u002FJCM.35.3.719-723.1997","https:\u002F\u002Fjournals.asm.org\u002Fdoi\u002F10.1128\u002Fjcm.35.3.719-723.1997",{"doi":2249},"10.1128\u002Fjcm.35.3.719-723.1997",{"id":588,"text":2251,"url":590,"identifiers":2252},"Sherman, 1995, Disparate responses to oxidative stress in saprophytic and pathogenic mycobacteria, 92, 6625",{"doi":592},{"id":2254,"text":2255,"url":2256,"identifiers":2257},"e12014b6-8960-4116-b36f-aa4549145e64","Deretic, 1995, Mycobacterium tuberculosis is a natural mutant with an inactivated oxidative-stress regulatory gene: implications for sensitivity to isoniazid, Mol Microbiol, 17, 889, 10.1111\u002Fj.1365-2958.1995.mmi_17050889.x","https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1111\u002Fj.1365-2958.1995.mmi_17050889.x",{"doi":2258},"10.1111\u002Fj.1365-2958.1995.mmi_17050889.x",{"id":2260,"text":2261,"url":2262,"identifiers":2263},"0826297f-0e90-4af1-95a0-eae0c6d79b8a","Wilson, 1995, Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis, Mol Microbiol, 15, 1009, 10.1111\u002Fj.1365-2958.1995.tb02276.x","https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1111\u002Fj.1365-2958.1995.tb02276.x",{"doi":2264},"10.1111\u002Fj.1365-2958.1995.tb02276.x",{"id":2266,"text":2267,"url":2268,"identifiers":2269},"cd588981-2473-446b-8eb8-9abce3d01de3","Sherman, 1996, Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis, Science, 272, 1641, 10.1126\u002Fscience.272.5268.1641","https:\u002F\u002Fwww.science.org\u002Fdoi\u002F10.1126\u002Fscience.272.5268.1641",{"doi":2270},"10.1126\u002Fscience.272.5268.1641",{"id":2272,"text":2273,"url":2274,"identifiers":2275},"dad5dc04-86d0-4b3d-b522-7cc4d829491d","Wilson, 1996, aphC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex, Mol Microbiol, 19, 1025, 10.1046\u002Fj.1365-2958.1996.449980.x","https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1046\u002Fj.1365-2958.1996.449980.x",{"doi":2276},"10.1046\u002Fj.1365-2958.1996.449980.x",{"id":588,"text":2278,"url":590,"identifiers":2279},"Zhang, 1996, Molecular basis for the exquisite sensitivity of Mycobacterium tuberculosis to isoniazid, 93, 13212",{"doi":592},{"id":2281,"text":2282,"url":2283,"identifiers":2284},"ea45cec6-3539-4f19-8ae2-05bbabd7ec78","Sreevatsan, 1997, Analysis of the oxyR-ahpC region in isoniazid-resistant and -susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities, Antimicrob Agents Chemother, 41, 600, 10.1128\u002FAAC.41.3.600","https:\u002F\u002Fjournals.asm.org\u002Fdoi\u002F10.1128\u002FAAC.41.3.600",{"doi":2285},"10.1128\u002Faac.41.3.600",{"id":2287,"text":2288,"url":2289,"identifiers":2290},"37ccc11d-45f4-4257-9aa5-bf767ad0f550","Kelley, 1997, Analysis of ahpC gene mutations in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis, Antimicrob Agents Chemother, 41, 2057, 10.1128\u002FAAC.41.9.2057","https:\u002F\u002Fjournals.asm.org\u002Fdoi\u002F10.1128\u002FAAC.41.9.2057",{"doi":2291},"10.1128\u002Faac.41.9.2057",{"id":18,"text":2293,"url":2294,"identifiers":2295},"Heym, 1997, Effects of overexpression of the alkylhydroperoxide reductase AhpC on the virulence and isoniazid resistance of Mycobacterium tuberculosis, Infect Immun, 65, 1395, 10.1128\u002FIAI.65.4.1395-1401.1997","http:\u002F\u002Fdx.doi.org\u002F10.1128\u002Fiai.65.4.1395-1401.1997",{"doi":2296},"10.1128\u002Fiai.65.4.1395-1401.1997",{"id":18,"text":2298,"url":18,"identifiers":2299},"Winder, 1982, Mode of action of antimycobacterial agents and associated aspects of the molecular biology of the mycobacteria, 353",{},{"id":18,"text":2301,"url":2302,"identifiers":2303},"Takayama, 1972, Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis, Antimicrob Agents Chemother, 2, 29, 10.1128\u002FAAC.2.1.29","https:\u002F\u002Fdoi.org\u002F10.1128\u002Faac.2.1.29",{"mag":2304,"pmc":2305,"openalex":2306,"pm":2307,"doi":2308},"2027340405","444261","W2027340405","4208567","10.1128\u002Faac.2.1.29",{"id":18,"text":2310,"url":2311,"identifiers":2312},"Takayama, 1973, Scanning electron microscopy of the H37Ra strain of Mycobacterium tuberculosis exposed to isoniazid, Antimicrob Agents Chemother, 4, 62, 10.1128\u002FAAC.4.1.62","https:\u002F\u002Fdoi.org\u002F10.1128\u002Faac.4.1.62",{"mag":2313,"pmc":2314,"openalex":2315,"pm":2316,"doi":2317},"2047760422","444505","W2047760422","4208900","10.1128\u002Faac.4.1.62",{"id":18,"text":2319,"url":2320,"identifiers":2321},"Takayama, 1975, Effect of isoniazid on the protoplasmic viscosity in Mycobacterium tuberculosis, Antimicrob Agents Chemother, 7, 22, 10.1128\u002FAAC.7.1.22","https:\u002F\u002Fdoi.org\u002F10.1128\u002Faac.7.1.22",{"mag":2322,"pmc":2323,"openalex":2324,"pm":2325,"doi":2326},"2095715452","429065","W2095715452","806256","10.1128\u002Faac.7.1.22",{"id":2328,"text":2329,"url":2330,"identifiers":2331},"664add24-dca1-4adf-815a-eab390925eda","Takayama, 1975, Site of inhibitory action of isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis, J Lipid Res, 16, 308, 10.1016\u002FS0022-2275(20)36719-5","https:\u002F\u002Flinkinghub.elsevier.com\u002Fretrieve\u002Fpii\u002FS0022227520367195",{"doi":2332},"10.1016\u002Fs0022-2275(20)36719-5",{"id":18,"text":2334,"url":2335,"identifiers":2336},"Davidson, 1979, Isoniazid inhibition of the synthesis of monounsaturated long-chain fatty acids in Mycobacterium tuberculosis H37Ra, Antimicrob Agents Chemother, 16, 104, 10.1128\u002FAAC.16.1.104","https:\u002F\u002Fdoi.org\u002F10.1128\u002Faac.16.1.104",{"mag":2337,"pmc":2338,"openalex":2339,"pm":2340,"doi":2341},"2092026968","352798","W2092026968","112917","10.1128\u002Faac.16.1.104",{"id":2343,"text":2344,"url":2345,"identifiers":2346},"844a1e7a-f198-453d-9adf-9f86c2608769","Banerjee, 1994, inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis, Science, 263, 227, 10.1126\u002Fscience.8284673","https:\u002F\u002Fwww.science.org\u002Fdoi\u002F10.1126\u002Fscience.8284673",{"doi":2347},"10.1126\u002Fscience.8284673",{"id":2349,"text":2350,"url":2351,"identifiers":2352},"c6cb1791-447e-4e58-8971-e058ac1e270a","Mdluli, 1996, Biochemical and genetic data suggest that InhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis, J Infect Dis, 174, 1085, 10.1093\u002Finfdis\u002F174.5.1085","https:\u002F\u002Facademic.oup.com\u002Fjid\u002Farticle-lookup\u002Fdoi\u002F10.1093\u002Finfdis\u002F174.5.1085",{"doi":2353},"10.1093\u002Finfdis\u002F174.5.1085",{"id":2355,"text":2356,"url":2357,"identifiers":2358},"6e650524-814f-4f78-b4db-53e2237383b9","Dessen, 1995, Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis, Science, 267, 1638, 10.1126\u002Fscience.7886450","https:\u002F\u002Fwww.science.org\u002Fdoi\u002F10.1126\u002Fscience.7886450",{"doi":2359},"10.1126\u002Fscience.7886450",{"id":2361,"text":2362,"url":2363,"identifiers":2364},"5fcc27dc-a5f5-4e02-a5c0-c0ed1f9dedc7","Quemard, 1995, Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis, Biochemistry, 34, 8235, 10.1021\u002Fbi00026a004","https:\u002F\u002Fpubs.acs.org\u002Fdoi\u002Fabs\u002F10.1021\u002Fbi00026a004",{"doi":2365},"10.1021\u002Fbi00026a004",{"id":2367,"text":2368,"url":2369,"identifiers":2370},"509c7e85-5f69-43dc-8358-4a14a6140393","Ristow, 1995, New isoniazid\u002Fethionamide resistance gene mutation and screening for multidrug-resistant Mycobacterium tuberculosis strains, Lancet, 346, 502, 10.1016\u002FS0140-6736(95)91351-3","https:\u002F\u002Flinkinghub.elsevier.com\u002Fretrieve\u002Fpii\u002FS0140673695913513",{"doi":2371},"10.1016\u002Fs0140-6736(95)91351-3",{"id":2373,"text":2374,"url":2375,"identifiers":2376},"52779f94-3c02-402e-82b3-d02baa39318b","Rouse, 1995, Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis, Antimicrob Agents Chemother, 39, 2472, 10.1128\u002FAAC.39.11.2472","https:\u002F\u002Fjournals.asm.org\u002Fdoi\u002F10.1128\u002FAAC.39.11.2472",{"doi":2377},"10.1128\u002Faac.39.11.2472",{"id":588,"text":2379,"url":590,"identifiers":2380},"Kapur, 1995, Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis by automated DNA sequencing, Arch Pathol Lab Med, 119, 131",{"doi":592},{"id":2382,"text":2383,"url":2384,"identifiers":2385},"dcb6a878-8450-4059-ba31-f1cb19c1c5c9","Shoeb, 1985, Evidence for the generation of active oxygen by isoniazid treatment of extracts of Mycobacterium tuberculosis H37Ra, Antimicrob Agents Chemother, 27, 404, 10.1128\u002FAAC.27.3.404","https:\u002F\u002Fjournals.asm.org\u002Fdoi\u002F10.1128\u002FAAC.27.3.404",{"doi":2386},"10.1128\u002Faac.27.3.404",{"id":2388,"text":2389,"url":2390,"identifiers":2391},"e8b903a6-ed0e-4af2-ab1d-21ed86eb0dc9","Shoeb, 1985, Enzymatic and nonenzymatic superoxide-generating reactions of isoniazid, Antimicrob Agents Chemother, 27, 408, 10.1128\u002FAAC.27.3.408","https:\u002F\u002Fjournals.asm.org\u002Fdoi\u002F10.1128\u002FAAC.27.3.408",{"doi":2392},"10.1128\u002Faac.27.3.408",{"id":2394,"text":2395,"url":2396,"identifiers":2397},"6d90b909-715b-410c-a642-eeea44108eb3","Mdluli, 1998, Mechanisms involved in the intrinsic isoniazid-resistance of Mycobacterium avium, Mol Microbiol, 10.1046\u002Fj.1365-2958.1998.00774.x","https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1046\u002Fj.1365-2958.1998.00774.x",{"doi":2398},"10.1046\u002Fj.1365-2958.1998.00774.x",{"id":2400,"createTime":2401,"updateTime":2402,"relativeEntities":2403,"slug":2404,"properties":2405,"entityType":115,"verifyStatus":116,"verifyTime":2414,"verifyNote":118,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":2415,"fullTextUrl":18,"authors":2416,"publicationType":279,"publisherRelationship":2549,"citationCount":18,"citationInfo":18,"publishDate":2602,"publishYear":2603,"citationAnalyzeStatus":2604,"lastCitationAnalyze":2605,"indexDatabases":2606,"openAccess":18,"references":18,"isForceReanalyzing":1548},"33428a0a-be31-4543-80d9-28e764da93f4","2024-01-22T00:44:09.045+00:00","2026-02-26T21:52:03.171+00:00",[],"Epigenetic-enzyme-mutations-as-mediators-of-anti-cancer-drug-resistance",{"title":2406,"gsPaper":2408,"references":2410,"doi":2412},{"EN":2407},"Epigenetic enzyme mutations as mediators of anti-cancer drug resistance",{"VOID":2409},"[]",{"VOID":2411},"Aleksakhina, 2019, Mechanisms of acquired tumor drug resistance, Biochim. Biophys. Acta Rev. Cancer, 1872, 10.1016\u002Fj.bbcan.2019.188310\nAndrei, 2020, Advanced technological tools to study multidrug resistance in cancer, Drug Resist. Updat., 48, 10.1016\u002Fj.drup.2019.100658\nAnwar, 2021, Noncanonical functions of the polycomb group protein EZH2 in breast cancer, Am. J. Pathol., 191, 774, 10.1016\u002Fj.ajpath.2021.01.013\nAries, 2018, PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia, J. Exp. Med., 215, 3094, 10.1084\u002Fjem.20180570\nArrowsmith, 2012, Epigenetic protein families: a new frontier for drug discovery, Nat. Rev. Drug Discov., 11, 384, 10.1038\u002Fnrd3674\nAsangani, 2013, Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer, Mol. Cell, 49, 80, 10.1016\u002Fj.molcel.2012.10.008\nAssaraf, 2019, The multi-factorial nature of clinical multidrug resistance in cancer, Drug Resist. Updat., 46, 10.1016\u002Fj.drup.2019.100645\nAudia, 2016, Histone modifications and cancer, Cold Spring Harb. Perspect. Biol., 8, 10.1101\u002Fcshperspect.a019521\nAwad, 2013, Acquired resistance to crizotinib from a mutation in CD74-ROS1, N. Engl. J. Med., 368, 2395, 10.1056\u002FNEJMoa1215530\nBachmann, 2010, Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition, Blood, 116, 3013, 10.1182\u002Fblood-2010-05-284968\nBailey, 2018, Comprehensive characterization of cancer driver genes and mutations, Cell, 173, 371, 10.1016\u002Fj.cell.2018.02.060\nBaker, 2015, Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors, Oncotarget, 6, 32646, 10.18632\u002Foncotarget.5066\nBakhshi, 2020, Genetic and epigenetic determinants of diffuse large B-cell lymphoma, Blood Cancer J., 10, 123, 10.1038\u002Fs41408-020-00389-w\nBansal, 2018, Glutathione metabolism in cancer progression and treatment resistance, J. Cell Biol., 217, 2291, 10.1083\u002Fjcb.201804161\nBaretti, 2018, DNA mismatch repair in cancer, Pharmacol. Ther., 189, 45, 10.1016\u002Fj.pharmthera.2018.04.004\nBates, 2020, Epigenetic therapies for cancer, N. Engl. J. Med., 383, 650, 10.1056\u002FNEJMra1805035\nBeerenwinkel, 2015, Cancer evolution: mathematical models and computational inference, Syst. Biol., 64, e1, 10.1093\u002Fsysbio\u002Fsyu081\nBertoli, 2018, Dexamethasone in hyperleukocytic acute myeloid leukemia, Haematologica, 103, 988, 10.3324\u002Fhaematol.2017.184267\nBhola, 2016, Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia, J. Clin. Invest., 126, 3827, 10.1172\u002FJCI82908\nBinenbaum, 2015, Gemcitabine resistance in pancreatic ductal adenocarcinoma, Drug Resist. Updat., 23, 55, 10.1016\u002Fj.drup.2015.10.002\nBisserier, 2018, Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas, Blood, 131, 2125, 10.1182\u002Fblood-2017-08-804344\nBouwman, 2012, The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance, Nat. Rev. Cancer, 12, 587, 10.1038\u002Fnrc3342\nBrooun, 2016, Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance, Nat. Commun., 7, 11384, 10.1038\u002Fncomms11384\nCampbell, 2016, Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas, Nat. Genet., 48, 607, 10.1038\u002Fng.3564\nCao, 2020, Towards the overcoming of anticancer drug resistance mediated by p53 mutations, Drug Resist. Updat., 49, 10.1016\u002Fj.drup.2019.100671\nChen, 2020, Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers, J. Cancer, 11, 3349, 10.7150\u002Fjca.38391\nCheung, 2011, Cysteine-rich intestinal protein 2 (CRIP2) acts as a repressor of NF-kappaB-mediated proangiogenic cytokine transcription to suppress tumorigenesis and angiogenesis, Proc. Natl. Acad. Sci. U. S. A., 108, 8390, 10.1073\u002Fpnas.1101747108\nChoe, 2020, Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML, Blood Adv., 4, 1894, 10.1182\u002Fbloodadvances.2020001503\nChoi, 2018, Temozolomide-associated hypermutation in gliomas, Neuro Oncol., 20, 1300, 10.1093\u002Fneuonc\u002Fnoy016\nChoueiri, 2017, Systemic therapy for metastatic renal-cell carcinoma, N. Engl. J. Med., 376, 354, 10.1056\u002FNEJMra1601333\nCucchi, 2020, Ex vivo cultures and drug testing of primary acute myeloid leukemia samples: current techniques and implications for experimental design and outcome, Drug Resist. Updat., 53, 10.1016\u002Fj.drup.2020.100730\nCui, 2020, Discovering anti-cancer drugs computational methods, Front. Pharmacol., 11, 733, 10.3389\u002Ffphar.2020.00733\nDang, 2017, Drugging the’ undruggable’ cancer targets, Nat. Rev. Cancer, 17, 502, 10.1038\u002Fnrc.2017.36\nDawson, 2017, The cancer epigenome: concepts, challenges, and therapeutic opportunities, Science, 355, 1147, 10.1126\u002Fscience.aam7304\nDawson, 2012, Cancer epigenetics: from mechanism to therapy, Cell, 150, 12, 10.1016\u002Fj.cell.2012.06.013\nDelvecchio, 2013, Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation, Nat. Struct. Mol. Biol., 20, 1040, 10.1038\u002Fnsmb.2642\nDong, 2019, SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints, Leukemia, 33, 2585, 10.1038\u002Fs41375-019-0456-2\nDu, 2021, Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors, Innovation (N. Y.), 2\nDuns, 2010, Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma, Cancer Res., 70, 4287, 10.1158\u002F0008-5472.CAN-10-0120\nDuy, 2019, Rational targeting of cooperating layers of the epigenome yields enhanced therapeutic efficacy against AML, Cancer Discov., 9, 872, 10.1158\u002F2159-8290.CD-19-0106\nElgendy, 2017, Dual modulation of MCL-1 and mTOR determines the response to sunitinib, J. Clin. Invest., 127, 153, 10.1172\u002FJCI84386\nElgendy, 2019, Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer, Int. J. Cancer, 145, 1991, 10.1002\u002Fijc.32256\nEmperle, 2019, Mutations of R882 change flanking sequence preferences of the DNA methyltransferase DNMT3A and cellular methylation patterns, Nucleic Acids Res., 47, 11355, 10.1093\u002Fnar\u002Fgkz911\nEpstein, 2013, The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe, Front. Oncol., 3, 304, 10.3389\u002Ffonc.2013.00304\nErin, 2020, Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance, Drug Resist. Updat., 53, 10.1016\u002Fj.drup.2020.100715\nFarooq, 2016, The many faces of histone H3K79 methylation, Mutat. Res. Rev. Mutat. Res., 768, 46, 10.1016\u002Fj.mrrev.2016.03.005\nFu, 2012, Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: possible impact on glioma cell metastasis and chemo-resistance, Int. J. Biochem. Cell Biol., 44, 770, 10.1016\u002Fj.biocel.2012.01.017\nGacche, 2018, Redundant angiogenic signaling and tumor drug resistance, Drug Resist. Updat., 36, 47, 10.1016\u002Fj.drup.2018.01.002\nGao, 2017, 3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets, Genome Med., 9, 4, 10.1186\u002Fs13073-016-0393-x\nGao, 2021, Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function, Drug Resist. Updat., 57, 10.1016\u002Fj.drup.2021.100770\nGarapaty-Rao, 2013, Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth, Chem. Biol., 20, 1329, 10.1016\u002Fj.chembiol.2013.09.013\nGeromichalos, 2016, Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I, J. BUON, 21, 764\nGhelli Luserna di Rora, 2017, The cell cycle checkpoint inhibitors in the treatment of leukemias, J. Hematol. Oncol., 10, 77, 10.1186\u002Fs13045-017-0443-x\nGhosh, 2020, Mitochondria targeting as an effective strategy for cancer therapy, Int. J. Mol. Sci., 21\nGibaja, 2016, Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors, Oncogene, 35, 558, 10.1038\u002Fonc.2015.114\nGillis, 2016, The pharmacogenomics of drug resistance to protein kinase inhibitors, Drug Resist. Updat., 28, 28, 10.1016\u002Fj.drup.2016.06.008\nGollner, 2017, Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia, Nat. Med., 23, 69, 10.1038\u002Fnm.4247\nGolub, 2019, Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics, Front. Oncol., 9, 417, 10.3389\u002Ffonc.2019.00417\nGotink, 2011, Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance, Clin. Cancer Res., 17, 7337, 10.1158\u002F1078-0432.CCR-11-1667\nGottesman, 2016, Toward a better understanding of the complexity of cancer drug resistance, Annu. Rev. Pharmacol. Toxicol., 56, 85, 10.1146\u002Fannurev-pharmtox-010715-103111\nGreif, 2018, Evolution of cytogenetically normal acute myeloid leukemia during therapy and relapse: an exome sequencing study of 50 patients, Clin. Cancer Res., 24, 1716, 10.1158\u002F1078-0432.CCR-17-2344\nGuryanova, 2016, DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling, Nat. Med., 22, 1488, 10.1038\u002Fnm.4210\nHan, 2019, Epigenetic enzyme mutations: role in tumorigenesis and molecular inhibitors, Front. Oncol., 9, 194, 10.3389\u002Ffonc.2019.00194\nHan, 2020, IDH mutation in glioma: molecular mechanisms and potential therapeutic targets, Br. J. Cancer, 122, 1580, 10.1038\u002Fs41416-020-0814-x\nHarding, 2018, Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition, Cancer Discov., 8, 1540, 10.1158\u002F2159-8290.CD-18-0877\nHelin, 2013, Chromatin proteins and modifications as drug targets, Nature, 502, 480, 10.1038\u002Fnature12751\nHervouet, 2018, Specific or not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma, Clin. Epigenetics, 10, 17, 10.1186\u002Fs13148-018-0450-y\nHirai, 2009, Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents, Mol. Cancer Ther., 8, 2992, 10.1158\u002F1535-7163.MCT-09-0463\nHo, 2020, Thirty years of HDAC inhibitors: 2020 insight and hindsight, J. Med. Chem., 63, 12460, 10.1021\u002Facs.jmedchem.0c00830\nHolliday, 1975, DNA modification mechanisms and gene activity during development, Science (New York, N. Y.), 187, 226, 10.1126\u002Fscience.187.4173.226\nHolohan, 2013, Cancer drug resistance: an evolving paradigm. Nature reviews, Cancer, 13, 714\nHsu, 2014, Development and applications of CRISPR-Cas9 for genome engineering, Cell, 157, 1262, 10.1016\u002Fj.cell.2014.05.010\nHu, 2016, Understanding the genetic mechanisms of cancer drug resistance using genomic approaches, Trends Genet., 32, 127, 10.1016\u002Fj.tig.2015.11.003\nInthal, 2012, CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia, Leukemia, 26, 1797, 10.1038\u002Fleu.2012.60\nIntlekofer, 2018, Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations, Nature, 559, 125, 10.1038\u002Fs41586-018-0251-7\nIpsaro, 2017, Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis, PLoS One, 12, 10.1371\u002Fjournal.pone.0172177\nIv Santaliz-Ruiz, 2014, Emerging role of nanog in tumorigenesis and cancer stem cells, Int. J. Cancer, 135, 2741, 10.1002\u002Fijc.28690\nJones, 2016, Targeting the cancer epigenome for therapy, Nat. Rev. Genet., 17, 630, 10.1038\u002Fnrg.2016.93\nJuchum, 2015, Fighting cancer drug resistance: opportunities and challenges for mutation-specific EGFR inhibitors, Drug Resist. Updat., 20, 12, 10.1016\u002Fj.drup.2015.05.002\nKaelin, 2013, Influence of metabolism on epigenetics and disease, Cell, 153, 56, 10.1016\u002Fj.cell.2013.03.004\nKats, 2014, Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance, Cell Stem Cell, 14, 329, 10.1016\u002Fj.stem.2013.12.016\nKempf, 2021, Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML, Sci. Rep., 11, 5838, 10.1038\u002Fs41598-021-84708-6\nKernytsky, 2015, IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition, Blood, 125, 296, 10.1182\u002Fblood-2013-10-533604\nKim, 2016, SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia, Cancer Chemother. Pharmacol., 78, 533, 10.1007\u002Fs00280-016-3103-x\nKim, 2019, IDH1(R132H) causes resistance to HDAC inhibitors by increasing NANOG in glioblastoma cells, Int. J. Mol. Sci., 20, 2679, 10.3390\u002Fijms20112679\nKim, 2019, Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer, Oncogene, 38, 180, 10.1038\u002Fs41388-018-0429-3\nKinnaird, 2016, Metabolic control of epigenetics in cancer, Nat. Rev. Cancer, 16, 694, 10.1038\u002Fnrc.2016.82\nKudithipudi, 2014, Role of somatic cancer mutations in human protein lysine methyltransferases, Biochim. Biophys. Acta, 1846, 366\nLafave, 2013, Mining the epigenetic landscape in ALL, Nat. Genet., 45, 1269, 10.1038\u002Fng.2808\nLee, 2018, Dot1 regulates nucleosome dynamics by its inherent histone chaperone activity in yeast, Nat. Commun., 9, 240, 10.1038\u002Fs41467-017-02759-8\nLee, 2020, Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity, Int. J. Mol. Sci., 21, 1102, 10.3390\u002Fijms21031102\nLeonetti, 2019, MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: current implications and future directions, Drug Resist. Updates, 42, 1, 10.1016\u002Fj.drup.2018.11.002\nLeonetti, 2019, Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer, Drug Resist. Updat., 46, 10.1016\u002Fj.drup.2019.100644\nLer, 2017, Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2, Sci. Transl. Med., 9, 10.1126\u002Fscitranslmed.aai8312\nLey, 2010, DNMT3A mutations in acute myeloid leukemia, N. Engl. J. Med., 363, 2424, 10.1056\u002FNEJMoa1005143\nLi, 2018, Human diseases from gain-of-function mutations in disordered protein regions, Cell, 175, 40, 10.1016\u002Fj.cell.2018.08.059\nLi, 2005, Solution structure of the Set2-Rpb1 interacting domain of human Set2 and its interaction with the hyperphosphorylated C-terminal domain of Rpb1, Proc. Natl. Acad. Sci. U. S. A., 102, 17636, 10.1073\u002Fpnas.0506350102\nLi, 2013, The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha, Cell, 153, 590, 10.1016\u002Fj.cell.2013.03.025\nLi, 2016, Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies, Drug Resist. Updat., 27, 14, 10.1016\u002Fj.drup.2016.05.001\nLi, 2019, Gain-of-function mutations: an emerging advantage for cancer biology, Trends Biochem. Sci., 44, 659, 10.1016\u002Fj.tibs.2019.03.009\nLi, 2020, Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia, Blood, 135, 41, 10.1182\u002Fblood.2019002220\nLi, 2021, PRC2 inhibitors overcome glucocorticoid resistance driven by NSD2 mutation in pediatric acute lymphoblastic leukemia, Cancer Discov., 12, 186, 10.1158\u002F2159-8290.CD-20-1771\nLi, 2020, Surmounting cancer drug resistance: new insights from the perspective of N(6)-methyladenosine RNA modification, Drug Resist. Updat., 53, 10.1016\u002Fj.drup.2020.100720\nLi, 2020, Somatic mutations drive specific, but reversible, epigenetic heterogeneity states in AML, Cancer Discov., 10, 1934, 10.1158\u002F2159-8290.CD-19-0897\nLicht, 2017, SETD2: a complex role in blood malignancy, Blood, 130, 2576, 10.1182\u002Fblood-2017-10-811927\nLiu, 2008, The structural basis of protein acetylation by the p300\u002FCBP transcriptional coactivator, Nature, 451, 846, 10.1038\u002Fnature06546\nLiu, 2020, Role of epigenetic in leukemia: from mechanism to therapy, Chem. Biol. Interact., 317, 10.1016\u002Fj.cbi.2020.108963\nLong, 2020, Genetic biomarkers of drug resistance: a compass of prognosis and targeted therapy in acute myeloid leukemia, Drug Resist. Updat., 52, 10.1016\u002Fj.drup.2020.100703\nLunning, 2015, Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas, Blood Cancer J., 5, e361, 10.1038\u002Fbcj.2015.89\nMajchrzak-Celinska, 2021, Novel approaches to epigenetic therapies: from drug combinations to epigenetic editing, Genes (Basel), 12, 208, 10.3390\u002Fgenes12020208\nMar, 2014, Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia, Nat. Commun., 5, 3469, 10.1038\u002Fncomms4469\nMar, 2017, SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia, Blood, 130, 2631, 10.1182\u002Fblood-2017-03-775569\nMartincorena, 2015, Somatic mutation in cancer and normal cells, Science (New York, N. Y.), 349, 1483, 10.1126\u002Fscience.aab4082\nMartinez-Jimenez, 2020, A compendium of mutational cancer driver genes, Nat. Rev. Cancer, 20, 555, 10.1038\u002Fs41568-020-0290-x\nMcCarthy, 2010, Leukaemia: MLL makes friends and influences, Nat. Rev. Cancer, 10, 529, 10.1038\u002Fnrc2904\nMin, 2003, Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase, Cell, 112, 711, 10.1016\u002FS0092-8674(03)00114-4\nMohammad, 2019, Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer, Nat. Med., 25, 403, 10.1038\u002Fs41591-019-0376-8\nMorel, 2017, Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism, Ann. Oncol., 28, 254, 10.1093\u002Fannonc\u002Fmdw552\nMorera, 2016, Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy, Clin. Epigenetics, 8, 57, 10.1186\u002Fs13148-016-0223-4\nMorin, 2010, Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin, Nat. Genet., 42, 181, 10.1038\u002Fng.518\nMoses, 2018, Hallmarks of cancer: the CRISPR generation, Eur. J. Cancer, 93, 10, 10.1016\u002Fj.ejca.2018.01.002\nMu, 2018, EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation, Epigenetics Chromatin, 11, 71, 10.1186\u002Fs13072-018-0242-9\nMullighan, 2011, CREBBP mutations in relapsed acute lymphoblastic leukaemia, Nature, 471, 235, 10.1038\u002Fnature09727\nOhba, 2014, Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance, Cancer Res., 74, 4836, 10.1158\u002F0008-5472.CAN-14-0924\nOkugawa, 2015, Epigenetic alterations in colorectal cancer: emerging biomarkers, Gastroenterology, 149, 1204, 10.1053\u002Fj.gastro.2015.07.011\nOxnard, 2018, Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib, JAMA Oncol., 4, 1527, 10.1001\u002Fjamaoncol.2018.2969\nOyer, 2014, Point mutation E1099K in MMSET\u002FNSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies, Leukemia, 28, 198, 10.1038\u002Fleu.2013.204\nPasqualucci, 2011, Inactivating mutations of acetyltransferase genes in B-cell lymphoma, Nature, 471, 189, 10.1038\u002Fnature09730\nPfister, 2015, Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation, Cancer Cell, 28, 557, 10.1016\u002Fj.ccell.2015.09.015\nPierro, 2020, The NSD2 p.E1099K mutation is enriched at relapse and confers drug resistance in a cell context-dependent manner in pediatric acute lymphoblastic leukemia, Mol. Cancer Res., 18, 1153, 10.1158\u002F1541-7786.MCR-20-0092\nPopovici-Muller, 2018, Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers, ACS Med. Chem. Lett., 9, 300, 10.1021\u002Facsmedchemlett.7b00421\nPorter, 2012, Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia, Leukemia, 26, 1266, 10.1038\u002Fleu.2011.392\nPurushottam Dharaskar, 2020, Mitochondrial chaperone, TRAP1 modulates mitochondrial dynamics and promotes tumor metastasis, Mitochondrion, 54, 92, 10.1016\u002Fj.mito.2020.08.001\nQuek, 2018, Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib, Nat. Med., 24, 1167, 10.1038\u002Fs41591-018-0115-6\nRebehmed, 2014, Expanding the SRI domain family: a common scaffold for binding the phosphorylated C-terminal domain of RNA polymerase II, FEBS Lett., 588, 4431, 10.1016\u002Fj.febslet.2014.10.014\nRobichaux, 2021, Structure-based classification predicts drug response in EGFR-mutant NSCLC, Nature, 597, 732, 10.1038\u002Fs41586-021-03898-1\nRopero, 2006, A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition, Nat. Genet., 38, 566, 10.1038\u002Fng1773\nRopero, 2008, Transforming pathways unleashed by a HDAC2 mutation in human cancer, Oncogene, 27, 4008, 10.1038\u002Fonc.2008.31\nRoy, 2014, Driver mutations of cancer epigenomes, Protein Cell, 5, 265, 10.1007\u002Fs13238-014-0031-6\nSakamoto, 2021, Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma, Cancer Med., 10, 119, 10.1002\u002Fcam4.3578\nSalgia, 2018, The genetic\u002Fnon-genetic duality of drug ’resistance’ in cancer, Trends Cancer, 4, 110, 10.1016\u002Fj.trecan.2018.01.001\nSanchez, 2011, The PHD finger: a versatile epigenome reader, Trends Biochem. Sci., 36, 364\nSanidas, 2014, Phosphoproteomics screen reveals akt isoform-specific signals linking RNA processing to lung cancer, Mol. Cell, 53, 577, 10.1016\u002Fj.molcel.2013.12.018\nSchulz, 2019, The histone demethylase UTX\u002FKDM6A in cancer: progress and puzzles, Int. J. Cancer, 145, 614, 10.1002\u002Fijc.32116\nSchwaller, 2020, Learning from mouse models of MLL fusion gene-driven acute leukemia, Biochim. Biophys. Acta Gene Regul. Mech., 1863, 10.1016\u002Fj.bbagrm.2020.194550\nShaffer, 2012, Drug resistance: still a daunting challenge to the successful treatment of AML, Drug Resist. Updat., 15, 62, 10.1016\u002Fj.drup.2012.02.001\nShah, 2016, MMSET\u002FWHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents, Oncogene, 35, 5905, 10.1038\u002Fonc.2016.116\nShahar, 2020, Inhibiting the inhibitors: targeting anti-apoptotic proteins in cancer and therapy resistance, Drug Resist. Updat., 52, 10.1016\u002Fj.drup.2020.100712\nShen, 2015, Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention, Curr. Opin. Oncol., 27, 57, 10.1097\u002FCCO.0000000000000151\nShkundina, 2021, New RAD51 inhibitors to target homologous recombination in human cells, Genes, 12, 920, 10.3390\u002Fgenes12060920\nSiegel, 2020, Cancer statistics, 2020, CA Cancer J. Clin., 70, 7, 10.3322\u002Fcaac.21590\nSkucha, 2019, Roles of SETD2 in leukemia-transcription, DNA-damage, and beyond, Int. J. Mol. Sci., 20, 1029, 10.3390\u002Fijms20051029\nSong, 2017, HDAC1 upregulation by NANOG promotes multidrug resistance and a stem-like phenotype in immune edited tumor cells, Cancer Res., 77, 5039, 10.1158\u002F0008-5472.CAN-17-0072\nStief, 2020, Loss of KDM6A confers drug resistance in acute myeloid leukemia, Leukemia, 34, 50, 10.1038\u002Fs41375-019-0497-6\nStiewe, 2018, How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance, Drug Resist. Updat., 38, 27, 10.1016\u002Fj.drup.2018.05.001\nSwaroop, 2019, An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia, Oncogene, 38, 671, 10.1038\u002Fs41388-018-0474-y\nTenorio, 2020, Further delineation of neuropsychiatric findings in Tatton-Brown-Rahman syndrome due to disease-causing variants in DNMT3A: seven new patients, Eur. J. Hum. Genet.: EJHG, 28, 469, 10.1038\u002Fs41431-019-0485-3\nTiffen, 2020, EZH2 cooperates with DNA methylation to downregulate key tumor suppressors and IFN gene signatures in melanoma, J. Invest. Dermatol., 140, 2442, 10.1016\u002Fj.jid.2020.02.042\nTong, 2020, Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine, BMC Med. Genomics, 13, 138, 10.1186\u002Fs12920-020-00794-x\nTran, 2020, Lysine demethylase KDM6A in differentiation, development, and cancer, Mol. Cell. Biol., 40, e00341, 10.1128\u002FMCB.00341-20\nTurcan, 2012, IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype, Nature, 483, 479, 10.1038\u002Fnature10866\nVan Linden, 2013, Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality, Mol. Cancer Ther., 12, 2675, 10.1158\u002F1535-7163.MCT-13-0424\nVasan, 2019, A view on drug resistance in cancer, Nature, 575, 299, 10.1038\u002Fs41586-019-1730-1\nViré, 2006, The Polycomb group protein EZH2 directly controls DNA methylation, Nature, 439, 871, 10.1038\u002Fnature04431\nWan, 2020, Impaired cell fate through gain-of-function mutations in a chromatin reader, Nature, 577, 121, 10.1038\u002Fs41586-019-1842-7\nWandler, 2020, Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia, Leukemia, 34, 2025, 10.1038\u002Fs41375-020-0748-6\nWang, 2019, UTX mutations in human cancer, Cancer Cell, 35, 168, 10.1016\u002Fj.ccell.2019.01.001\nWang, 2009, Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II, Mol. Cell. Biol., 29, 6074, 10.1128\u002FMCB.00924-09\nWang, 2020, Characterization of a novel HDAC\u002FRXR\u002FHtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer, Mol. Cancer, 19, 134, 10.1186\u002Fs12943-020-01256-9\nWang, 2021, Multidrug resistance proteins (MRPs): structure, function and the overcoming of cancer multidrug resistance, Drug Resist. Updat., 54, 10.1016\u002Fj.drup.2021.100743\nWeirich, 2015, Somatic cancer mutations in the MLL3-SET domain alter the catalytic properties of the enzyme, Clin. Epigenetics, 7, 36, 10.1186\u002Fs13148-015-0075-3\nWiesel-Motiuk, 2020, The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology, Drug Resist. Updat., 53, 10.1016\u002Fj.drup.2020.100729\nWilting, 2012, Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance, Drug Resist. Updat., 15, 21, 10.1016\u002Fj.drup.2012.01.008\nWu, 2018, Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer, Mol. Cancer, 17, 38, 10.1186\u002Fs12943-018-0777-1\nWu, 2013, Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations, PLoS One, 8, 10.1371\u002Fjournal.pone.0083737\nWu, 2016, Novel variants in MLL confer to bladder cancer recurrence identified by whole-exome sequencing, Oncotarget, 7, 2629, 10.18632\u002Foncotarget.6380\nXiao, 2019, Haploinsufficiency of drives glucocorticoid resistance in adult acute lymphoblastic leukemia cells by down-regulating the mitochondrial apoptosis axis, and is sensitive to Bcl-2 blockage, Cancer Cell Int., 19, 218, 10.1186\u002Fs12935-019-0940-9\nXu, 2012, EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent, Science, 338, 1465, 10.1126\u002Fscience.1227604\nYang, 2017, Novel impact of the DNMT3A R882H mutation on GSH metabolism in a K562 cell model established by TALENs, Oncotarget, 8, 30395, 10.18632\u002Foncotarget.16449\nYang, 2019, Epigenetic synthetic lethality approaches in cancer therapy, Clin. Epigenetics, 11, 136, 10.1186\u002Fs13148-019-0734-x\nYang, 2020, Histone methyltransferase and drug resistance in cancers, J. Exp. Clin. Cancer Res., 39, 173, 10.1186\u002Fs13046-020-01682-z\nYen, 2017, AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic mutations, Cancer Discov., 7, 478, 10.1158\u002F2159-8290.CD-16-1034\nYou, 2012, Cancer genetics and epigenetics: two sides of the same coin?, Cancer Cell, 22, 9, 10.1016\u002Fj.ccr.2012.06.008\nYuan, 2020, SETD2 restricts prostate cancer metastasis by integrating EZH2 and AMPK signaling pathways, Cancer Cell, 38, 350, 10.1016\u002Fj.ccell.2020.05.022\nZerbino, 2018, Ensembl 2018, Nucleic Acids Res., 46, D754, 10.1093\u002Fnar\u002Fgkx1098\nZhang, 2017, A pan-cancer proteogenomic atlas of PI3K\u002FAKT\u002FmTOR pathway alterations, Cancer Cell, 31, 820, 10.1016\u002Fj.ccell.2017.04.013\nZhang, 2020, DNA methyltransferases in cancer: biology, paradox, aberrations, and targeted therapy, Cancers (Basel), 12, 2123, 10.3390\u002Fcancers12082123\nZhao, 2009, Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha, Science, 324, 261, 10.1126\u002Fscience.1170944\nZhitomirsky, 2016, Lysosomes as mediators of drug resistance in cancer, Drug Resist. Updat., 24, 23, 10.1016\u002Fj.drup.2015.11.004\nZhou, 2019, Intrinsically disordered domains: sequence disorder function relationships, Protein Sci., 28, 1652, 10.1002\u002Fpro.3680",{"VOID":2413},"10.1016\u002Fj.drup.2022.100821","2024-05-12T20:38:11.528+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1368764622000206",[2417,2441,2461,2481,2501,2516,2529],{"id":2418,"sortIndex":19,"researcher":18,"roles":2419,"affiliations":2420,"properties":2438,"displayName":2440,"givenName":18,"familyName":18},"91b0e4ce-67a3-400b-b7cd-2de0b3c1b39f",[124],[2421,2429],{"id":2422,"sortIndex":19,"affiliation":2423,"properties":18},"0e4d2892-6470-409a-a610-495a485b197f",{"id":2422,"createTime":18,"updateTime":18,"relativeEntities":2424,"slug":18,"properties":2425,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2428,"statistic":18},[],{"title":2426},{"VI":2427},"Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, PR China",[],{"id":2430,"sortIndex":136,"affiliation":2431,"properties":2437},"492af572-a254-405d-949a-26d66e134b0b",{"id":2430,"createTime":18,"updateTime":18,"relativeEntities":2432,"slug":18,"properties":2433,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2436,"statistic":18},[],{"title":2434},{"VI":2435},"Benxi Institute of Pharmaceutical Research, Shenyang Pharmaceutical University, Shenyang, PR China",[],{},{"title":2439},{"VI":2440},"Sihong Chen",{"id":2442,"sortIndex":136,"researcher":18,"roles":2443,"affiliations":2444,"properties":2458,"displayName":2460,"givenName":18,"familyName":18},"d23733f2-b706-443a-a65f-315da84dfab2",[124],[2445,2451],{"id":2422,"sortIndex":19,"affiliation":2446,"properties":18},{"id":2422,"createTime":18,"updateTime":18,"relativeEntities":2447,"slug":18,"properties":2448,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2450,"statistic":18},[],{"title":2449},{"VI":2427},[],{"id":2430,"sortIndex":136,"affiliation":2452,"properties":2457},{"id":2430,"createTime":18,"updateTime":18,"relativeEntities":2453,"slug":18,"properties":2454,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2456,"statistic":18},[],{"title":2455},{"VI":2435},[],{},{"title":2459},{"VI":2460},"Yingxi Zhao",{"id":2462,"sortIndex":172,"researcher":18,"roles":2463,"affiliations":2464,"properties":2478,"displayName":2480,"givenName":18,"familyName":18},"67369124-71eb-42b1-9e18-bc890aa46597",[124],[2465,2471],{"id":2422,"sortIndex":19,"affiliation":2466,"properties":18},{"id":2422,"createTime":18,"updateTime":18,"relativeEntities":2467,"slug":18,"properties":2468,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2470,"statistic":18},[],{"title":2469},{"VI":2427},[],{"id":2430,"sortIndex":136,"affiliation":2472,"properties":2477},{"id":2430,"createTime":18,"updateTime":18,"relativeEntities":2473,"slug":18,"properties":2474,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2476,"statistic":18},[],{"title":2475},{"VI":2435},[],{},{"title":2479},{"VI":2480},"Shougeng Liu",{"id":2482,"sortIndex":193,"researcher":18,"roles":2483,"affiliations":2484,"properties":2498,"displayName":2500,"givenName":18,"familyName":18},"51d9075e-feab-431e-8929-07ee5f308bd8",[124],[2485,2491],{"id":2422,"sortIndex":19,"affiliation":2486,"properties":18},{"id":2422,"createTime":18,"updateTime":18,"relativeEntities":2487,"slug":18,"properties":2488,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2490,"statistic":18},[],{"title":2489},{"VI":2427},[],{"id":2430,"sortIndex":136,"affiliation":2492,"properties":2497},{"id":2430,"createTime":18,"updateTime":18,"relativeEntities":2493,"slug":18,"properties":2494,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2496,"statistic":18},[],{"title":2495},{"VI":2435},[],{},{"title":2499},{"VI":2500},"Jiayu Zhang",{"id":2502,"sortIndex":214,"researcher":18,"roles":2503,"affiliations":2504,"properties":2513,"displayName":2515,"givenName":18,"familyName":18},"a054ffd0-11ec-4491-9103-4dd839927e80",[124],[2505],{"id":2506,"sortIndex":19,"affiliation":2507,"properties":18},"3d83558b-2882-4732-8ef8-e3e8f509e55a",{"id":2506,"createTime":18,"updateTime":18,"relativeEntities":2508,"slug":18,"properties":2509,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2512,"statistic":18},[],{"title":2510},{"VI":2511},"The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa 3200003, Israel",[],{"title":2514},{"VI":2515},"Yehuda G. Assaraf",{"id":2517,"sortIndex":237,"researcher":18,"roles":2518,"affiliations":2519,"properties":2526,"displayName":2528,"givenName":18,"familyName":18},"27b6f15d-f727-4ae8-b0a2-0fcdf23b4760",[124],[2520],{"id":2422,"sortIndex":19,"affiliation":2521,"properties":18},{"id":2422,"createTime":18,"updateTime":18,"relativeEntities":2522,"slug":18,"properties":2523,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2525,"statistic":18},[],{"title":2524},{"VI":2427},[],{"title":2527},{"VI":2528},"Wei Cui",{"id":2530,"sortIndex":260,"researcher":18,"roles":2531,"affiliations":2532,"properties":2546,"displayName":2548,"givenName":18,"familyName":18},"67b1d1ce-6c2c-4586-9074-6a7e2944c9ff",[124],[2533,2539],{"id":2422,"sortIndex":19,"affiliation":2534,"properties":18},{"id":2422,"createTime":18,"updateTime":18,"relativeEntities":2535,"slug":18,"properties":2536,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2538,"statistic":18},[],{"title":2537},{"VI":2427},[],{"id":2430,"sortIndex":136,"affiliation":2540,"properties":2545},{"id":2430,"createTime":18,"updateTime":18,"relativeEntities":2541,"slug":18,"properties":2542,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2544,"statistic":18},[],{"title":2543},{"VI":2435},[],{},{"title":2547},{"VI":2548},"Lihui Wang",{"url":2415,"publisher":2550,"properties":2597},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2551,"slug":10,"properties":2552,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":2555,"manageAffiliations":2576,"indexDatabases":2582,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":2553,"title":2554},{"VOID":13},{"EN":15},[2556,2560,2564,2568,2572],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":2557,"label":2558,"description":2559,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":2561,"label":2562,"description":2563,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":31},{},{"id":34,"createTime":18,"updateTime":18,"relativeEntities":2565,"label":2566,"description":2567,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":37},{},{"id":40,"createTime":18,"updateTime":18,"relativeEntities":2569,"label":2570,"description":2571,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":43},{},{"id":46,"createTime":18,"updateTime":18,"relativeEntities":2573,"label":2574,"description":2575,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":49},{},[2577],{"id":53,"createTime":18,"updateTime":18,"relativeEntities":2578,"slug":18,"properties":2579,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2581,"statistic":18},[],{"title":2580},{"EN":57},[],[2583,2590],{"id":61,"indexDatabase":2584,"url":74,"indexYears":18,"academicFieldIds":2589,"indexDatabaseRanking":18},{"id":63,"createTime":18,"updateTime":18,"relativeEntities":2585,"label":2586,"description":2587,"key":70,"publicationTags":2588,"standard":18},[],{"EN":66,"VI":66},{"EN":68,"VI":69},[72,73],[76],{"id":78,"indexDatabase":2591,"url":89,"indexYears":90,"academicFieldIds":2596,"indexDatabaseRanking":97},{"id":80,"createTime":18,"updateTime":18,"relativeEntities":2592,"label":2593,"description":2594,"key":86,"publicationTags":2595,"standard":18},[],{"EN":83,"VI":83},{"EN":83,"VI":85},[88],[92,93,94,95,96],{"pages":2598,"volume":2600},{"VOID":2599},"100821",{"VOID":2601},"61","2022-03-01",2022,"ERROR_IN_GET_PLATFORM_ID","2026-02-26T21:52:03.169+00:00",[72,97],{"id":2608,"createTime":2609,"updateTime":2610,"relativeEntities":2611,"slug":2612,"properties":2613,"entityType":115,"verifyStatus":116,"verifyTime":2621,"verifyNote":118,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":2622,"fullTextUrl":18,"authors":2623,"publicationType":279,"publisherRelationship":2654,"citationCount":18,"citationInfo":18,"publishDate":2707,"publishYear":2708,"citationAnalyzeStatus":2604,"lastCitationAnalyze":2610,"indexDatabases":2709,"openAccess":18,"references":18,"isForceReanalyzing":1548},"ec145c8f-c0f7-499f-80d6-b3282e6974d5","2023-12-29T19:43:59.739+00:00","2026-02-14T11:17:34.150+00:00",[],"Dysregulation-of-ubiquitin-ligases-in-cancer",{"title":2614,"gsPaper":2616,"references":2617,"doi":2619},{"EN":2615},"Dysregulation of ubiquitin ligases in cancer",{"VOID":2409},{"VOID":2618},"Agirre, 2006, Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia, Int. J. Cancer, 118, 1945, 10.1002\u002Fijc.21584\nAkhoondi, 2007, FBXW7\u002FhCDC4 is a general tumor suppressor in human cancer, Cancer Res., 67, 9006, 10.1158\u002F0008-5472.CAN-07-1320\nAn, 2014, Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants, Cell Rep., 6, 657, 10.1016\u002Fj.celrep.2014.01.013\nAndreu, 2005, BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells, Cancer Res., 65, 3264, 10.1158\u002F0008-5472.CAN-04-1357\nAnglesio, 2004, Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase Hace1, in sporadic Wilms’ tumor versus normal kidney, Hum. Mol. Genet., 13, 2061, 10.1093\u002Fhmg\u002Fddh215\nAntoniou, 2003, Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies, Am. J. Hum. Genet., 72, 1117, 10.1086\u002F375033\nAppleman, 2006, CD28 costimulation mediates transcription of SKP2 and CKS1, the substrate recognition components of SCFSkp2 ubiquitin ligase that leads p27kip1 to degradation, Cell Cycle, 5, 2123, 10.4161\u002Fcc.5.18.3139\nAssie, 2014, Integrated genomic characterization of adrenocortical carcinoma, Nat. Genet., 46, 607, 10.1038\u002Fng.2953\nBabaei-Jadidi, 2011, FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation, J. Exp. Med., 208, 295, 10.1084\u002Fjem.20100830\nBadciong, 2002, MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination, J. Biol. Chem., 277, 49668, 10.1074\u002Fjbc.M208593200\nBai, 1996, SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box, Cell, 86, 263, 10.1016\u002FS0092-8674(00)80098-7\nBarbieri, 2012, Exome sequencing identifies recurrent SPOP FOXA1 and MED12 mutations in prostate cancer, Nat. Genet., 44, 685, 10.1038\u002Fng.2279\nBartel, 2001, Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines, Oncol. Res., 12, 451, 10.3727\u002F096504001108747459\nBartel, 2001, Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma, Int. J. Cancer, 95, 168, 10.1002\u002F1097-0215(20010520)95:3\u003C168::AID-IJC1029>3.0.CO;2-A\nBatuello, 2015, Src phosphorylation converts Mdm2 from a ubiquitinating to a neddylating E3 ligase, Proc. Natl. Acad. Sci. USA, 112, 1749, 10.1073\u002Fpnas.1416656112\nBea, 2013, Landscape of somatic mutations and clonal evolution in mantle cell lymphoma, Proc. Natl Acad. Sci. USA, 110, 18250, 10.1073\u002Fpnas.1314608110\nBeroukhim, 2010, The landscape of somatic copy-number alteration across human cancers, Nature, 463, 899, 10.1038\u002Fnature08822\nBirnbaum, 2011, Genome profiling of pancreatic adenocarcinoma, Gene. Chromosome. Cancer, 50, 456, 10.1002\u002Fgcc.20870\nBjornslett, 2012, Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers, BMC Cancer, 12, 454, 10.1186\u002F1471-2407-12-454\nBlattner, 2014, SPOP mutations in prostate cancer across demographically diverse patient cohorts, Neoplasia, 16, 14, 10.1593\u002Fneo.131704\nBond, 2004, A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans, Cell, 119, 591, 10.1016\u002Fj.cell.2004.11.022\nBoyd, 2000, An intact HDM2 RING-finger domain is required for nuclear exclusion of p53, Nat. Cell Biol., 2, 563, 10.1038\u002F35023500\nBretones, 2011, SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells, J. Biol. Chem., 286, 9815, 10.1074\u002Fjbc.M110.165977\nCahilly-Snyder, 1987, Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line, Somatic Cell Mol. Genet., 13, 235, 10.1007\u002FBF01535205\nCarrano, 1999, SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27, Nat. Cell Biol., 1, 193, 10.1038\u002F12013\nCesari, 2003, Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27, Proc. Natl Acad. Sci. USA, 100, 5956, 10.1073\u002Fpnas.0931262100\nChakraborty, 2015, The E3 ubiquitin ligase Trim7 mediates c-Jun\u002FAP-1 activation by Ras signalling, Nat. Commun., 6, 6782, 10.1038\u002Fncomms7782\nChen, 2015, Alternative splicing in cancer: implications for biology and therapy, Oncogene, 34, 1, 10.1038\u002Fonc.2013.570\nChen, 1998, The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers, Cancer Res., 58, 3677\nChen, 2007, Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer, Oncogene, 26, 2386, 10.1038\u002Fsj.onc.1210021\nChen, 2007, The amplified WWP1 gene is a potential molecular target in breast cancer, Int. J. Cancer, 121, 80, 10.1002\u002Fijc.22653\nChen, 2010, An insertion\u002Fdeletion polymorphism in the 3’ untranslated region of beta-transducin repeat-containing protein (betaTrCP) is associated with susceptibility for hepatocellular carcinoma in Chinese, Biochem. Biophys. Res. Commun., 391, 552, 10.1016\u002Fj.bbrc.2009.11.096\nChoschzick, 2010, MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer, Cancer Biomar., 8, 53, 10.3233\u002FDMA-2011-0806\nChuri, 2014, Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications, PloS one, 9, e115383, 10.1371\u002Fjournal.pone.0115383\nCleary, 2013, Identification of driver genes in hepatocellular carcinoma by exome sequencing, Hepatology, 58, 1693, 10.1002\u002Fhep.26540\nCorvi, 1995, Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma, Oncogene, 10, 1081\nCrossey, 1994, Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours, Hum. Genet., 93, 53, 10.1007\u002FBF00218913\nCrusio, 2010, The ubiquitous nature of cancer: the role of the SCF(Fbw7) complex in development and transformation, Oncogene, 29, 4865, 10.1038\u002Fonc.2010.222\nDavis, 2014, Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities, Cancer Cell, 26, 455, 10.1016\u002Fj.ccell.2014.09.013\nDeng, 2014, Methylation of CpG sites in RNF180 DNA promoter prediction poor survival of gastric cancer, Oncotarget, 5, 3173, 10.18632\u002Foncotarget.1888\nDenison, 2003, Alterations in the common fragile site gene Parkin in ovarian and other cancers, Oncogene, 22, 8370, 10.1038\u002Fsj.onc.1207072\nDrost, 2011, BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance, Cancer Cell, 20, 797, 10.1016\u002Fj.ccr.2011.11.014\nDurcan, 2015, The three ‘P's of mitophagy: PARKIN, PINK1, and post-translational modifications, Gene. Dev., 29, 989, 10.1101\u002Fgad.262758.115\nEakin, 2007, Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase, Proc. Natl. Acad. Sci. USA, 104, 5794, 10.1073\u002Fpnas.0610887104\nEinama, 2006, High-level Skp2 expression in pancreatic ductal adenocarcinoma: correlation with the extent of lymph node metastasis, higher histological grade, and poorer patient outcome, Pancreas, 32, 376, 10.1097\u002F01.mpa.0000220862.78248.c4\nElgazzar, 2012, A genome-wide association study identifies a genetic variant in the SIAH2 locus associated with hormonal receptor-positive breast cancer in Japanese, J. Hum. Genet., 57, 766, 10.1038\u002Fjhg.2012.108\nEskandari-Nasab, 2015, Effect of TP53 16-bp and beta-TrCP 9-bp INS\u002FDEL polymorphisms in relation to risk of breast cancer, Gene, 568, 181, 10.1016\u002Fj.gene.2015.05.048\nEvans, 2015, SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma, Canc. Lett., 363, 37, 10.1016\u002Fj.canlet.2015.03.044\nFan, 2015, The steroidogenic enzyme AKR1C3 regulates stability of the ubiquitin ligase Siah2 in prostate cancer cells, J. Biol. Chem., 10.1074\u002Fjbc.M115.662155\nFimiani, 1992, Anti-tumor properties of the organometallic complex cis-dimethylbis[sulfinylbis[methane]-S]platinum(II), Anti-cancer Drugs, 3, 9, 10.1097\u002F00001813-199202000-00002\nFlorenes, 1994, MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status, J. Natl. Cancer Inst., 86, 1297, 10.1093\u002Fjnci\u002F86.17.1297\nFord, 1998, Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium, Am. J. Hum. Genet., 62, 676, 10.1086\u002F301749\nForslund, 2008, MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers, Mol. Cancer Res., 6, 205, 10.1158\u002F1541-7786.MCR-07-0239\nFoulkes, 2008, Inherited susceptibility to common cancers, New Engl. J. Med., 359, 2143, 10.1056\u002FNEJMra0802968\nFridman, 2003, Tumor promotion by Mdm2 splice variants unable to bind p53, Cancer Res., 63, 5703\nFuchs, 1996, Phosphorylation-dependent targeting of c-Jun ubiquitination by Jun N-kinase, Oncogene, 13, 1531\nFuchs, 1998, Stress-activated kinases regulate protein stability, Oncogene, 17, 1483, 10.1038\u002Fsj.onc.1202184\nFuchs, 1998, JNK targets p53 ubiquitination and degradation in nonstressed cells, Gene. Dev., 12, 2658, 10.1101\u002Fgad.12.17.2658\nGarcia-Dios, 2013, High-throughput interrogation of PIK3CA, PTEN, KRAS FBXW7 and TP53 mutations in primary endometrial carcinoma, Gynecol. Oncol., 128, 327, 10.1016\u002Fj.ygyno.2012.11.037\nGeng, 2013, Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover, Proc. Natl Acad. Sci. USA, 110, 6997, 10.1073\u002Fpnas.1304502110\nGeng, 2014, Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer, Cancer Res., 74, 5631, 10.1158\u002F0008-5472.CAN-14-0476\nGenschik, 2013, The emerging family of CULLIN3-RING ubiquitin ligases (CRL3s): cellular functions and disease implications, EMBO J., 32, 2307, 10.1038\u002Femboj.2013.173\nGiannakis, 2014, RNF43 is frequently mutated in colorectal and endometrial cancers, Nat. Genet., 46, 1264, 10.1038\u002Fng.3127\nGnarra, 1994, Mutations of the VHL tumour suppressor gene in renal carcinoma, Nat. Genet., 7, 85, 10.1038\u002Fng0594-85\nGoldberg, 2002, Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation, EMBO J., 21, 3715, 10.1093\u002Femboj\u002Fcdf384\nGong, 2014, Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1\u002FS cyclins, Nat. Genet., 46, 588, 10.1038\u002Fng.2981\nGossage, 2015, VHL, the story of a tumour suppressor gene, Nat. Rev. Cancer, 15, 55, 10.1038\u002Fnrc3844\nGunther, 2000, Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations, Mod. Pathol., 13, 621, 10.1038\u002Fmodpathol.3880107\nHarris, 2005, MDM2 splice variants and their therapeutic implications, Curr. Cancer Drug Targets, 5, 21, 10.2174\u002F1568009053332654\nHaupt, 1997, Mdm2 promotes the rapid degradation of p53, Nature, 387, 296, 10.1038\u002F387296a0\nHav, 2011, MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option?, Virchows ArchivInt. J. Pathol., 458, 197, 10.1007\u002Fs00428-010-1012-7\nHibi, 2008, Aberrant methylation of the HACE1 gene is frequently detected in advanced colorectal cancer, Anticancer Res., 28, 1581\nHorwitz, 2007, A mechanism for transcriptional repression dependent on the BRCA1 E3 ubiquitin ligase, Proc. Natl Acad. Sci. USA, 104, 6614, 10.1073\u002Fpnas.0610481104\nHuang, 2011, The p53 inhibitors MDM2\u002FMDMX complex is required for control of p53 activity in vivo, Proc. Natl Acad. Sci. USA, 108, 12001, 10.1073\u002Fpnas.1102309108\nHuang, 2012, Stat3 induces oncogenic Skp2 expression in human cervical carcinoma cells, Biochem. Biophys. Res. Commun., 418, 186, 10.1016\u002Fj.bbrc.2012.01.004\nHuen, 2007, RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly, Cell, 131, 901, 10.1016\u002Fj.cell.2007.09.041\nHui, 2001, Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization, Lab. Invest. J. Tech. Methods Pathol., 81, 717, 10.1038\u002Flabinvest.3780280\nHung, 2011, Cul4A is an oncogene in malignant pleural mesothelioma, J. Cell. Mol. Med., 15, 350, 10.1111\u002Fj.1582-4934.2009.00971.x\nHuo, 2013, Roles of functional NFKB1 and beta-TrCP insertion\u002Fdeletion polymorphisms in mRNA expression and epithelial ovarian cancer susceptibility, Genet. Mol. Res., 12, 3435, 10.4238\u002F2013.March.11.6\nIwakawa, 2012, Contribution of germline mutations to PARK2 gene inactivation in lung adenocarcinoma, Gene. Chromosome. Canc., 51, 462, 10.1002\u002Fgcc.21933\nIwatsuki, 2010, Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance, Int. J. Cancer, 126, 1828, 10.1002\u002Fijc.24879\nJeon, 2015, Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies, Cancer Cell, 27, 354, 10.1016\u002Fj.ccell.2015.02.006\nJiang, 2014, Clinical significance of the ubiquitin ligase UBE3C in hepatocellular carcinoma revealed by exome sequencing, Hepatology, 59, 2216, 10.1002\u002Fhep.27012\nJiao, 2014, Whole-exome sequencing of pancreatic neoplasms with acinar differentiation, J. Pathol., 232, 428, 10.1002\u002Fpath.4310\nJones, 1998, Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis, Proc. Natl. Acad. Sci. USA, 95, 15608, 10.1073\u002Fpnas.95.26.15608\nJuhlin, 2015, Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma, J. Clin. Endocrinol. Metab., 100, E493, 10.1210\u002Fjc.2014-3282\nKalb, 2014, BRCA1 is a histone-H2A-specific ubiquitin ligase, Cell Rep., 8, 999, 10.1016\u002Fj.celrep.2014.07.025\nKamura, 2003, Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation, Proc. Natl. Acad. Sci. USA, 100, 10231, 10.1073\u002Fpnas.1831009100\nKandoth, 2013, Integrated genomic characterization of endometrial carcinoma, Nature, 497, 67, 10.1038\u002Fnature12113\nKatzav, 2015, Mutations of c-Cbl in myeloid malignancies, Oncotarget, 6, 10689, 10.18632\u002Foncotarget.3986\nKeats, 2007, Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma, Cancer Cell, 12, 131, 10.1016\u002Fj.ccr.2007.07.003\nKhosravi, 1999, Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage, Proc. Natl Acad. Sci. USA, 96, 14973, 10.1073\u002Fpnas.96.26.14973\nKhurana, 2006, Regulation of the ring finger E3 ligase Siah2 by p38 MAPK, J. Biol. Chem., 281, 35316, 10.1074\u002Fjbc.M606568200\nKim, 2003, The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer, Curr. Opin. Genet. Dev., 13, 55, 10.1016\u002FS0959-437X(02)00010-2\nKim, 2014, Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients, J. Clin. Oncol., 32, 121, 10.1200\u002FJCO.2013.50.8556\nKim, 2015, Downregulation of the Ubiquitin ligase RNF125 underlies resistance of melanoma cells to BRAF inhibitors via JAK1 deregulation, Cell Rep., 11, 1458, 10.1016\u002Fj.celrep.2015.04.049\nKnappskog, 2011, The MDM2 promoter SNP285C\u002F309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians, Cancer Cell, 19, 273, 10.1016\u002Fj.ccr.2010.12.019\nKnappskog, 2012, SNP285C modulates oestrogen receptor\u002FSp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer, Eur. J. Cancer, 48, 1988, 10.1016\u002Fj.ejca.2011.10.024\nKoch, 2005, Elevated expression of Wnt antagonists is a common event in hepatoblastomas, Clin. Cancer Res., 11, 4295, 10.1158\u002F1078-0432.CCR-04-1162\nKoepp, 2001, Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase, Science, 294, 173, 10.1126\u002Fscience.1065203\nKoyano, 2014, Ubiquitin is phosphorylated by PINK1 to activate parkin, Nature, 510, 162, 10.1038\u002Fnature13392\nKudo, 2004, Role of F-box protein betaTrcp1 in mammary gland development and tumorigenesis, Mol. Cell. Biol., 24, 8184, 10.1128\u002FMCB.24.18.8184-8194.2004\nKuhn, 2012, Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses, J. Natl. Cancer Inst., 104, 1503, 10.1093\u002Fjnci\u002Fdjs345\nKumar, 2014, Notch and NF-kB signaling pathways regulate miR-223\u002FFBXW7 axis in T-cell acute lymphoblastic leukemia, Leukemia, 28, 2324, 10.1038\u002Fleu.2014.133\nKurashige, 2012, Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma, Brit. J. Cancer, 106, 182, 10.1038\u002Fbjc.2011.509\nKwei, 2011, SMURF1 amplification promotes invasiveness in pancreatic cancer, PloS one, 6, e23924, 10.1371\u002Fjournal.pone.0023924\nLandre, 2014, Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities, Oncotarget, 5, 7988, 10.18632\u002Foncotarget.2431\nLaney, 1999, Substrate targeting in the ubiquitin system, Cell, 97, 427, 10.1016\u002FS0092-8674(00)80752-7\nLee, 2014, Genomic profile analysis of diffuse-type gastric cancers, Genome Biol., 15, R55, 10.1186\u002Fgb-2014-15-4-r55\nLe Gallo, 2012, Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes, Nat. Genet., 44, 1310, 10.1038\u002Fng.2455\nLerner, 2011, MiRNA-27a controls FBW7\u002FhCDC4-dependent cyclin E degradation and cell cycle progression, Cell Cycle, 10, 2172, 10.4161\u002Fcc.10.13.16248\nLi, 2003, Mono- versus polyubiquitination: differential control of p53 fate by Mdm2, Science, 302, 1972, 10.1126\u002Fscience.1091362\nLi, 2004, Correlation of Skp2 with carcinogenesis, invasion, metastasis, and prognosis in colorectal tumors, Int. J. Oncol., 25, 87\nLi, 2011, KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma, J. Hum. Genet., 56, 230, 10.1038\u002Fjhg.2010.172\nLi, 2012, Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics, Clin. Cancer Res., 18, 1598, 10.1158\u002F1078-0432.CCR-11-3077\nLi, 2012, MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7\u002FhCdc4, J. Cancer Res. Clin. Oncol., 138, 763, 10.1007\u002Fs00432-012-1154-x\nLi, 2014, Sequential expression of miR-182 and miR-503 cooperatively targets FBXW7, contributing to the malignant transformation of colon adenoma to adenocarcinoma, J. Pathol., 234, 488, 10.1002\u002Fpath.4407\nLi, 2014, TRIM65 regulates microRNA activity by ubiquitination of TNRC6, Proc. Natl. Acad. Sci. USA, 111, 6970, 10.1073\u002Fpnas.1322545111\nLi, 2015, Promoter methylation and expression changes of in cancerous tissues of patients with sporadic breast cancer, Oncol. Lett., 9, 1807, 10.3892\u002Fol.2015.2908\nLi, 2015, c-Abl regulates proteasome abundance by controlling the ubiquitin-proteasomal degradation of PSMA7 subunit, Cell Rep., 10, 484, 10.1016\u002Fj.celrep.2014.12.044\nLin, 2015, MicroRNA biogenesis pathways in cancer, Nat. Rev. Cancer, 15, 321, 10.1038\u002Fnrc3932\nLin, 2010, Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence, Nature, 464, 374, 10.1038\u002Fnature08815\nLinares, 2003, HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53, Proc. Natl Acad. Sci. USA, 100, 12009, 10.1073\u002Fpnas.2030930100\nLiu, 2012, Multiple novel alternative splicing forms of FBXW7alpha have a translational modulatory function and show specific alteration in human cancer, PloS one, 7, e49453, 10.1371\u002Fjournal.pone.0049453\nLiu, 2015, Targeting the ubiquitin pathway for cancer treatment, Biochim. Biophys. Acta, 1855, 50\nLott, 2009, DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer, PLoS Med., 6, e1000068, 10.1371\u002Fjournal.pmed.1000068\nLu, 2012, MiR-25 regulates Wwp2 and Fbxw7 and promotes reprogramming of mouse fibroblast cells to iPSCs, PloS one, 7, e40938, 10.1371\u002Fjournal.pone.0040938\nLucking, 2000, Association between early-onset Parkinson's disease and mutations in the parkin gene, New Engl. J. Med., 342, 1560, 10.1056\u002FNEJM200005253422103\nLukas, 2001, Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer, Cancer Res., 61, 3212\nMailand, 2007, RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins, Cell, 131, 887, 10.1016\u002Fj.cell.2007.09.040\nMallery, 2002, Activation of the E3 ligase function of the BRCA1\u002FBARD1 complex by polyubiquitin chains, EMBO J., 21, 6755, 10.1093\u002Femboj\u002Fcdf691\nMalyukova, 2007, The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling, Cancer Res., 67, 5611, 10.1158\u002F0008-5472.CAN-06-4381\nMansour, 2013, The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia, J. Exp. Med., 210, 1545, 10.1084\u002Fjem.20122516\nMao, 2004, Fbxw7\u002FCdc4 is a p53-dependent, haploinsufficient tumour suppressor gene, Nature, 432, 775, 10.1038\u002Fnature03155\nMao, 2008, FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression, Science, 321, 1499, 10.1126\u002Fscience.1162981\nMartinez, 2013, Frequent concerted genetic mechanisms disrupt multiple components of the NRF2 inhibitor KEAP1\u002FCUL3\u002FRBX1 E3-ubiquitin ligase complex in thyroid cancer, Mol. Cancer, 12, 124, 10.1186\u002F1476-4598-12-124\nMasuda, 2002, Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis, Cancer Res., 62, 3819\nMatsumoto, 1998, Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms, Cancer Res., 58, 609\nMeissner, 2013, The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma, Blood, 121, 3161, 10.1182\u002Fblood-2013-01-478834\nMerup, 1997, Amplification of multiple regions of chromosome 12, including 12q13-15, in chronic lymphocytic leukaemia, Eur. J. Haematol., 58, 174, 10.1111\u002Fj.1600-0609.1997.tb00944.x\nMilne, 2010, Loss of CDC4\u002FFBXW7 in gastric carcinoma, Cell. Oncol., 32, 347\nMomand, 1998, The MDM2 gene amplification database, Nucleic Acids Res., 26, 3453, 10.1093\u002Fnar\u002F26.15.3453\nMoradi, 2013, Helicobacter pylori infection and MDM2 SNP309 association with gastric cancer susceptibility, Genet. Test. Mol. Biomarkers, 17, 794, 10.1089\u002Fgtmb.2013.0173\nMuerkoster, 2005, Increased expression of the E3-ubiquitin ligase receptor subunit betaTRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells, Cancer Res., 65, 1316, 10.1158\u002F0008-5472.CAN-04-1626\nMuller, 2013, p53 mutations in cancer, Nat. Cell Biol., 15, 2, 10.1038\u002Fncb2641\nMuscarella, 2011, Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer, Epigenetics, 6, 710, 10.4161\u002Fepi.6.6.15773\nNakayama, 2000, Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication, EMBO J., 19, 2069, 10.1093\u002Femboj\u002F19.9.2069\nNakayama, 2004, Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia, Cell, 117, 941, 10.1016\u002Fj.cell.2004.06.001\nNiemeyer, 2010, mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia, Nat. Genet., 42, 794, 10.1038\u002Fng.641\nOfir-Rosenfeld, 2008, Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26, Mol. Cell, 32, 180, 10.1016\u002Fj.molcel.2008.08.031\nOjesina, 2014, Landscape of genomic alterations in cervical carcinomas, Nature, 506, 371, 10.1038\u002Fnature12881\nOkoro, 2013, Endogenous human MDM2-C is highly expressed in human cancers and functions as a p53-independent growth activator, PloS one, 8, e77643, 10.1371\u002Fjournal.pone.0077643\nOliner, 1993, Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53, Nature, 362, 857, 10.1038\u002F362857a0\nOnel, 2004, MDM2 and prognosis, Mol. Cancer Res., 2, 1, 10.1158\u002F1541-7786.1.2.1\nOng, 2012, Exome sequencing of liver fluke-associated cholangiocarcinoma, Nat. Genet., 44, 690, 10.1038\u002Fng.2273\nOnoyama, 2007, Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis, J. Exp. Med., 204, 2875, 10.1084\u002Fjem.20062299\nOrlicky, 2003, Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase, Cell, 112, 243, 10.1016\u002FS0092-8674(03)00034-5\nOugolkov, 2004, Associations among beta-TrCP, an E3 ubiquitin ligase receptor, beta-catenin, and NF-kappaB in colorectal cancer, J. Natl. Cancer Inst., 96, 1161, 10.1093\u002Fjnci\u002Fdjh219\nPal, 2014, Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer, Cancer Res., 74, 4955, 10.1158\u002F0008-5472.CAN-14-1211\nParsons, 2008, An integrated genomic analysis of human glioblastoma multiforme, Science, 321, 1807, 10.1126\u002Fscience.1164382\nPolonio-Vallon, 2014, Src kinase modulates the apoptotic p53 pathway by altering HIPK2 localization, Cell Cycle, 13, 115, 10.4161\u002Fcc.26857\nPost, 2010, A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development, Cancer Cell, 18, 220, 10.1016\u002Fj.ccr.2010.07.010\nPoulogiannis, 2010, PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice, Proc. Natl Acad. Sci. USA, 107, 15145, 10.1073\u002Fpnas.1009941107\nQi, 2013, The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity, Cancer Cell, 23, 332, 10.1016\u002Fj.ccr.2013.02.016\nReichert, 2007, Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells, Cancer Res., 67, 4149, 10.1158\u002F0008-5472.CAN-06-4484\nRose, 2011, Clinical relevance of SKP2 alterations in metastatic melanoma, Pigm. Cell Melanoma Res., 24, 197, 10.1111\u002Fj.1755-148X.2010.00784.x\nRossi, 2011, Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma, Blood, 118, 4930, 10.1182\u002Fblood-2011-06-359166\nRuffner, 2001, Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity, Proc. Natl. Acad. Sci. USA, 98, 5134, 10.1073\u002Fpnas.081068398\nRyland, 2013, RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary, J. Pathol., 229, 469, 10.1002\u002Fpath.4134\nSaigusa, 2005, Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas, Cancer Sci., 96, 676, 10.1111\u002Fj.1349-7006.2005.00099.x\nSakamoto, 2015, Clinicopathological significance of somatic RNF43 mutation and aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms of the pancreas, Mod. Pathol., 28, 261, 10.1038\u002Fmodpathol.2014.98\nSakata, 2009, Methylation of HACE1 in gastric carcinoma, Anticancer Res., 29, 2231\nSakata, 2013, Methylation of the HACE1 gene is frequently detected in hepatocellular carcinoma, Hepato-gastroenterology, 60, 781\nSanada, 2009, Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms, Nature, 460, 904, 10.1038\u002Fnature08240\nSato, 2013, Integrated molecular analysis of clear-cell renal cell carcinoma, Nat. Genet., 45, 860, 10.1038\u002Fng.2699\nSchneider, 2006, IKKalpha controls p52\u002FRelB at the skp2 gene promoter to regulate G1- to S-phase progression, EMBO J., 25, 3801, 10.1038\u002Fsj.emboj.7601259\nScortegagna, 2011, USP13 enzyme regulates Siah2 ligase stability and activity via noncatalytic ubiquitin-binding domains, J. Biol. Chem., 286, 27333, 10.1074\u002Fjbc.M111.218214\nScortegagna, 2014, Fine tuning of the UPR by the ubiquitin ligases Siah1\u002F2, PLoS Genet., 10, e1004348, 10.1371\u002Fjournal.pgen.1004348\nShanmugam, 2014, Ubiquitin-specific peptidase 20 regulates Rad17 stability, checkpoint kinase 1 phosphorylation and DNA repair by homologous recombination, J. Biol. Chem., 289, 22739, 10.1074\u002Fjbc.M114.550459\nShakya, 2011, BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity, Science, 334, 525, 10.1126\u002Fscience.1209909\nSharma, 2014, The prognostic value of promoter methylation in early stage triple negative breast cancer, J. Cancer Ther. Res., 3, 1, 10.7243\u002F2049-7962-3-2\nShim, 2003, Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate, Cancer Res., 63, 1583\nShimura, 2000, Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase, Nat. Genet., 25, 302, 10.1038\u002F77060\nShinomiya, 1999, Comparative genomic hybridization of squamous cell carcinoma of the esophagus: the possible involvement of the DPI gene in the 13q34 amplicon, Gene. Chromosome. Cancer, 24, 337, 10.1002\u002F(SICI)1098-2264(199904)24:4\u003C337::AID-GCC7>3.0.CO;2-O\nShrikhande, 2010, O-glycosylation regulates ubiquitination and degradation of the anti-inflammatory protein A20 to accelerate atherosclerosis in diabetic ApoE-null mice, PloS one, 5, e14240, 10.1371\u002Fjournal.pone.0014240\nSingh, 2006, Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer, PLoS Med., 3, e420, 10.1371\u002Fjournal.pmed.0030420\nSkaar, 2014, SCF ubiquitin ligase-targeted therapies, Nat. Rev. Drug Disc., 13, 889, 10.1038\u002Fnrd4432\nSpruck, 2002, hCDC4 gene mutations in endometrial cancer, Cancer Res., 62, 4535\nStarita, 2005, BRCA1\u002FBARD1 ubiquitinate phosphorylated RNA polymerase II, J. Biol. Chem., 280, 24498, 10.1074\u002Fjbc.M414020200\nSteinman, 2004, An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis, J. Biol. Chem., 279, 4877, 10.1074\u002Fjbc.M305966200\nSuryaraja, 2013, The E3 ubiquitin ligase Itch regulates tumor suppressor protein RASSF5\u002FNORE1 stability in an acetylation-dependent manner, Cell Death Dis., 4, e565, 10.1038\u002Fcddis.2013.91\nTan, 2010, CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases, PloS one, 5, e8972, 10.1371\u002Fjournal.pone.0008972\nTheurillat, 2014, Prostate cancer Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer, Science, 346, 85, 10.1126\u002Fscience.1250255\nTraub, 2006, Prognostic impact of Skp2 and p27 in human breast cancer, Breast Cancer Res. Treat., 99, 185, 10.1007\u002Fs10549-006-9202-3\nTruong, 2014, BRCA1 promoter hypermethylation signature for early detection of breast cancer in the Vietnamese population, Asian Pacific J. Cancer Prev., 15, 9607, 10.7314\u002FAPJCP.2014.15.22.9607\nTsai, 2010, Inhibition of FOXO3 tumor suppressor function by betaTrCP1 through ubiquitin-mediated degradation in a tumor mouse model, PloS one, 5, e11171, 10.1371\u002Fjournal.pone.0011171\nTsunematsu, 2004, Mouse Fbw7\u002FSel-10\u002FCdc4 is required for notch degradation during vascular development, J. Biol. Chem., 279, 9417, 10.1074\u002Fjbc.M312337200\nVeeriah, 2010, Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies, Nat. Genet., 42, 77, 10.1038\u002Fng.491\nViotti, 2014, Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity, Oncogene, 33, 1764, 10.1038\u002Fonc.2013.124\nWang, 2009, Suppression of anoikis by SKP2 amplification and overexpression promotes metastasis of esophageal squamous cell carcinoma, Mol. Cancer Res., 7, 12, 10.1158\u002F1541-7786.MCR-08-0092\nWang, 2011, Upregulation of miR-27a contributes to the malignant transformation of human bronchial epithelial cells induced by SV40 small T antigen, Oncogene, 30, 3875, 10.1038\u002Fonc.2011.103\nWang, 2011, MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination, J. Biol. Chem., 286, 23725, 10.1074\u002Fjbc.M110.213868\nWang, 2014, miR-214-mediated downregulation of RNF8 induces chromosomal instability in ovarian cancer cells, Cell Cycle, 13, 3519, 10.4161\u002F15384101.2014.958413\nWang, 2014, Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer, Nat. Genet., 46, 573, 10.1038\u002Fng.2983\nWang, 2014, CHIP\u002FStub1 functions as a tumor suppressor and represses NF-kappaB-mediated signaling in colorectal cancer, Carcinogenesis, 35, 983, 10.1093\u002Fcarcin\u002Fbgt393\nWei, 2005, The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase, Cancer Cell, 8, 25, 10.1016\u002Fj.ccr.2005.06.005\nWeir, 2007, Characterizing the cancer genome in lung adenocarcinoma, Nature, 450, 893, 10.1038\u002Fnature06358\nWelcker, 2008, FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation, Nat. Rev. Cancer, 8, 83, 10.1038\u002Fnrc2290\nWelcker, 2004, The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation, Proc. Natl Acad. Sci. USA, 101, 9085, 10.1073\u002Fpnas.0402770101\nWelcker, 2004, A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size, Curr. Biol., 14, 1852, 10.1016\u002Fj.cub.2004.09.083\nWelcsh, 2001, BRCA1 and BRCA2 and the genetics of breast and ovarian cancer, Hum. Mol. Genet., 10, 705, 10.1093\u002Fhmg\u002F10.7.705\nWertz, 2011, Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7, Nature, 471, 110, 10.1038\u002Fnature09779\nWestbrook, 2008, SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation, Nature, 452, 370, 10.1038\u002Fnature06780\nWilliams, 2010, Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms’ tumor, Clin. Cancer Res., 16, 2036, 10.1158\u002F1078-0432.CCR-09-2890\nWinston, 1999, The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro, Genes Dev., 13, 270, 10.1101\u002Fgad.13.3.270\nWinter, 2008, Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR, Nat. Cell Biol., 10, 812, 10.1038\u002Fncb1743\nWu, 1996, Identification of a RING protein that can interact in vivo with the BRCA1 gene product, Nat. Genet., 14, 430, 10.1038\u002Fng1296-430\nXie, 2015, Evaluating the clinical feasibility: the direct bisulfite genomic sequencing for examination of methylated status of E3 ubiquitin ligase RNF180 DNA promoter to predict the survival of gastric cancer, Cancer Biomarkers, 10.3233\u002FCBM-150466\nXiong, 2009, Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia, Leukemia Res., 33, 1454, 10.1016\u002Fj.leukres.2009.04.007\nXiong, 2015, A recurrent mutation in PARK2 is associated with familial lung cancer, Am. J. Hum. Genet., 96, 301, 10.1016\u002Fj.ajhg.2014.12.016\nXu, 2010, MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7, J. Biol. Chem., 285, 34439, 10.1074\u002Fjbc.M110.152306\nYada, 2004, Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7, EMBO J., 23, 2116, 10.1038\u002Fsj.emboj.7600217\nYamashita, 2015, Epigenetic inactivation of BRCA1 through promoter hypermethylation and its clinical importance in triple-negative breast cancer, Clin Breast Cancer, 10.1016\u002Fj.clbc.2015.06.009\nYang, 2002, Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival, Clin. Cancer Res., 8, 3419\nYang, 2015, The oncogenic microRNA-21 inhibits the tumor suppressive activity of FBXO11 to promote tumorigenesis, J. Biol. Chem., 290, 6037, 10.1074\u002Fjbc.M114.632125\nYasui, 2002, TFDP1 CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas, Hepatology, 35, 1476, 10.1053\u002Fjhep.2002.33683\nYasunaga, 2011, Ubiquitin-specific peptidase 20 targets TRAF6 and human T cell leukemia virus type 1 tax to negatively regulate NF-kappaB signaling, J. Virol., 85, 6212, 10.1128\u002FJVI.00079-11\nYe, 2004, Recognition of phosphodegron motifs in human cyclin E by the SCF(Fbw7) ubiquitin ligase, J. Biol. Chem., 279, 50110, 10.1074\u002Fjbc.M409226200\nYokobori, 2012, Copy number loss of FBXW7 is related to gene expression and poor prognosis in esophageal squamous cell carcinoma, Int. J. Oncol., 41, 253\nYokoi, 2004, Amplification and overexpression of SKP2 are associated with metastasis of non-small-cell lung cancers to lymph nodes, Am. J. Pathol., 165, 175, 10.1016\u002FS0002-9440(10)63286-5\nYu, 1998, Human CUL-1 associates with the SKP1\u002FSKP2 complex and regulates p21(CIP1\u002FWAF1) and cyclin D proteins, Proc. Natl Acad. Sci. USA, 95, 11324, 10.1073\u002Fpnas.95.19.11324\nYu, 2006, BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP, Gene. Dev., 20, 1721, 10.1101\u002Fgad.1431006\nYu, 2009, Genetic susceptibility to the development and progression of breast cancer associated with polymorphism of cell cycle and ubiquitin ligase genes, Carcinogenesis, 30, 1562, 10.1093\u002Fcarcin\u002Fbgp173\nZbar, 1987, Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma, Nature, 327, 721, 10.1038\u002F327721a0\nZhang, 2006, F-box protein Skp2: a novel transcriptional target of E2F, Oncogene, 25, 2615, 10.1038\u002Fsj.onc.1209286\nZhang, 2012, The MDM2 309 T\u002FG polymorphism is associated with head and neck cancer risk especially in nasopharyngeal cancer: a meta-analysis, Onkologie, 35, 666, 10.1159\u002F000343639\nZhang, 2013, A common variant in the SIAH2 locus is associated with estrogen receptor-positive breast cancer in the Chinese Han population, PloS one, 8, e79365, 10.1371\u002Fjournal.pone.0079365\nZhang, 2013, Deubiquitylation and stabilization of PTEN by USP13, Nat. Cell Biol., 15, 1486, 10.1038\u002Fncb2874\nZhang, 2015, Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-alpha protein turnover, Cell Death Dis., 6, e1687, 10.1038\u002Fcddis.2015.47\nZhao, 2013, Ligases as attractive anti-cancer targets, Curr. Pharm. Design, 19, 3215, 10.2174\u002F13816128113199990300\nZhao, 2010, The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation, Cancer Res., 70, 4728, 10.1158\u002F0008-5472.CAN-10-0040\nZhao, 2013, Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma, Proc. Natl Acad. Sci. USA, 110, 2916, 10.1073\u002Fpnas.1222577110\nZheng, 2013, Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis, Nat. Commun., 4, 2996, 10.1038\u002Fncomms3996\nZhou, 2015, miR-92a is upregulated in cervical cancer and promotes cell proliferation and invasion by targeting FBXW7, Biochem. Biophys. Res. Commun., 458, 63, 10.1016\u002Fj.bbrc.2015.01.066\nZhu, 2004, Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras mutation is a poor prognostic marker, Clin. Cancer Res., 10, 1984, 10.1158\u002F1078-0432.CCR-03-0470\nZhu, 2015, Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer, Breast Cancer Res. Treat., 150, 479, 10.1007\u002Fs10549-015-3338-y\nZou, 2013, RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma but absent in other subtypes of ovarian cancer, Gene, 531, 112, 10.1016\u002Fj.gene.2013.08.054",{"VOID":2620},"10.1016\u002Fj.drup.2015.09.001","2024-05-12T06:12:37.113+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1368764615000515",[2624,2639],{"id":2625,"sortIndex":19,"researcher":18,"roles":2626,"affiliations":2627,"properties":2636,"displayName":2638,"givenName":18,"familyName":18},"4af5d513-51e5-401a-92ba-218b03803691",[124],[2628],{"id":2629,"sortIndex":19,"affiliation":2630,"properties":18},"0418044f-9d0d-42d4-8a48-e9d7ff77cc1e",{"id":2629,"createTime":18,"updateTime":18,"relativeEntities":2631,"slug":18,"properties":2632,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2635,"statistic":18},[],{"title":2633},{"VI":2634},"University of Maryland School of Medicine, Baltimore, 21201, USA",[],{"title":2637},{"VI":2638},"Jianfei Qi",{"id":2640,"sortIndex":136,"researcher":18,"roles":2641,"affiliations":2642,"properties":2651,"displayName":2653,"givenName":18,"familyName":18},"3c50cdfe-2a2e-4cb1-9503-3fc450bfd9d6",[124],[2643],{"id":2644,"sortIndex":19,"affiliation":2645,"properties":18},"aabdf108-2578-4cff-a71a-9c958f933a7d",{"id":2644,"createTime":18,"updateTime":18,"relativeEntities":2646,"slug":18,"properties":2647,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2650,"statistic":18},[],{"title":2648},{"VI":2649},"Sanford Burnham Prebys Medical Discovery Institute, La Jolla, 92037, USA",[],{"title":2652},{"VI":2653},"Ze’ev A. Ronai",{"url":2622,"publisher":2655,"properties":2702},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2656,"slug":10,"properties":2657,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":2660,"manageAffiliations":2681,"indexDatabases":2687,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":2658,"title":2659},{"VOID":13},{"EN":15},[2661,2665,2669,2673,2677],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":2662,"label":2663,"description":2664,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":2666,"label":2667,"description":2668,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":31},{},{"id":34,"createTime":18,"updateTime":18,"relativeEntities":2670,"label":2671,"description":2672,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":37},{},{"id":40,"createTime":18,"updateTime":18,"relativeEntities":2674,"label":2675,"description":2676,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":43},{},{"id":46,"createTime":18,"updateTime":18,"relativeEntities":2678,"label":2679,"description":2680,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":49},{},[2682],{"id":53,"createTime":18,"updateTime":18,"relativeEntities":2683,"slug":18,"properties":2684,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2686,"statistic":18},[],{"title":2685},{"EN":57},[],[2688,2695],{"id":61,"indexDatabase":2689,"url":74,"indexYears":18,"academicFieldIds":2694,"indexDatabaseRanking":18},{"id":63,"createTime":18,"updateTime":18,"relativeEntities":2690,"label":2691,"description":2692,"key":70,"publicationTags":2693,"standard":18},[],{"EN":66,"VI":66},{"EN":68,"VI":69},[72,73],[76],{"id":78,"indexDatabase":2696,"url":89,"indexYears":90,"academicFieldIds":2701,"indexDatabaseRanking":97},{"id":80,"createTime":18,"updateTime":18,"relativeEntities":2697,"label":2698,"description":2699,"key":86,"publicationTags":2700,"standard":18},[],{"EN":83,"VI":83},{"EN":83,"VI":85},[88],[92,93,94,95,96],{"pages":2703,"volume":2705},{"VOID":2704},"1-11",{"VOID":2706},"23","2015-11-01",2015,[72,97],{"id":2711,"createTime":2712,"updateTime":2713,"relativeEntities":2714,"slug":2715,"properties":2716,"entityType":115,"verifyStatus":116,"verifyTime":2724,"verifyNote":118,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":2725,"fullTextUrl":18,"authors":2726,"publicationType":279,"publisherRelationship":2742,"citationCount":18,"citationInfo":18,"publishDate":2794,"publishYear":1638,"citationAnalyzeStatus":2604,"lastCitationAnalyze":2795,"indexDatabases":2796,"openAccess":18,"references":18,"isForceReanalyzing":1548},"b7401f79-f8f7-4b52-80c9-1c560b636cc0","2023-12-13T03:43:05.152+00:00","2026-02-07T22:31:58.598+00:00",[],"Hypoxic-cytotoxic-agents-a-new-approach-to-cancer-chemotherapy",{"title":2717,"gsPaper":2719,"references":2720,"doi":2722},{"EN":2718},"Hypoxic cytotoxic agents: a new approach to cancer chemotherapy",{"VOID":2409},{"VOID":2721},"Gray, 1953, Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy, Br J Radiol, 26, 638, 10.1259\u002F0007-1285-26-312-638\nGrau, 1988, Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay, Radiother Oncol, 13, 301, 10.1016\u002F0167-8140(88)90225-3\nSimpson-Herren, 1988, Variability of tumor response to chemotherapy. II. Contribution of tumor heterogeneity, Cancer Chemother Pharmacol, 22, 131, 10.1007\u002FBF00257310\nDurand, 1994, The influence of microenvironmental factors during cancer therapy, In vivo, 8, 691\nTeicher, 1994, Hypoxia and drug resistance, Cancer Metastasis Rev, 13, 139, 10.1007\u002FBF00689633\nMueller-Klieser, 1981, Intracapillary oxyhemoglobin saturation of malignant tumors in humans, Int J Radiat Oncol Biol Phys, 7, 1397, 10.1016\u002F0360-3016(81)90036-5\nRaleigh, 1998, Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker, Cancer Res, 58, 3765\nOlive, 1993, Gel electrophoresis of individual cells to quantify hypoxic fraction in human breast cancers, Cancer Res, 53, 733\nVaupel, 1991, Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements, Cancer Res, 51, 3316\nNordsmark, 1994, Measurement of human tumour oxygenation status by a polarographic needle electrode, Acta Oncol, 33, 383, 10.3109\u002F02841869409098433\nBrizel, 1997, Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck, Int J Radiat Oncol Biol Phys, 38, 285, 10.1016\u002FS0360-3016(97)00101-6\nWouters, 1997, Cells at intermediate oxygen levels can be more important than the ‘hypoxic fraction’ in determining tumor response to fractionated radiotherapy, Radiat Res, 147, 541, 10.2307\u002F3579620\nNordsmark, 1996, Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck, Radiother Oncol, 41, 31, 10.1016\u002FS0167-8140(96)91811-3\nFyles, 1998, Oxygenation predicts radiation response and survival in patients with cervix cancer, Radiother Oncol, 48, 149, 10.1016\u002FS0167-8140(98)00044-9\nHockel, 1996, Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix, Cancer Res, 56, 4509\nGraeber, 1996, Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours, Nature, 379, 88, 10.1038\u002F379088a0\nBrizel, 1996, Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma, Cancer Res, 56, 941\nSundfor, 1998, Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix, Br J Cancer, 78, 822, 10.1038\u002Fbjc.1998.586\nTannock, 1981, Response of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions, Br J Cancer, 42, 245, 10.1038\u002Fbjc.1981.37\nTeicher, 1981, Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells, Cancer Research, 41, 73\nEnsley, 1983, Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck, Cancer, 54, 811, 10.1002\u002F1097-0142(19840901)54:5\u003C811::AID-CNCR2820540508>3.0.CO;2-E\nJaulerry, 1992, Induction chemotherapy in advanced head and neck tumors: Results of two randomized trials, Int J Radiat Oncol Biol Phys, 23, 483, 10.1016\u002F0360-3016(92)90002-Y\nBourhis, 1999, Meta-analyses in head and neck squamous cell carcinoma, What is the role of chemotherapy? Hematol Oncol Clin North Am, 13, 769, 10.1016\u002FS0889-8588(05)70091-5\nMunck, 1991, Computed tomographic density of metastatic lymph nodes as a treatment-related prognostic factor in advanced head and neck cancer, J Natl Cancer Inst, 83, 569, 10.1093\u002Fjnci\u002F83.8.569\nGrabenbauer, 1998, Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III\u002FIV head and neck cancer, Radiother Oncol, 47, 175, 10.1016\u002FS0167-8140(98)00016-4\nIyer, 1964, Mitomycins and porfiromycin: chemical mechanism of activation and crosslinking of DNA, Science, 145, 55, 10.1126\u002Fscience.145.3627.55\nRockwell, 1982, Mitomycin-C as a prototype bioreductive alkylating agent: in vitro studies of metabolism and cytotoxicity, Int J Radiat Oncol Biol Phys, 8, 753, 10.1016\u002F0360-3016(82)90728-3\nBrown, 1996, Hypoxia-specific cytotoxins in cancer therapy, Semin Radiol Oncol, 6, 22, 10.1016\u002FS1053-4296(96)80033-6\nHaffty, 1993, Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomized clinical trials [see comments], Int J Radiat Oncol Biol Phys, 27, 241, 10.1016\u002F0360-3016(93)90234-M\nWang, 1992, Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation, Cancer Res, 52, 4473\nLloyd, 1991, Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical, Mol Pharmacol, 40, 440\nBrown, 1990, Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors, Cancer Research, 50, 7745\nDorie, 1993, Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin, Cancer Res, 53, 4633\nPatterson, 1993, Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent, Cancer Metastasis Rev, 12, 119, 10.1007\u002FBF00689805\nMcKeown, 1995, AQ4N: an alkylaminoanthraquinone N-oxides showing bioreductive potential and positive interaction with radiation in vivo, Br J Cancer, 72, 76, 10.1038\u002Fbjc.1995.280\nMcKeown, 1996, Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation, Br J Cancer Suppl, 27, S39\nvon Pawel, 1998, Survival benefit from tirazone (tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC) patients: Final results from the international phase III CATAPULT 1 trial, Proc Amer Soc Clin Oncol, 17, 454a\nBrown, 1999, The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture, Cancer Res, 59, 5863\nBrown, 1993, SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours, Br J Cancer, 67, 1163, 10.1038\u002Fbjc.1993.220",{"VOID":2723},"10.1054\u002Fdrup.2000.0120","2024-05-11T20:39:43.579+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1368764600901201",[2727],{"id":2728,"sortIndex":19,"researcher":18,"roles":2729,"affiliations":2730,"properties":2739,"displayName":2741,"givenName":18,"familyName":18},"0838ce94-4569-4606-8ab6-0533eeb406e6",[124],[2731],{"id":2732,"sortIndex":19,"affiliation":2733,"properties":18},"3d3dd6ee-5c5a-4c52-a78c-5d58553e32ba",{"id":2732,"createTime":18,"updateTime":18,"relativeEntities":2734,"slug":18,"properties":2735,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2738,"statistic":18},[],{"title":2736},{"VI":2737},"Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA",[],{"title":2740},{"VI":2741},"J.Martin Brown",{"url":2725,"publisher":2743,"properties":2790},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2744,"slug":10,"properties":2745,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":2748,"manageAffiliations":2769,"indexDatabases":2775,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":2746,"title":2747},{"VOID":13},{"EN":15},[2749,2753,2757,2761,2765],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":2750,"label":2751,"description":2752,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":2754,"label":2755,"description":2756,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":31},{},{"id":34,"createTime":18,"updateTime":18,"relativeEntities":2758,"label":2759,"description":2760,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":37},{},{"id":40,"createTime":18,"updateTime":18,"relativeEntities":2762,"label":2763,"description":2764,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":43},{},{"id":46,"createTime":18,"updateTime":18,"relativeEntities":2766,"label":2767,"description":2768,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":49},{},[2770],{"id":53,"createTime":18,"updateTime":18,"relativeEntities":2771,"slug":18,"properties":2772,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2774,"statistic":18},[],{"title":2773},{"EN":57},[],[2776,2783],{"id":61,"indexDatabase":2777,"url":74,"indexYears":18,"academicFieldIds":2782,"indexDatabaseRanking":18},{"id":63,"createTime":18,"updateTime":18,"relativeEntities":2778,"label":2779,"description":2780,"key":70,"publicationTags":2781,"standard":18},[],{"EN":66,"VI":66},{"EN":68,"VI":69},[72,73],[76],{"id":78,"indexDatabase":2784,"url":89,"indexYears":90,"academicFieldIds":2789,"indexDatabaseRanking":97},{"id":80,"createTime":18,"updateTime":18,"relativeEntities":2785,"label":2786,"description":2787,"key":86,"publicationTags":2788,"standard":18},[],{"EN":83,"VI":83},{"EN":83,"VI":85},[88],[92,93,94,95,96],{"pages":2791,"volume":2793},{"VOID":2792},"7-13",{"VOID":1636},"2000-02-01","2026-02-07T22:31:58.597+00:00",[72,97],{"id":2798,"createTime":2799,"updateTime":2800,"relativeEntities":2801,"slug":2802,"properties":2803,"entityType":115,"verifyStatus":116,"verifyTime":2800,"verifyNote":118,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":2810,"fullTextUrl":18,"authors":2811,"publicationType":279,"publisherRelationship":2849,"citationCount":18,"citationInfo":18,"publishDate":2902,"publishYear":2903,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":2904,"openAccess":18,"references":18,"isForceReanalyzing":1548},"8fe1c7ee-4781-4fe7-b55c-1033ecc8b48a","2024-02-08T11:47:24.187+00:00","2025-02-27T02:13:36.494+00:00",[],"The-AbaR-antibiotic-resistance-islands-found-in-Acinetobacter-baumannii-global-clone-1-Structure-origin-and-evolution",{"title":2804,"references":2806,"doi":2808},{"EN":2805},"The AbaR antibiotic resistance islands found in Acinetobacter baumannii global clone 1 – Structure, origin and evolution",{"VOID":2807},"Adams, 2010, Genomewide analysis of divergence of antibiotic resistance determinants in closely related isolates of Acinetobacter baumannii, Antimicrob. Agents Chemother., 54, 3569, 10.1128\u002FAAC.00057-10\nAdams, 2008, Comparative genome sequence analysis of multidrug-resistant Acinetobacter baumannii, J. Bacteriol., 190, 8053, 10.1128\u002FJB.00834-08\nBlackwell, 2016, IncM plasmid R1215 is the source of chromosomally located regions containing multiple antibiotic resistance genes in the globally disseminated Acinetobacter baumannii GC1 and GC2 clones, mSphere, 1, 10.1128\u002FmSphere.00117-16\nBlackwell, 2015, Evolution of AbGRI2-0, the progenitor of the AbGRI2 resistance island in global clone 2 of Acinetobacter baumannii, Antimicrob. Agents Chemother., 60, 1421, 10.1128\u002FAAC.02662-15\nBoucher, 2009, Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America, Clin. Infect. Dis., 48, 1, 10.1086\u002F595011\nBröer, 1993, Arsenic efflux governed by the arsenic resistance determinant of Staphylococcus aureus plasmid pI258, J. Bacteriol., 175, 3480, 10.1128\u002Fjb.175.11.3480-3485.1993\nChristie-Oleza, 2010, TnpR encoded by an ISPpu12 isoform regulates transposition of two different ISL3-like insertion sequences in Pseudomonas stutzeri after conjugative interaction, J. Bacteriol., 192, 1423, 10.1128\u002FJB.01336-09\nClark, 2016, Emergence of antimicrobial resistance among Acinetobacter species: a global threat, Curr. Opin. Crit. Care, 22, 491, 10.1097\u002FMCC.0000000000000337\nCollis, 1993, Site-specific insertion of gene cassettes into integrons, Mol. Microbiol., 9, 41, 10.1111\u002Fj.1365-2958.1993.tb01667.x\nCoyne, 2010, Acquisition of multidrug resistance transposon Tn6061 and IS6100-mediated large chromosomal inversions in Pseudomonas aeruginosa clinical isolates, Microbiology, 156, 1448, 10.1099\u002Fmic.0.033639-0\nCraig, 1996, Transposon Tn, Curr. Top. Microbiol. Immunol., 204, 27\nDevaud, 1982, Transposon-mediated multiple antibiotic resistance in Acinetobacter strains, Antimicrob. Agents Chemother., 22, 323, 10.1128\u002FAAC.22.2.323\nDi Nocera, 2011, Genome organization of epidemic Acinetobacter baumannii strains, BMC Microbiol., 11, 224, 10.1186\u002F1471-2180-11-224\nDiancourt, 2010, The population structure of Acinetobacter baumannii: expanding multiresistant clones from an ancestral susceptible genetic pool, PLoS One, 5, e10034, 10.1371\u002Fjournal.pone.0010034\nDijkshoorn, 1996, Comparison of outbreak and nonoutbreak Acinetobacter baumannii strains by genotypic and phenotypic methods, J. Clin. Microbiol., 34, 1519, 10.1128\u002FJCM.34.6.1519-1525.1996\nFournier, 2006, Comparative genomics of multidrug resistance in Acinetobacter baumannii, PLoS Genet., 2, e7, 10.1371\u002Fjournal.pgen.0020007\nFu, 2010, Wide dissemination of OXA-23-producing carbapenem-resistant Acinetobacter baumannii clonal complex 22 in multiple cities of China, J. Antimicrob. Chemother., 65, 644, 10.1093\u002Fjac\u002Fdkq027\nGallagher, 2015, Resources for genetic and genomic analysis of emerging pathogen Acinetobacter baumannii, J. Bacteriol., 197, 2027, 10.1128\u002FJB.00131-15\nGrosso, 2011, OXA-23-producing Acinetobacter baumannii: a new hotspot of diversity in Rio de Janeiro?, J. Antimicrob. Chemother., 66, 62, 10.1093\u002Fjac\u002Fdkq406\nHall, 1995, Mobile gene cassettes and integrons: capture and spread of genes by site-specific recombination, Mol. Microbiol., 15, 593, 10.1111\u002Fj.1365-2958.1995.tb02368.x\nHamidian, 2011, AbaR4 replaces AbaR3 in a carbapenem resistant Acinetobacter baumannii isolate belonging to global clone 1 from an Australian hospital, J. Antimicrob. Chemother., 66, 2484, 10.1093\u002Fjac\u002Fdkr356\nHamidian, 2017, Origin of the AbGRI1 antibiotic resistance island found in the comM gene of Acinetobacter baumannii GC2 isolates, J. Antimicrob. Chemother., 72, 2944, 10.1093\u002Fjac\u002Fdkx206\nHamidian, 2017, Origin of the AbGRI1 antibiotic resistance island found in the comM gene of Acinetobacter baumannii GC2 isolates, J. Antimicrob. Chemother., 72, 2944, 10.1093\u002Fjac\u002Fdkx206\nHamidian, 2015, Genome sequence of Acinetobacter baumannii strain D36, an antibiotic-resistant isolate from lineage 2 of global clone 1, Genome Announc., 3, 10.1128\u002FgenomeA.01478-15\nHamidian, 2014, A GC1 Acinetobacter baumannii isolate carrying AbaR3 and the aminoglycoside resistance transposon TnaphA6 in a conjugative plasmid, J. Antimicrob. Chemother., 69, 955, 10.1093\u002Fjac\u002Fdkt454\nHamidian, 2017, Corrected genome of Acinetobacter baumannii strain AB0057, an antibiotic resistant isolate from lineage 1 of Global Clone 1, Genome Announc., 5, 10.1128\u002FgenomeA.00836-17\nHamidian, 2014, Identification of a marker for two lineages within the GC1 clone of Acinetobacter baumannii, J. Antimicrob. Chemother., 69, 557, 10.1093\u002Fjac\u002Fdkt379\nHamouda, 2010, Characterization of epidemiologically unrelated Acinetobacter baumannii isolates from four continents by use of multilocus sequence typing, pulsed-field gel electrophoresis, and sequence-based typing of blaOXA-51-like genes, J. Clin. Microbiol., 48, 2476, 10.1128\u002FJCM.02431-09\nHiggins, 2010, Global spread of carbapenem-resistant Acinetobacter baumannii, J. Antimicrob. Chemother., 65, 233, 10.1093\u002Fjac\u002Fdkp428\nHolt, 2015, Genome sequence of Acinetobacter baumannii strain A1, an early example of antibiotic-resistant Global Clone 1, Genome Announc., 3, e00032, 10.1128\u002FgenomeA.00032-15\nHolt, 2016, Five decades of genome evolution in the globally distributed, extensively antibiotic-resistant Acinetobacter baumannii global clone 1, MGen, 2\nIacono, 2008, Whole-genome pyrosequencing of an epidemic multidrug-resistant Acinetobacter baumannii strain belonging to the European clone II group, Antimicrob. Agents Chemother., 52, 2616, 10.1128\u002FAAC.01643-07\nKamali-Moghaddam, 2001, Arrayed transposase-binding sequences on the ends of transposon Tn5090\u002FTn402, Nucl. Acids Res., 29, 1005, 10.1093\u002Fnar\u002F29.4.1005\nKamali-Moghaddam, 2000, Transposon targeting determined by resolvase, FEMS Microbiol. Letts., 186, 55, 10.1111\u002Fj.1574-6968.2000.tb09081.x\nKholodii, 1995, Four genes, two ends, and a res region are involved in transposition of Tn5053: a paradigm for a novel family of transposons carrying either a mer operon or an integron, Mol. Microbiol., 17, 1189, 10.1111\u002Fj.1365-2958.1995.mmi_17061189.x\nKim, 2013, Spread of carbapenem-resistant Acinetobacter baumannii global clone 2 in Asia and AbaR-type resistance islands, Antimicrob. Agents Chemother., 57, 5239, 10.1128\u002FAAC.00633-13\nKochar, 2012, Deletion of TnAbaR23 results in both expected and unexpected antibiogram changes in a multidrug-resistant Acinetobacter baumannii strain, Antimicrob. Agents Chemother., 56, 1845, 10.1128\u002FAAC.05334-11\nKrizova, 2011, Diversity and evolution of AbaR genomic resistance islands in Acinetobacter baumannii strains of European clone I, Antimicrob. Agents Chemother., 55, 3201, 10.1128\u002FAAC.00221-11\nKrizova, 2010, A 63 kb genomic resistance island found in a multidrug-resistant Acinetobacter baumannii isolate of European clone I from 1977, J. Antimicrob. Chemother., 65, 1915, 10.1093\u002Fjac\u002Fdkq223\nKrizova, 2013, TEM-1 β-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii, J. Antimicrob. Chemother., 68, 2786, 10.1093\u002Fjac\u002Fdkt275\nLee, 2011, Carbapenem-non-susceptible Acinetobacter baumannii of sequence type 92 or its single-locus variants with a G428T substitution in zone 2 of the rpoB gene, J. Antimicrob. Chemother., 66, 66, 10.1093\u002Fjac\u002Fdkq402\nLevings, 2008, SGI2, a relative of Salmonella genomic island SGI1 with an independent origin, Antimicrob. Agents Chemother., 52, 2529, 10.1128\u002FAAC.00189-08\nLiebert, 1999, Transposon Tn21, flagship of the floating genome, Microbiol. Mol. Biol. Rev., 63, 507, 10.1128\u002FMMBR.63.3.507-522.1999\nMcGann, 2014, Amplification of aminoglycoside resistance gene aphA1 in Acinetobacter baumannii results in tobramycin therapy failure, MBio, 5, e00915, 10.1128\u002FmBio.00915-14\nMessens, 2006, Arsenate reduction: thiol cascade chemistry with convergent evolution, J. Mol. Biol., 362, 1, 10.1016\u002Fj.jmb.2006.07.002\nMugnier, 2010, Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii, Emerg. Infect. Dis., 16, 35, 10.3201\u002Feid1601.090852\nNemec, 2008, Emergence of carbapenem resistance in Acinetobacter baumannii in the Czech Republic is associated with the spread of multidrug-resistant strains of European clone II, J. Antimicrob. Chemother., 62, 484, 10.1093\u002Fjac\u002Fdkn205\nNigro, 2013, A novel family of genomic resistance islands, AbGRI2, contributing to aminoglycoside resistance in Acinetobacter baumannii isolates belonging to global clone 2, J. Antimicrob. Chemother., 68, 554, 10.1093\u002Fjac\u002Fdks459\nNigro, 2012, Antibiotic resistance islands in A320 (RUH134), the reference strain for Acinetobacter baumannii global clone 2, J. Antimicrob. Chemother., 67, 335, 10.1093\u002Fjac\u002Fdkr447\nNigro, 2011, J. Antimicrob. Chemother., 66, 2175, 10.1093\u002Fjac\u002Fdkr230\nNigro, 2016, Loss and gain of aminoglycoside resistance in global clone 2 Acinetobacter baumannii in Australia via modification of genomic resistance islands and acquisition of plasmids, J. Antimicrob. Chemother., 71, 2432, 10.1093\u002Fjac\u002Fdkw176\nNigro, 2016, Structure and context of Acinetobacter transposons carrying the oxa23 carbapenemase gene, J. Antimicrob. Chemother., 71, 1135, 10.1093\u002Fjac\u002Fdkv440\nNigro, 2012, Tn6167, an antibiotic resistance island in an Australian carbapenem resistant Acinetobacter baumannii GC2, ST92 isolate, J. Antimicrob. Chemother., 67, 1342, 10.1093\u002Fjac\u002Fdks037\nNigro, 2011, The multiresistant Acinetobacter baumannii European clone I type strain RUH875 (A297) carries a genomic antibiotic resistance island AbaR21, plasmid pRAY and a cluster containing ISAba1-sul2-CR2-strB-strA, J. Antimicrob. Chemother., 66, 1928, 10.1093\u002Fjac\u002Fdkr213\nPartridge, 2001, Transposons Tn1696 and Tn21 and their integrons In4 and In2 have independent origins, Antimicrob. Agents Chemother., 45, 1263, 10.1128\u002FAAC.45.4.1263-1270.2001\nPartridge, 2003, In34, a complex In5 family class 1 integron containing orf513 and dfrA10, Antimicrob. Agents Chemother., 47, 342, 10.1128\u002FAAC.47.1.342-349.2003\nPartridge, 2001, Family of class 1 integrons related to In4 from Tn1696, Antimicrob. Agents Chemother., 45, 3014, 10.1128\u002FAAC.45.11.3014-3020.2001\nPendleton, 2013, Clinical relevance of the ESKAPE pathogens, Expert Rev. Anti. Ther., 11, 297, 10.1586\u002Feri.13.12\nPerez, 2007, Global challenge of multidrug-resistant Acinetobacter baumannii, Antimicrob. Agents Chemother., 51, 3471, 10.1128\u002FAAC.01464-06\nPermina, 2006, Comparative genomics of regulation of heavy metal resistance in Eubacteria, BMC Microbiol., 6, 49, 10.1186\u002F1471-2180-6-49\nJ.E. Peters, Tn7., Microbiol Spectr. 2 (2014), pp. microbiolspec.MDNA3-0010-2014.\nPeters, 2001, Tn7: smarter than we thought, Nat. Rev. Mol. Cell Biol., 2, 806, 10.1038\u002F35099006\nPetrovski, 2010, Tn502 and Tn512 are res site hunters that provide evidence of resolvase-independent transposition to random sites, J. Bacteriol., 192, 1865, 10.1128\u002FJB.01322-09\nPeymani, 2012, Characterisation and clonal dissemination of OXA-23-producing Acinetobacter baumannii in Tabriz, northwest Iran, Int. J. Antimicrob. Agents, 39, 526, 10.1016\u002Fj.ijantimicag.2012.02.014\nPost, 2009, AbaR5, a large multiple antibiotic resistance region found in Acinetobacter baumannii, Antimicrob. Agents Chemother., 53, 2667, 10.1128\u002FAAC.01407-08\nPost, 2012, Antibiotic-resistant Acinetobacter baumannii variants belonging to global clone 1, J. Antimicrob. Chemother., 67, 1039, 10.1093\u002Fjac\u002Fdkr586\nPost, 2010, Evolution of AbaR-type genomic resistance islands in multiply antibiotic-resistant Acinetobacter baumannii, J. Antimicrob. Chemother., 16, 1162, 10.1093\u002Fjac\u002Fdkq095\nRamírez, 2013, Spreading of AbaR-type genomic islands in multidrug resistance Acinetobacter baumannii strains belonging to different clonal complexes, Curr. Microbiol., 67, 9, 10.1007\u002Fs00284-013-0326-5\nRoca, 2009, CraA, a major facilitator superfamily efflux pump associated with chloramphenicol resistance in Acinetobacter baumannii, Antimicrob. Agents Chemother., 53, 4013, 10.1128\u002FAAC.00584-09\nRosen, 1995, Resistance mechanisms to arsenicals and antimonials, J. Basic Clin. Physiol. Pharmacol., 6, 251, 10.1515\u002FJBCPP.1995.6.3-4.251\nSaule, 2013, Dissemination of a carbapenem-resistant Acinetobacter baumannii strain belonging to international clone II\u002Fsequence type 2 and harboring a novel AbaR4-like resistance island in Latvia, Antimicrob. Agents Chemother., 57, 1069, 10.1128\u002FAAC.01783-12\nSeputiene, 2012, Novel variants of AbaR resistance islands with a common backbone in Acinetobacter baumannii isolates of european clone II, Antimicrob. Agents Chemother., 56, 1969, 10.1128\u002FAAC.05678-11\nShaikh, 2009, ATPase genes of diverse multidrug-resistant Acinetobacter baumannii isolates frequently harbour integrated DNA, J. Antimicrob. Chemother., 63, 260, 10.1093\u002Fjac\u002Fdkn481\nSmith, 2007, New insights into Acinetobacter baumannii pathogenesis revealed by high-density pyrosequencing and transposon mutagenesis, Genes Dev., 21, 601, 10.1101\u002Fgad.1510307\nSolomennyi, 2015, Extensively drug-resistant Acinetobacter baumannii belonging to the international clonal lineage I in a Russian burn intensive care unit, Int. J. Antimicrob. Agents, 45, 525, 10.1016\u002Fj.ijantimicag.2014.10.017\nSung, 2012, AbaR7, a genomic resistance island found in multidrug-resistant Acinetobacter baumannii isolates in Daejeon, Korea, Ann. Lab. Med., 32, 324, 10.3343\u002Falm.2012.32.5.324\nTowner, 2009, Acinetobacter: an old friend, but a new enemy, J. Hosp. Infect., 73, 355, 10.1016\u002Fj.jhin.2009.03.032\nTurton, 2007, Use of sequence-based typing and multiplex PCR to identify clonal lineages of outbreak strains of Acinetobacter baumannii, Clin. Microbiol. Infect., 13, 807, 10.1111\u002Fj.1469-0691.2007.01759.x\nvan Dessel, 2004, Identification of a new geographically widespread multiresistant Acinetobacter baumannii clone from European hospitals, Res. Microbiol., 155, 105, 10.1016\u002Fj.resmic.2003.10.003\nWilliams, 2002, A third transposable element, ISPpu12, from the toluene-xylene catabolic plasmid pWW0 of Pseudomonas putida mt-2, J. Bacteriol., 184, 6572, 10.1128\u002FJB.184.23.6572-6580.2002\nWong, 2017, Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges, Clin. Microbiol. Rev., 30, 409, 10.1128\u002FCMR.00058-16\nWright, 2014, New insights into dissemination and variation of the health care-associated pathogen Acinetobacter baumannii from genomic analysis, mBio, 5, e00963, 10.1128\u002FmBio.00963-13\nYang, 2018, Molecular epidemiology and mechanism of sulbactam resistance in Acinetobacter baumannii isolates with diverse genetic background in China, Antimicrob. Agents Chemother., 62, 10.1128\u002FAAC.01947-17\nZarrilli, 2013, Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages, Int. J. Antimicrob. Agents, 41, 11, 10.1016\u002Fj.ijantimicag.2012.09.008\nZhou, 2011, Genomic analysis of the multidrug-resistant Acinetobacter baumannii strain MDR-ZJ06 widely spread in China, Antimicrob. Agents Chemother., 55, 4506, 10.1128\u002FAAC.01134-10",{"VOID":2809},"10.1016\u002Fj.drup.2018.10.003","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1368764618300499",[2812,2836],{"id":2813,"sortIndex":19,"researcher":18,"roles":2814,"affiliations":2815,"properties":2833,"displayName":2835,"givenName":18,"familyName":18},"cef49cd9-11c0-47aa-bda7-c07b529a0d74",[124],[2816,2824],{"id":2817,"sortIndex":19,"affiliation":2818,"properties":18},"5de03180-88a5-4c03-b91e-fa6d0196d17c",{"id":2817,"createTime":18,"updateTime":18,"relativeEntities":2819,"slug":18,"properties":2820,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2823,"statistic":18},[],{"title":2821},{"VI":2822},"School of Molecular and Microbial Biosciences, The University of Sydney, NSW 2006, Australia",[],{"id":2825,"sortIndex":136,"affiliation":2826,"properties":2832},"17c03c87-1ebc-4a03-885a-33893de5bcc5",{"id":2825,"createTime":18,"updateTime":18,"relativeEntities":2827,"slug":18,"properties":2828,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2831,"statistic":18},[],{"title":2829},{"VI":2830},"The ithree institute, University of Technology Sydney, Ultimo 2007, NSW, Australia",[],{},{"title":2834},{"VI":2835},"Mohammad Hamidian",{"id":2837,"sortIndex":136,"researcher":18,"roles":2838,"affiliations":2839,"properties":2846,"displayName":2848,"givenName":18,"familyName":18},"02f2466f-f1d5-4b5d-9d35-d41b3bdeb135",[124],[2840],{"id":2817,"sortIndex":19,"affiliation":2841,"properties":18},{"id":2817,"createTime":18,"updateTime":18,"relativeEntities":2842,"slug":18,"properties":2843,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2845,"statistic":18},[],{"title":2844},{"VI":2822},[],{"title":2847},{"VI":2848},"Ruth M. Hall",{"url":2810,"publisher":2850,"properties":2897},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2851,"slug":10,"properties":2852,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":2855,"manageAffiliations":2876,"indexDatabases":2882,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":2853,"title":2854},{"VOID":13},{"EN":15},[2856,2860,2864,2868,2872],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":2857,"label":2858,"description":2859,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":2861,"label":2862,"description":2863,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":31},{},{"id":34,"createTime":18,"updateTime":18,"relativeEntities":2865,"label":2866,"description":2867,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":37},{},{"id":40,"createTime":18,"updateTime":18,"relativeEntities":2869,"label":2870,"description":2871,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":43},{},{"id":46,"createTime":18,"updateTime":18,"relativeEntities":2873,"label":2874,"description":2875,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":49},{},[2877],{"id":53,"createTime":18,"updateTime":18,"relativeEntities":2878,"slug":18,"properties":2879,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2881,"statistic":18},[],{"title":2880},{"EN":57},[],[2883,2890],{"id":61,"indexDatabase":2884,"url":74,"indexYears":18,"academicFieldIds":2889,"indexDatabaseRanking":18},{"id":63,"createTime":18,"updateTime":18,"relativeEntities":2885,"label":2886,"description":2887,"key":70,"publicationTags":2888,"standard":18},[],{"EN":66,"VI":66},{"EN":68,"VI":69},[72,73],[76],{"id":78,"indexDatabase":2891,"url":89,"indexYears":90,"academicFieldIds":2896,"indexDatabaseRanking":97},{"id":80,"createTime":18,"updateTime":18,"relativeEntities":2892,"label":2893,"description":2894,"key":86,"publicationTags":2895,"standard":18},[],{"EN":83,"VI":83},{"EN":83,"VI":85},[88],[92,93,94,95,96],{"pages":2898,"volume":2900},{"VOID":2899},"26-39",{"VOID":2901},"41","2018-11-01",2018,[72,97],{"id":2906,"createTime":2907,"updateTime":2908,"relativeEntities":2909,"slug":2910,"properties":2911,"entityType":115,"verifyStatus":116,"verifyTime":2908,"verifyNote":118,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":2918,"fullTextUrl":18,"authors":2919,"publicationType":279,"publisherRelationship":2947,"citationCount":18,"citationInfo":18,"publishDate":2106,"publishYear":2104,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":2999,"openAccess":18,"references":18,"isForceReanalyzing":1548},"6e565537-ccab-429c-b50e-fcf004069e3b","2023-11-25T20:07:23.697+00:00","2025-02-26T18:55:52.840+00:00",[],"Antibiotic-resistance-in-gram-negative-bacteria-the-role-of-gene-cassettes-and-integrons",{"title":2912,"references":2914,"doi":2916},{"EN":2913},"Antibiotic resistance in gram-negative bacteria: the role of gene cassettes and integrons",{"VOID":2915},"Hall, 1991, Site-specific insertion of genes into integrons: role of the 59-base element and determination of the recombination crossover point, Mol Microbiol, 5, 1941, 10.1111\u002Fj.1365-2958.1991.tb00817.x\nRecchia, 1995, Gene cassettes: a new class of mobile element, Microbiol, 141, 3015, 10.1099\u002F13500872-141-12-3015\nStokes, 1989, A novel family of potentially mobile DNA elements encoding site-specific gene-integration functions: integrons, Mol Microbiol, 3, 1669, 10.1111\u002Fj.1365-2958.1989.tb00153.x\nHall, 1995, Mobile gene cassettes and integrons: capture and spread of genes by site-specific recombination, Mol Microbiol, 15, 593, 10.1111\u002Fj.1365-2958.1995.tb02368.x\nRecchia, 1997, Origins of the mobile gene cassettes found in integrons, Trends Microbiol, 5, 389, 10.1016\u002FS0966-842X(97)01123-2\nHall, 1997, Mobile gene cassettes and integrons: moving antibiotic resistance genes in Gram-negative bacteria, 192\nCollis, 1992, Gene cassettes from the insert region of integrons are excised as covalently closed circles, Mol Microbiol, 6, 2875, 10.1111\u002Fj.1365-2958.1992.tb01467.x\nJones, 1997, Widespread occurrence of integrons causing multiple antibiotic resistance in bacteria, Lancet, 349, 1742, 10.1016\u002FS0140-6736(05)62954-6\nClark, 1997, VCR repetitive sequence elements in the Vibrio cholerae chromosome constitute a mega-integron, Mol Microbiol, 26, 1137\nStokes, 1997, Structure and function of 59-base element recombination sites associated with mobile gene cassettes, Mol Microbiol, 26, 731, 10.1046\u002Fj.1365-2958.1997.6091980.x\nMartinez, 1990, Genetic elements involved in Tn2\u002F site-specific integration, a novel mechanism for the dissemination of antibiotic-resistance genes, EMBO J, 9, 275, 10.1002\u002Fj.1460-2075.1990.tb08236.x\nCollis, 1992, Site-specific deletion and rearrangement of integron insert genes catalyzed by the integron DNA integrase, J Bacteriol, 174, 1574, 10.1128\u002Fjb.174.5.1574-1585.1992\nBunny, 1995, New mobile cassettes containing an aminoglycoside resistance gene, aacA7, and a chloramphenicol resistance gene, catB3, in an integron in pBWH301, Antimicrob Agents Chemother, 39, 686, 10.1128\u002FAAC.39.3.686\nO'Gorman, 1994, The role of the 59-base element core site in integron-mediated site-specific recombination\nCameron, 1996, Nucleotide sequence of the AAD(2″) aminoglycoside adenylytransferase determinant aadB. Evolutionary relationship of this region with those surrounding aadA in R538-1 and dhfrII in R388, Nucleic Acid Res, 14, 8625, 10.1093\u002Fnar\u002F14.21.8625\nHall, 1987, The region of the IncN plasmid R46 coding for resistance to β-lactam antibiotics, streptomycin\u002Fspectinomycin and sulphonamides is closely related to antibiotic resistance segments found in IncW plasmids and in Tn2\u002F-like transposons, Nucleic Acid Res, 15, 7491, 10.1093\u002Fnar\u002F15.18.7491\nWiedemann, 1987, Insertions of resistance genes into Tn2\u002F-like transposons, J Antimicrob Chemother, 18, 85, 10.1093\u002Fjac\u002F18.Supplement_C.85\nOuellette, 1987, Precise insertion of antibiotic resistance determinants into Tn2\u002F-like transposons: nucleotide sequence of the OXA-1 β-lactamase gene, 84, 7378\nSundström, 1988, Site-specific recombination promotes linkage between trimethoprim- and sulfonamide resistance genes. Sequence characterization of dhfrV and sull and a recombination active locus of Tn2\u002F, Mol Gen Genet, 213, 191, 10.1007\u002FBF00339581\nTietze, 1987, Relationships among the streptothricin resistance transposons Tn\u002F825 and Tn\u002F826 and the trimethoprim resistance transposon Tn7, Plasmid, 18, 246, 10.1016\u002F0147-619X(87)90067-9\nYoung, 1994, Nucleotide sequence and genetic analysis of the type Ib trimethoprim-resistant, Tn4132-encoded dihydrofolate reductase, J Antimicrob Chemother, 34, 715, 10.1093\u002Fjac\u002F34.5.715\nArakawa, 1995, A novel integron-like element carrying the metallo-β-lactamase gene blaIMP, Antimicrob Agents Chemother, 39, 1612, 10.1128\u002FAAC.39.7.1612\nBissonnette, 1992, Characterization of Pseudomonas aeruginosa plasmid pVSI, an ancestor of integrons of multiresistance plasmids and transposons of gram-negative bacteria, J Bacteriol, 174, 1248, 10.1128\u002Fjb.174.4.1248-1257.1992\nSundström, 1990, The dhfrl trimethoprim resistance gene can be found at specific sites in other genetic surroundings, Antimicrob Agents Chemother, 34, 642, 10.1128\u002FAAC.34.4.642\nRecchia, 1994, Characterisation of specific and secondary sites recognised by the integron DNA integrase, Nucleic Acid Res, 22, 2071, 10.1093\u002Fnar\u002F22.11.2071\nHansson, 1997, Nonpalindromic attl sites of integrons are capable of site-specific recombination with one another and with secondary targets, Mol Microbiol, 26, 441, 10.1046\u002Fj.1365-2958.1997.5401964.x\nCollis, 1993, Site-specific insertion of gene cassettes into integrons, Mol Microbiol, 9, 41, 10.1111\u002Fj.1365-2958.1993.tb01667.x\nTietze, 1989, Characterization of new resistance plasmids belonging to incompatibility group IncQ, J Basic Microbiol, 29, 695, 10.1002\u002Fjobm.3620291013\nRecchia, 1995, Plasmid evolution by acquisition of mobile gene cassettes: plasmid pIE723 contains the aadB gene cassette precisely inserted at a secondary site in the IncQ plasmid RSF1010, Mol Microbiol, 15, 179, 10.1111\u002Fj.1365-2958.1995.tb02232.x\nFrancia, 1993, Secondary sites for integration mediated by the Tn2\u002F integrase, Mol Microbiol, 10, 823, 10.1111\u002Fj.1365-2958.1993.tb00952.x\nSegal, 1997, Identification and characterization of an aadB gene cassette at a secondary site in a plasmid from Acinetobacter, FEMS Lett, 153, 321, 10.1111\u002Fj.1574-6968.1997.tb12591.x\nCollis, 1995, Expression of antibiotic resistance genes in the integrated cassettes of integrons, Antimicrob Agents Chemother, 39, 155, 10.1128\u002FAAC.39.1.155\nLévesque, 1994, Diversity and relative strength of tandem promoters for the antibiotic-resistance genes of several integrons, Gene, 142, 49, 10.1016\u002F0378-1119(94)90353-0\nBunny, 1997, Expression of cassette-associated antibiotic resistance genes in class I integrons\nSchmidt, 1988, Nucleotide sequence analysis of 2″-aminoglycoside nucleotidyl-transferase ANT(2″) from Tn4000: its relationship with AAD(3″) and impact on Tn2\u002F evolution, Mol Microbiol, 2, 709, 10.1111\u002Fj.1365-2958.1988.tb00081.x\nStokes, 1991, Sequence analysis of the inducible chloramphenicol resistance determinant in the Tn\u002F696 integron suggests regulation by translational attenuation, Plasmid, 26, 10, 10.1016\u002F0147-619X(91)90032-R\nBissonnette, 1991, Characterization of the nonenzymatic chloramphenicol resistance (cm\u002FA) gene of the In4 integron of Tn\u002F696: similarity of the product to transmembrane transport proteins, J Bacteriol, 173, 4493, 10.1128\u002Fjb.173.14.4493-4502.1991\nPaulsen, 1993, The 3′-conserved segment of integrons contains a gene associated with multidrug resistance to antiseptics and antibiotics, Antimicrob Agents Chemother, 37, 761, 10.1128\u002FAAC.37.4.761\nGuerineau, 1990, Expression of the sulfonamide resistance gene from plasmid R46, Plasmid, 23, 35, 10.1016\u002F0147-619X(90)90042-B\nBito, 1994, Revised analysis of aadA2 gene of plasmid pSa, Antimicrob Agents Chemother, 38, 1172, 10.1128\u002FAAC.38.5.1172\nWohlleben, 1989, On the evolution of Tn2\u002F-like multiresistance transposons: Sequence analysis of the gene (aacCI) for gentamicin acetyltransferase-3-I(AAC(3)-I), another member of the Tn2\u002F-based expression cassette, Mol Gen Genet, 217, 202, 10.1007\u002FBF02464882\nMabilat, 1992, A new example of physical linkage between Tn\u002F and Tn2\u002F: the antibiotic multiple-resistance region of plasmid pCFF04 encoding extended-spectrum β-lactamase TEM-3, Mol Gen Genet, 235, 113, 10.1007\u002FBF00286188\nAdrian, 1995, Prevalence of trimethoprim resistant dihydrofolate reductase genes identified with oligonucleotide probes in plasmids from isolates of commensal faecal flora, J Antimicrob Chemother, 35, 497, 10.1093\u002Fjac\u002F35.4.497\nAdrian, 1995, Prevalence and genetic location of non-transferable trimethoprim resistant dihydrofolate reductase genes in South African commensal faecal isolates, Epidemiol Infect, 115, 255, 10.1017\u002FS0950268800058386\nBush, 1995, A functional classification scheme for β-lactamases and its correlation with molecular structure, Antimicrob Agents Chemother, 39, 1211, 10.1128\u002FAAC.39.6.1211\nMedeiros, 1989, Plasmid-determined beta-lactamases, 101\nDanel, 1997, OXA-15, an extended-spectrum variant of OXA-2 β-lactamase, isolated from a Pseudomonas aeruginosa strain, Antimicrob Agents Chemother, 41, 785, 10.1128\u002FAAC.41.4.785\nSenda, 1996, PCR detection of metallo-β-lactamase gene (blaIMP) in gram-negative rods resistant to broad-spectrum β-lactams, J Clin Microbiol, 34, 2909, 10.1128\u002FJCM.34.12.2909-2913.1996\nSundström, 1995, A new dhfrVIII trimethoprim resistance gene, flanked by IS26, whose product is remote from other dihydrofolate reductases in parsimony analysis, Gene, 154, 7, 10.1016\u002F0378-1119(94)00905-8\nSundström, 1993, Characterization of transposon Tn5086, carrying the site-specifically inserted gene dhfrVII mediating trimethoprim resistance, J Bacteriol, 175, 1796, 10.1128\u002Fjb.175.6.1796-1805.1993\nHuovinen, 1995, Trimethoprim and sulfonamide resistance, Antimicrob Agents Chemother, 39, 279, 10.1128\u002FAAC.39.2.279\nSingh, 1992, Identification by DNA sequence analysis of a new plasmid-encoded trimethoprim resistance gene in fecal Escherichia coli isolates from children in day-care centres, Antimicrob Agents Chemother, 36, 1720, 10.1128\u002FAAC.36.8.1720\nParent, 1992, The chloramphenicol acetyltransferase gene of Tn2424: a new breed of cat, J Bacteriol, 174, 2891, 10.1128\u002Fjb.174.9.2891-2897.1992\nWatanabe, 1968, Transduction of various R factors by phage PI in Escherichia coli and by phage P22 in Salmonella typhimurium, J Bacteriol, 96, 1791, 10.1128\u002FJB.96.5.1791-1795.1968\nShaw, 1991, Correlation between aminoglycoside resistance profiles and DNA hybridization of clinical isolates, Antimicrob Agents Chemother, 35, 2253, 10.1128\u002FAAC.35.11.2253\nRather, 1992, Genetic analysis of bacterial acetyltransferases: identification of amino acids determining the specificities of the aminoglycoside 6′-N-acetyltransferase lb and lla proteins, J Bacteriol, 174, 3196, 10.1128\u002Fjb.174.10.3196-3203.1992\nShaw, 1993, Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes, Microbiol Rev, 57, 138, 10.1128\u002FMMBR.57.1.138-163.1993\nSundström, 1991, Site-specific insertion of three structural genes in transposon Tn7, J Bacteriol, 173, 3025, 10.1128\u002Fjb.173.9.3025-3028.1991\nTietze, 1991, The trimethoprim resistance transposon Tn7 contains a cryptic streptothricin resistance gene, Plasmid, 25, 217, 10.1016\u002F0147-619X(91)90015-O\nSmalla, 1993, Distribution of streptothricin acetyltransferase encoding determinants among environmental bacteria, Mol Ecology, 2, 27, 10.1111\u002Fj.1365-294X.1993.tb00096.x\nLittlejohn, 1991, Structure and evolution of a family of genes encoding antiseptic and disinfectant resistance in Stophylococcus aureus, Gene, 101, 59, 10.1016\u002F0378-1119(91)90224-Y\nRådström, 1994, Transposon 5090 of plasmid R751, which carries an integron, is related to Tn7, Mu and the retroelements, J Bacteriol, 176, 3257, 10.1128\u002Fjb.176.11.3257-3268.1994\nRecchia, 1994, Mobile gene cassettes and integrons: evolutionary and recombinational studies\nStokes, 1993, The partial 3′-conserved segment duplications in the integrons In6 from pSa and In7 from pDGO100 have a common origin, Plasmid, 30, 39, 10.1006\u002Fplas.1993.1032\nHall, 1994, Integrons found in different locations have identical 5′ ends but variable 3′ ends, J Bacteriol, 176, 6286, 10.1128\u002Fjb.176.20.6286-6294.1994\nBrown, 1996, The integrons In0, In2, and In5 are defective transposon derivatives, J Bacteriol, 178, 4429, 10.1128\u002Fjb.178.15.4429-4437.1996\nMartin, 1990, Transposition of an antibiotic resistance element in mycobacteria, Nature, 345, 739, 10.1038\u002F345739a0\nTolmasky, 1990, Sequencing and expression of aadA, bla and tnpR from the multiresistance transposon Tn\u002F331, Plasmid, 24, 218, 10.1016\u002F0147-619X(90)90005-W\nTolmasky, 1993, Genetic organization of antibiotic resistance genes (aac(6′)-lb, aadA and oxa9) on the multidrug transposon Tn\u002F331, Plasmid, 29, 31, 10.1006\u002Fplas.1993.1004",{"VOID":2917},"10.1016\u002Fs1368-7646(98)80026-5","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1368764698800265",[2920,2934],{"id":2921,"sortIndex":19,"researcher":18,"roles":2922,"affiliations":2923,"properties":2932,"displayName":2848,"givenName":18,"familyName":18},"e055074a-63d2-4641-b847-d169b1a8840a",[124],[2924],{"id":2925,"sortIndex":19,"affiliation":2926,"properties":18},"21b64a1e-f495-4e30-9a1d-fa1a7bcd2f02",{"id":2925,"createTime":18,"updateTime":18,"relativeEntities":2927,"slug":18,"properties":2928,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2931,"statistic":18},[],{"title":2929},{"VI":2930},"CSIRO Molecular Science, Sydney Laboratory, New South Wales, Australia",[],{"title":2933},{"VI":2848},{"id":2935,"sortIndex":136,"researcher":18,"roles":2936,"affiliations":2937,"properties":2944,"displayName":2946,"givenName":18,"familyName":18},"9bbfbdb1-f4e0-479c-a79e-66b2f434f0a2",[124],[2938],{"id":2925,"sortIndex":19,"affiliation":2939,"properties":18},{"id":2925,"createTime":18,"updateTime":18,"relativeEntities":2940,"slug":18,"properties":2941,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2943,"statistic":18},[],{"title":2942},{"VI":2930},[],{"title":2945},{"VI":2946},"Christina M. Collis",{"url":2918,"publisher":2948,"properties":2995},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2949,"slug":10,"properties":2950,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":2953,"manageAffiliations":2974,"indexDatabases":2980,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":2951,"title":2952},{"VOID":13},{"EN":15},[2954,2958,2962,2966,2970],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":2955,"label":2956,"description":2957,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":2959,"label":2960,"description":2961,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":31},{},{"id":34,"createTime":18,"updateTime":18,"relativeEntities":2963,"label":2964,"description":2965,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":37},{},{"id":40,"createTime":18,"updateTime":18,"relativeEntities":2967,"label":2968,"description":2969,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":43},{},{"id":46,"createTime":18,"updateTime":18,"relativeEntities":2971,"label":2972,"description":2973,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":49},{},[2975],{"id":53,"createTime":18,"updateTime":18,"relativeEntities":2976,"slug":18,"properties":2977,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":2979,"statistic":18},[],{"title":2978},{"EN":57},[],[2981,2988],{"id":61,"indexDatabase":2982,"url":74,"indexYears":18,"academicFieldIds":2987,"indexDatabaseRanking":18},{"id":63,"createTime":18,"updateTime":18,"relativeEntities":2983,"label":2984,"description":2985,"key":70,"publicationTags":2986,"standard":18},[],{"EN":66,"VI":66},{"EN":68,"VI":69},[72,73],[76],{"id":78,"indexDatabase":2989,"url":89,"indexYears":90,"academicFieldIds":2994,"indexDatabaseRanking":97},{"id":80,"createTime":18,"updateTime":18,"relativeEntities":2990,"label":2991,"description":2992,"key":86,"publicationTags":2993,"standard":18},[],{"EN":83,"VI":83},{"EN":83,"VI":85},[88],[92,93,94,95,96],{"pages":2996,"volume":2998},{"VOID":2997},"109-119",{"VOID":2101},[72,97],{"id":3001,"createTime":3002,"updateTime":3003,"relativeEntities":3004,"slug":3005,"properties":3006,"entityType":115,"verifyStatus":116,"verifyTime":3003,"verifyNote":118,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":3011,"fullTextUrl":18,"authors":3012,"publicationType":279,"publisherRelationship":3078,"citationCount":18,"citationInfo":18,"publishDate":3131,"publishYear":3132,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":3133,"openAccess":18,"references":18,"isForceReanalyzing":1548},"2daea5d4-22f6-4249-b513-483967bbba01","2024-01-01T17:35:55.462+00:00","2025-02-26T15:24:55.052+00:00",[],"Vascular-remodeling-and-clinical-resistance-to-antiangiogenic-cancer-therapy",{"title":3007,"doi":3009},{"EN":3008},"Vascular remodeling and clinical resistance to antiangiogenic cancer therapy",{"VOID":3010},"10.1016\u002Fj.drup.2004.09.001","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1368764604000688",[3013,3028,3043,3058],{"id":3014,"sortIndex":19,"researcher":18,"roles":3015,"affiliations":3016,"properties":3025,"displayName":3027,"givenName":18,"familyName":18},"39f98898-9976-4803-85fb-28db2aa67f11",[124],[3017],{"id":3018,"sortIndex":19,"affiliation":3019,"properties":18},"6e3e448b-712d-4517-a5ee-04a366eb1bf1",{"id":3018,"createTime":18,"updateTime":18,"relativeEntities":3020,"slug":18,"properties":3021,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":3024,"statistic":18},[],{"title":3022},{"VI":3023},"Division of Pediatric Oncology, College of Physicians and Surgeons at Columbia University, Irving Pavilion 7, 161 Fort Washington Avenue, New York, NY 10032, USA",[],{"title":3026},{"VI":3027},"Julia Glade Bender",{"id":3029,"sortIndex":136,"researcher":18,"roles":3030,"affiliations":3031,"properties":3040,"displayName":3042,"givenName":18,"familyName":18},"c3af993b-ef3c-40f5-b531-07c4330c81fe",[124],[3032],{"id":3033,"sortIndex":19,"affiliation":3034,"properties":18},"0067df81-cb9c-46df-8e87-9459b2c939ac",{"id":3033,"createTime":18,"updateTime":18,"relativeEntities":3035,"slug":18,"properties":3036,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":3039,"statistic":18},[],{"title":3037},{"VI":3038},"Division of Pediatric Hematology and Blood and Marrow Transplantation. College of Physicians and Surgeons at Columbia University, New York, NY, USA",[],{"title":3041},{"VI":3042},"Erin M. Cooney",{"id":3044,"sortIndex":172,"researcher":18,"roles":3045,"affiliations":3046,"properties":3055,"displayName":3057,"givenName":18,"familyName":18},"81ea66dc-86d0-4e6c-8b81-0ea3bfaa6690",[124],[3047],{"id":3048,"sortIndex":19,"affiliation":3049,"properties":18},"f8f0963a-7900-41fc-b870-6770386cc844",{"id":3048,"createTime":18,"updateTime":18,"relativeEntities":3050,"slug":18,"properties":3051,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":3054,"statistic":18},[],{"title":3052},{"VI":3053},"Division of Pediatric Surgery, College of Physicians and Surgeons at Columbia University, New York, NY, USA",[],{"title":3056},{"VI":3057},"Jessica J. Kandel",{"id":3059,"sortIndex":193,"researcher":18,"roles":3060,"affiliations":3061,"properties":3075,"displayName":3077,"givenName":18,"familyName":18},"7805ddb6-2c5a-43da-9bbe-71c292453030",[124],[3062,3068],{"id":3018,"sortIndex":19,"affiliation":3063,"properties":18},{"id":3018,"createTime":18,"updateTime":18,"relativeEntities":3064,"slug":18,"properties":3065,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":3067,"statistic":18},[],{"title":3066},{"VI":3023},[],{"id":3048,"sortIndex":136,"affiliation":3069,"properties":3074},{"id":3048,"createTime":18,"updateTime":18,"relativeEntities":3070,"slug":18,"properties":3071,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":3073,"statistic":18},[],{"title":3072},{"VI":3053},[],{},{"title":3076},{"VI":3077},"Darrell J. Yamashiro",{"url":3011,"publisher":3079,"properties":3126},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":3080,"slug":10,"properties":3081,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":3084,"manageAffiliations":3105,"indexDatabases":3111,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":3082,"title":3083},{"VOID":13},{"EN":15},[3085,3089,3093,3097,3101],{"id":22,"createTime":18,"updateTime":18,"relativeEntities":3086,"label":3087,"description":3088,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":25},{},{"id":28,"createTime":18,"updateTime":18,"relativeEntities":3090,"label":3091,"description":3092,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":31},{},{"id":34,"createTime":18,"updateTime":18,"relativeEntities":3094,"label":3095,"description":3096,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":37},{},{"id":40,"createTime":18,"updateTime":18,"relativeEntities":3098,"label":3099,"description":3100,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":43},{},{"id":46,"createTime":18,"updateTime":18,"relativeEntities":3102,"label":3103,"description":3104,"parentId":18,"standard":18,"scholarHubFieldId":18},[],{"EN":49},{},[3106],{"id":53,"createTime":18,"updateTime":18,"relativeEntities":3107,"slug":18,"properties":3108,"entityType":18,"verifyStatus":18,"verifyTime":18,"verifyNote":18,"languages":18,"translateLanguages":18,"viewCount":18,"url":18,"parentIds":3110,"statistic":18},[],{"title":3109},{"EN":57},[],[3112,3119],{"id":61,"indexDatabase":3113,"url":74,"indexYears":18,"academicFieldIds":3118,"indexDatabaseRanking":18},{"id":63,"createTime":18,"updateTime":18,"relativeEntities":3114,"label":3115,"description":3116,"key":70,"publicationTags":3117,"standard":18},[],{"EN":66,"VI":66},{"EN":68,"VI":69},[72,73],[76],{"id":78,"indexDatabase":3120,"url":89,"indexYears":90,"academicFieldIds":3125,"indexDatabaseRanking":97},{"id":80,"createTime":18,"updateTime":18,"relativeEntities":3121,"label":3122,"description":3123,"key":86,"publicationTags":3124,"standard":18},[],{"EN":83,"VI":83},{"EN":83,"VI":85},[88],[92,93,94,95,96],{"pages":3127,"volume":3129},{"VOID":3128},"289-300",{"VOID":3130},"7","2004-10-01",2004,[72,97]]